6	FANAPT.xml:S1:4:1	O
ADVERSE	FANAPT.xml:S1:10:7	O
REACTIONS	FANAPT.xml:S1:18:9	O

EXCERPT	FANAPT.xml:S1:31:7	O
:	FANAPT.xml:S1:38:1	O
Commonly	FANAPT.xml:S1:42:8	O
observed	FANAPT.xml:S1:51:8	O
adverse	FANAPT.xml:S1:60:7	O
reactions	FANAPT.xml:S1:68:9	O
(	FANAPT.xml:S1:78:1	O
incidence	FANAPT.xml:S1:79:9	O
5%	FANAPT.xml:S1:91:2	O
and	FANAPT.xml:S1:94:3	O
2	FANAPT.xml:S1:98:1	O
-	FANAPT.xml:S1:99:1	O
fold	FANAPT.xml:S1:100:4	O
greater	FANAPT.xml:S1:105:7	O
than	FANAPT.xml:S1:113:4	O
placebo	FANAPT.xml:S1:118:7	O
)	FANAPT.xml:S1:125:1	O
were	FANAPT.xml:S1:127:4	O
:	FANAPT.xml:S1:131:1	O
dizziness	FANAPT.xml:S1:133:9	B-AdverseReaction
,	FANAPT.xml:S1:142:1	O
dry	FANAPT.xml:S1:144:3	B-AdverseReaction
mouth	FANAPT.xml:S1:148:5	I-AdverseReaction
,	FANAPT.xml:S1:153:1	O
fatigue	FANAPT.xml:S1:155:7	B-AdverseReaction
,	FANAPT.xml:S1:162:1	O
nasal	FANAPT.xml:S1:164:5	B-AdverseReaction
congestion	FANAPT.xml:S1:170:10	I-AdverseReaction
,	FANAPT.xml:S1:180:1	O
orthostatic	FANAPT.xml:S1:182:11	B-AdverseReaction
hypotension	FANAPT.xml:S1:194:11	I-AdverseReaction
,	FANAPT.xml:S1:205:1	O
somnolence	FANAPT.xml:S1:207:10	B-AdverseReaction
,	FANAPT.xml:S1:217:1	O
tachycardia	FANAPT.xml:S1:219:11	B-AdverseReaction
,	FANAPT.xml:S1:230:1	O
and	FANAPT.xml:S1:232:3	O
weight	FANAPT.xml:S1:236:6	B-AdverseReaction
increased	FANAPT.xml:S1:243:9	I-AdverseReaction
.	FANAPT.xml:S1:252:1	O

(	FANAPT.xml:S1:254:1	O
6.1	FANAPT.xml:S1:257:3	O
)	FANAPT.xml:S1:262:1	O

To	FANAPT.xml:S1:270:2	O
report	FANAPT.xml:S1:273:6	O
SUSPECTED	FANAPT.xml:S1:280:9	O
ADVERSE	FANAPT.xml:S1:290:7	O
REACTIONS	FANAPT.xml:S1:298:9	O
,	FANAPT.xml:S1:307:1	O
contact	FANAPT.xml:S1:309:7	O
Novartis	FANAPT.xml:S1:317:8	O
Pharmaceuticals	FANAPT.xml:S1:326:15	O
Corporation	FANAPT.xml:S1:342:11	O
at	FANAPT.xml:S1:354:2	O
1	FANAPT.xml:S1:357:1	O
-	FANAPT.xml:S1:358:1	O
888	FANAPT.xml:S1:359:3	O
-	FANAPT.xml:S1:362:1	O
669	FANAPT.xml:S1:363:3	O
-	FANAPT.xml:S1:366:1	O
6682	FANAPT.xml:S1:367:4	O
or	FANAPT.xml:S1:372:2	O
FDA	FANAPT.xml:S1:375:3	O
at	FANAPT.xml:S1:379:2	O
1	FANAPT.xml:S1:382:1	O
-	FANAPT.xml:S1:383:1	O
800	FANAPT.xml:S1:384:3	O
-	FANAPT.xml:S1:387:1	O
FDA	FANAPT.xml:S1:388:3	O
-	FANAPT.xml:S1:391:1	O
1088	FANAPT.xml:S1:392:4	O
or	FANAPT.xml:S1:397:2	O
www	FANAPT.xml:S1:401:3	O
.	FANAPT.xml:S1:404:1	O
fda	FANAPT.xml:S1:405:3	O
.	FANAPT.xml:S1:408:1	O
gov	FANAPT.xml:S1:409:3	O
medwatch	FANAPT.xml:S1:413:8	O
.	FANAPT.xml:S1:423:1	O

6.1	FANAPT.xml:S1:435:3	O

Clinical	FANAPT.xml:S1:443:8	O
Studies	FANAPT.xml:S1:452:7	O
Experience	FANAPT.xml:S1:460:10	O

Because	FANAPT.xml:S1:474:7	O
clinical	FANAPT.xml:S1:482:8	O
trials	FANAPT.xml:S1:491:6	O
are	FANAPT.xml:S1:498:3	O
conducted	FANAPT.xml:S1:502:9	O
under	FANAPT.xml:S1:512:5	O
widely	FANAPT.xml:S1:518:6	O
varying	FANAPT.xml:S1:525:7	O
conditions	FANAPT.xml:S1:533:10	O
,	FANAPT.xml:S1:543:1	O
adverse	FANAPT.xml:S1:545:7	O
reaction	FANAPT.xml:S1:553:8	O
rates	FANAPT.xml:S1:562:5	O
observed	FANAPT.xml:S1:568:8	O
in	FANAPT.xml:S1:577:2	O
the	FANAPT.xml:S1:580:3	O
clinical	FANAPT.xml:S1:584:8	O
trial	FANAPT.xml:S1:593:5	O
of	FANAPT.xml:S1:599:2	O
a	FANAPT.xml:S1:602:1	O
drug	FANAPT.xml:S1:604:4	O
cannot	FANAPT.xml:S1:609:6	O
be	FANAPT.xml:S1:616:2	O
directly	FANAPT.xml:S1:619:8	O
compared	FANAPT.xml:S1:628:8	O
to	FANAPT.xml:S1:637:2	O
rates	FANAPT.xml:S1:640:5	O
in	FANAPT.xml:S1:646:2	O
the	FANAPT.xml:S1:649:3	O
clinical	FANAPT.xml:S1:653:8	O
trials	FANAPT.xml:S1:662:6	O
of	FANAPT.xml:S1:669:2	O
another	FANAPT.xml:S1:672:7	O
drug	FANAPT.xml:S1:680:4	O
and	FANAPT.xml:S1:685:3	O
may	FANAPT.xml:S1:689:3	O
not	FANAPT.xml:S1:693:3	O
reflect	FANAPT.xml:S1:697:7	O
the	FANAPT.xml:S1:705:3	O
rates	FANAPT.xml:S1:709:5	O
observed	FANAPT.xml:S1:715:8	O
in	FANAPT.xml:S1:724:2	O
clinical	FANAPT.xml:S1:727:8	O
practice	FANAPT.xml:S1:736:8	O
.	FANAPT.xml:S1:744:1	O

The	FANAPT.xml:S1:746:3	O
information	FANAPT.xml:S1:750:11	O
below	FANAPT.xml:S1:762:5	O
is	FANAPT.xml:S1:768:2	O
derived	FANAPT.xml:S1:771:7	O
from	FANAPT.xml:S1:779:4	O
a	FANAPT.xml:S1:784:1	O
clinical	FANAPT.xml:S1:786:8	O
trial	FANAPT.xml:S1:795:5	O
database	FANAPT.xml:S1:801:8	O
for	FANAPT.xml:S1:810:3	O
FANAPT	FANAPT.xml:S1:814:6	O
consisting	FANAPT.xml:S1:821:10	O
of	FANAPT.xml:S1:832:2	O
2070	FANAPT.xml:S1:835:4	O
patients	FANAPT.xml:S1:840:8	O
exposed	FANAPT.xml:S1:849:7	O
to	FANAPT.xml:S1:857:2	O
FANAPT	FANAPT.xml:S1:860:6	O
at	FANAPT.xml:S1:867:2	O
doses	FANAPT.xml:S1:870:5	O
of	FANAPT.xml:S1:876:2	O
10	FANAPT.xml:S1:879:2	O
mg	FANAPT.xml:S1:882:2	O
day	FANAPT.xml:S1:885:3	O
or	FANAPT.xml:S1:889:2	O
greater	FANAPT.xml:S1:892:7	O
,	FANAPT.xml:S1:899:1	O
for	FANAPT.xml:S1:901:3	O
the	FANAPT.xml:S1:905:3	O
treatment	FANAPT.xml:S1:909:9	O
of	FANAPT.xml:S1:919:2	O
schizophrenia	FANAPT.xml:S1:922:13	O
.	FANAPT.xml:S1:935:1	O

Of	FANAPT.xml:S1:937:2	O
these	FANAPT.xml:S1:940:5	O
,	FANAPT.xml:S1:945:1	O
806	FANAPT.xml:S1:947:3	O
received	FANAPT.xml:S1:951:8	O
FANAPT	FANAPT.xml:S1:960:6	O
for	FANAPT.xml:S1:967:3	O
at	FANAPT.xml:S1:971:2	O
least	FANAPT.xml:S1:974:5	O
6	FANAPT.xml:S1:980:1	O
months	FANAPT.xml:S1:982:6	O
,	FANAPT.xml:S1:988:1	O
with	FANAPT.xml:S1:990:4	O
463	FANAPT.xml:S1:995:3	O
exposed	FANAPT.xml:S1:999:7	O
to	FANAPT.xml:S1:1007:2	O
FANAPT	FANAPT.xml:S1:1010:6	O
for	FANAPT.xml:S1:1017:3	O
at	FANAPT.xml:S1:1021:2	O
least	FANAPT.xml:S1:1024:5	O
12	FANAPT.xml:S1:1030:2	O
months	FANAPT.xml:S1:1033:6	O
.	FANAPT.xml:S1:1039:1	O

All	FANAPT.xml:S1:1041:3	O
of	FANAPT.xml:S1:1045:2	O
these	FANAPT.xml:S1:1048:5	O
patients	FANAPT.xml:S1:1054:8	O
who	FANAPT.xml:S1:1063:3	O
received	FANAPT.xml:S1:1067:8	O
FANAPT	FANAPT.xml:S1:1076:6	O
were	FANAPT.xml:S1:1083:4	O
participating	FANAPT.xml:S1:1088:13	O
in	FANAPT.xml:S1:1102:2	O
multiple	FANAPT.xml:S1:1105:8	O
-	FANAPT.xml:S1:1113:1	O
dose	FANAPT.xml:S1:1114:4	O
clinical	FANAPT.xml:S1:1119:8	O
trials	FANAPT.xml:S1:1128:6	O
.	FANAPT.xml:S1:1134:1	O

The	FANAPT.xml:S1:1136:3	O
conditions	FANAPT.xml:S1:1140:10	O
and	FANAPT.xml:S1:1151:3	O
duration	FANAPT.xml:S1:1155:8	O
of	FANAPT.xml:S1:1164:2	O
treatment	FANAPT.xml:S1:1167:9	O
with	FANAPT.xml:S1:1177:4	O
FANAPT	FANAPT.xml:S1:1182:6	O
varied	FANAPT.xml:S1:1189:6	O
greatly	FANAPT.xml:S1:1196:7	O
and	FANAPT.xml:S1:1204:3	O
included	FANAPT.xml:S1:1208:8	O
(	FANAPT.xml:S1:1217:1	O
in	FANAPT.xml:S1:1218:2	O
overlapping	FANAPT.xml:S1:1221:11	O
categories	FANAPT.xml:S1:1233:10	O
)	FANAPT.xml:S1:1243:1	O
,	FANAPT.xml:S1:1244:1	O
open	FANAPT.xml:S1:1246:4	O
-	FANAPT.xml:S1:1250:1	O
label	FANAPT.xml:S1:1251:5	O
and	FANAPT.xml:S1:1257:3	O
double	FANAPT.xml:S1:1261:6	O
-	FANAPT.xml:S1:1267:1	O
blind	FANAPT.xml:S1:1268:5	O
phases	FANAPT.xml:S1:1274:6	O
of	FANAPT.xml:S1:1281:2	O
studies	FANAPT.xml:S1:1284:7	O
,	FANAPT.xml:S1:1291:1	O
inpatients	FANAPT.xml:S1:1293:10	O
and	FANAPT.xml:S1:1304:3	O
outpatients	FANAPT.xml:S1:1308:11	O
,	FANAPT.xml:S1:1319:1	O
fixed	FANAPT.xml:S1:1321:5	O
-	FANAPT.xml:S1:1326:1	O
dose	FANAPT.xml:S1:1327:4	O
and	FANAPT.xml:S1:1332:3	O
flexible	FANAPT.xml:S1:1336:8	O
-	FANAPT.xml:S1:1344:1	O
dose	FANAPT.xml:S1:1345:4	O
studies	FANAPT.xml:S1:1350:7	O
,	FANAPT.xml:S1:1357:1	O
and	FANAPT.xml:S1:1359:3	O
short	FANAPT.xml:S1:1363:5	O
-	FANAPT.xml:S1:1368:1	O
term	FANAPT.xml:S1:1369:4	O
and	FANAPT.xml:S1:1374:3	O
longer	FANAPT.xml:S1:1378:6	O
-	FANAPT.xml:S1:1384:1	O
term	FANAPT.xml:S1:1385:4	O
exposure	FANAPT.xml:S1:1390:8	O
.	FANAPT.xml:S1:1398:1	O

Adverse	FANAPT.xml:S1:1404:7	O
reactions	FANAPT.xml:S1:1412:9	O
during	FANAPT.xml:S1:1422:6	O
exposure	FANAPT.xml:S1:1429:8	O
were	FANAPT.xml:S1:1438:4	O
obtained	FANAPT.xml:S1:1443:8	O
by	FANAPT.xml:S1:1452:2	O
general	FANAPT.xml:S1:1455:7	O
inquiry	FANAPT.xml:S1:1463:7	O
and	FANAPT.xml:S1:1471:3	O
recorded	FANAPT.xml:S1:1475:8	O
by	FANAPT.xml:S1:1484:2	O
clinical	FANAPT.xml:S1:1487:8	O
investigators	FANAPT.xml:S1:1496:13	O
using	FANAPT.xml:S1:1510:5	O
their	FANAPT.xml:S1:1516:5	O
own	FANAPT.xml:S1:1522:3	O
terminology	FANAPT.xml:S1:1526:11	O
.	FANAPT.xml:S1:1537:1	O

Consequently	FANAPT.xml:S1:1539:12	O
,	FANAPT.xml:S1:1551:1	O
to	FANAPT.xml:S1:1553:2	O
provide	FANAPT.xml:S1:1556:7	O
a	FANAPT.xml:S1:1564:1	O
meaningful	FANAPT.xml:S1:1566:10	O
estimate	FANAPT.xml:S1:1577:8	O
of	FANAPT.xml:S1:1586:2	O
the	FANAPT.xml:S1:1589:3	O
proportion	FANAPT.xml:S1:1593:10	O
of	FANAPT.xml:S1:1604:2	O
individuals	FANAPT.xml:S1:1607:11	O
experiencing	FANAPT.xml:S1:1619:12	O
adverse	FANAPT.xml:S1:1632:7	O
reactions	FANAPT.xml:S1:1640:9	O
,	FANAPT.xml:S1:1649:1	O
reactions	FANAPT.xml:S1:1651:9	O
were	FANAPT.xml:S1:1661:4	O
grouped	FANAPT.xml:S1:1666:7	O
in	FANAPT.xml:S1:1674:2	O
standardized	FANAPT.xml:S1:1677:12	O
categories	FANAPT.xml:S1:1690:10	O
using	FANAPT.xml:S1:1701:5	O
MedDRA	FANAPT.xml:S1:1707:6	O
terminology	FANAPT.xml:S1:1714:11	O
.	FANAPT.xml:S1:1725:1	O

The	FANAPT.xml:S1:1731:3	O
stated	FANAPT.xml:S1:1735:6	O
frequencies	FANAPT.xml:S1:1742:11	O
of	FANAPT.xml:S1:1754:2	O
adverse	FANAPT.xml:S1:1757:7	O
reactions	FANAPT.xml:S1:1765:9	O
represent	FANAPT.xml:S1:1775:9	O
the	FANAPT.xml:S1:1785:3	O
proportions	FANAPT.xml:S1:1789:11	O
of	FANAPT.xml:S1:1801:2	O
individuals	FANAPT.xml:S1:1804:11	O
who	FANAPT.xml:S1:1816:3	O
experienced	FANAPT.xml:S1:1820:11	O
a	FANAPT.xml:S1:1832:1	O
treatment	FANAPT.xml:S1:1834:9	O
-	FANAPT.xml:S1:1843:1	O
emergent	FANAPT.xml:S1:1844:8	O
adverse	FANAPT.xml:S1:1853:7	O
reaction	FANAPT.xml:S1:1861:8	O
of	FANAPT.xml:S1:1870:2	O
the	FANAPT.xml:S1:1873:3	O
type	FANAPT.xml:S1:1877:4	O
listed	FANAPT.xml:S1:1882:6	O
.	FANAPT.xml:S1:1888:1	O

A	FANAPT.xml:S1:1890:1	O
reaction	FANAPT.xml:S1:1892:8	O
was	FANAPT.xml:S1:1901:3	O
considered	FANAPT.xml:S1:1905:10	O
treatment	FANAPT.xml:S1:1916:9	O
-	FANAPT.xml:S1:1925:1	O
emergent	FANAPT.xml:S1:1926:8	O
if	FANAPT.xml:S1:1935:2	O
it	FANAPT.xml:S1:1938:2	O
occurred	FANAPT.xml:S1:1941:8	O
for	FANAPT.xml:S1:1950:3	O
the	FANAPT.xml:S1:1954:3	O
first	FANAPT.xml:S1:1958:5	O
time	FANAPT.xml:S1:1964:4	O
or	FANAPT.xml:S1:1969:2	O
worsened	FANAPT.xml:S1:1972:8	O
while	FANAPT.xml:S1:1981:5	O
receiving	FANAPT.xml:S1:1987:9	O
therapy	FANAPT.xml:S1:1997:7	O
following	FANAPT.xml:S1:2005:9	O
baseline	FANAPT.xml:S1:2015:8	O
evaluation	FANAPT.xml:S1:2024:10	O
.	FANAPT.xml:S1:2034:1	O

The	FANAPT.xml:S1:2040:3	O
information	FANAPT.xml:S1:2044:11	O
presented	FANAPT.xml:S1:2056:9	O
in	FANAPT.xml:S1:2066:2	O
these	FANAPT.xml:S1:2069:5	O
sections	FANAPT.xml:S1:2075:8	O
was	FANAPT.xml:S1:2084:3	O
derived	FANAPT.xml:S1:2088:7	O
from	FANAPT.xml:S1:2096:4	O
pooled	FANAPT.xml:S1:2101:6	O
data	FANAPT.xml:S1:2108:4	O
from	FANAPT.xml:S1:2113:4	O
4	FANAPT.xml:S1:2118:1	O
placebo	FANAPT.xml:S1:2120:7	O
-	FANAPT.xml:S1:2127:1	O
controlled	FANAPT.xml:S1:2128:10	O
,	FANAPT.xml:S1:2138:1	O
4	FANAPT.xml:S1:2140:1	O
-	FANAPT.xml:S1:2141:1	O
or	FANAPT.xml:S1:2143:2	O
6	FANAPT.xml:S1:2146:1	O
-	FANAPT.xml:S1:2147:1	O
week	FANAPT.xml:S1:2148:4	O
,	FANAPT.xml:S1:2152:1	O
fixed	FANAPT.xml:S1:2154:5	O
-	FANAPT.xml:S1:2159:1	O
or	FANAPT.xml:S1:2161:2	O
flexible	FANAPT.xml:S1:2164:8	O
-	FANAPT.xml:S1:2172:1	O
dose	FANAPT.xml:S1:2173:4	O
studies	FANAPT.xml:S1:2178:7	O
in	FANAPT.xml:S1:2186:2	O
patients	FANAPT.xml:S1:2189:8	O
who	FANAPT.xml:S1:2198:3	O
received	FANAPT.xml:S1:2202:8	O
FANAPT	FANAPT.xml:S1:2211:6	O
at	FANAPT.xml:S1:2218:2	O
daily	FANAPT.xml:S1:2221:5	O
doses	FANAPT.xml:S1:2227:5	O
within	FANAPT.xml:S1:2233:6	O
a	FANAPT.xml:S1:2240:1	O
range	FANAPT.xml:S1:2242:5	O
of	FANAPT.xml:S1:2248:2	O
10	FANAPT.xml:S1:2251:2	O
to	FANAPT.xml:S1:2254:2	O
24	FANAPT.xml:S1:2257:2	O
mg	FANAPT.xml:S1:2260:2	O
(	FANAPT.xml:S1:2263:1	O
n	FANAPT.xml:S1:2264:1	O
874	FANAPT.xml:S1:2266:3	O
)	FANAPT.xml:S1:2269:1	O
.	FANAPT.xml:S1:2270:1	O

Adverse	FANAPT.xml:S1:2279:7	O
Reactions	FANAPT.xml:S1:2287:9	O
Occurring	FANAPT.xml:S1:2297:9	O
at	FANAPT.xml:S1:2307:2	O
an	FANAPT.xml:S1:2310:2	O
Incidence	FANAPT.xml:S1:2313:9	O
of	FANAPT.xml:S1:2323:2	O
2%	FANAPT.xml:S1:2326:2	O
or	FANAPT.xml:S1:2329:2	O
More	FANAPT.xml:S1:2332:4	O
among	FANAPT.xml:S1:2337:5	O
FANAPT	FANAPT.xml:S1:2346:6	O
-	FANAPT.xml:S1:2356:1	O
Treated	FANAPT.xml:S1:2357:7	O
Patients	FANAPT.xml:S1:2365:8	O
and	FANAPT.xml:S1:2382:3	O
More	FANAPT.xml:S1:2386:4	O
Frequent	FANAPT.xml:S1:2394:8	O
than	FANAPT.xml:S1:2403:4	O
Placebo	FANAPT.xml:S1:2408:7	O

Table	FANAPT.xml:S1:2422:5	O
7	FANAPT.xml:S1:2428:1	O
enumerates	FANAPT.xml:S1:2430:10	O
the	FANAPT.xml:S1:2441:3	O
pooled	FANAPT.xml:S1:2445:6	O
incidences	FANAPT.xml:S1:2452:10	O
of	FANAPT.xml:S1:2463:2	O
treatment	FANAPT.xml:S1:2466:9	O
-	FANAPT.xml:S1:2475:1	O
emergent	FANAPT.xml:S1:2476:8	O
adverse	FANAPT.xml:S1:2485:7	O
reactions	FANAPT.xml:S1:2493:9	O
that	FANAPT.xml:S1:2503:4	O
were	FANAPT.xml:S1:2508:4	O
spontaneously	FANAPT.xml:S1:2513:13	O
reported	FANAPT.xml:S1:2527:8	O
in	FANAPT.xml:S1:2536:2	O
four	FANAPT.xml:S1:2539:4	O
placebo	FANAPT.xml:S1:2544:7	O
-	FANAPT.xml:S1:2551:1	O
controlled	FANAPT.xml:S1:2552:10	O
,	FANAPT.xml:S1:2562:1	O
4	FANAPT.xml:S1:2564:1	O
-	FANAPT.xml:S1:2565:1	O
or	FANAPT.xml:S1:2567:2	O
6	FANAPT.xml:S1:2570:1	O
-	FANAPT.xml:S1:2571:1	O
week	FANAPT.xml:S1:2572:4	O
,	FANAPT.xml:S1:2576:1	O
fixed	FANAPT.xml:S1:2578:5	O
-	FANAPT.xml:S1:2583:1	O
or	FANAPT.xml:S1:2585:2	O
flexible	FANAPT.xml:S1:2588:8	O
-	FANAPT.xml:S1:2596:1	O
dose	FANAPT.xml:S1:2597:4	O
studies	FANAPT.xml:S1:2602:7	O
,	FANAPT.xml:S1:2609:1	O
listing	FANAPT.xml:S1:2611:7	O
those	FANAPT.xml:S1:2619:5	O
reactions	FANAPT.xml:S1:2625:9	O
that	FANAPT.xml:S1:2635:4	O
occurred	FANAPT.xml:S1:2640:8	O
in	FANAPT.xml:S1:2649:2	O
2%	FANAPT.xml:S1:2652:2	O
or	FANAPT.xml:S1:2655:2	O
more	FANAPT.xml:S1:2658:4	O
of	FANAPT.xml:S1:2663:2	O
patients	FANAPT.xml:S1:2666:8	O
treated	FANAPT.xml:S1:2675:7	O
with	FANAPT.xml:S1:2683:4	O
FANAPT	FANAPT.xml:S1:2688:6	O
in	FANAPT.xml:S1:2695:2	O
any	FANAPT.xml:S1:2698:3	O
of	FANAPT.xml:S1:2702:2	O
the	FANAPT.xml:S1:2705:3	O
dose	FANAPT.xml:S1:2709:4	O
groups	FANAPT.xml:S1:2714:6	O
,	FANAPT.xml:S1:2720:1	O
and	FANAPT.xml:S1:2722:3	O
for	FANAPT.xml:S1:2726:3	O
which	FANAPT.xml:S1:2730:5	O
the	FANAPT.xml:S1:2736:3	O
incidence	FANAPT.xml:S1:2740:9	O
in	FANAPT.xml:S1:2750:2	O
FANAPT	FANAPT.xml:S1:2753:6	O
-	FANAPT.xml:S1:2759:1	O
treated	FANAPT.xml:S1:2760:7	O
patients	FANAPT.xml:S1:2768:8	O
in	FANAPT.xml:S1:2777:2	O
any	FANAPT.xml:S1:2780:3	O
dose	FANAPT.xml:S1:2784:4	O
group	FANAPT.xml:S1:2789:5	O
was	FANAPT.xml:S1:2795:3	O
greater	FANAPT.xml:S1:2799:7	O
than	FANAPT.xml:S1:2807:4	O
the	FANAPT.xml:S1:2812:3	O
incidence	FANAPT.xml:S1:2816:9	O
in	FANAPT.xml:S1:2826:2	O
patients	FANAPT.xml:S1:2829:8	O
treated	FANAPT.xml:S1:2838:7	O
with	FANAPT.xml:S1:2846:4	O
placebo	FANAPT.xml:S1:2851:7	O
.	FANAPT.xml:S1:2858:1	O

Table	FANAPT.xml:S1:2865:5	O
7	FANAPT.xml:S1:2871:1	O
:	FANAPT.xml:S1:2872:1	O
Percentage	FANAPT.xml:S1:2874:10	O
of	FANAPT.xml:S1:2885:2	O
Treatment	FANAPT.xml:S1:2888:9	O
-	FANAPT.xml:S1:2897:1	O
Emergent	FANAPT.xml:S1:2898:8	O
Adverse	FANAPT.xml:S1:2907:7	O
Reactions	FANAPT.xml:S1:2915:9	O
in	FANAPT.xml:S1:2925:2	O
Short	FANAPT.xml:S1:2928:5	O
-	FANAPT.xml:S1:2933:1	O
Term	FANAPT.xml:S1:2934:4	O
,	FANAPT.xml:S1:2938:1	O
Fixed	FANAPT.xml:S1:2940:5	O
-	FANAPT.xml:S1:2945:1	O
or	FANAPT.xml:S1:2947:2	O
Flexible	FANAPT.xml:S1:2950:8	O
-	FANAPT.xml:S1:2958:1	O
Dose	FANAPT.xml:S1:2959:4	O
,	FANAPT.xml:S1:2963:1	O
Placebo	FANAPT.xml:S1:2965:7	O
-	FANAPT.xml:S1:2972:1	O
Controlled	FANAPT.xml:S1:2973:10	O
Trials	FANAPT.xml:S1:2984:6	O
in	FANAPT.xml:S1:2991:2	O
Adult	FANAPT.xml:S1:2994:5	O
Patients	FANAPT.xml:S1:3000:8	O

Body	FANAPT.xml:S1:3014:4	O
System	FANAPT.xml:S1:3019:6	O
or	FANAPT.xml:S1:3026:2	O
Organ	FANAPT.xml:S1:3029:5	O
Class	FANAPT.xml:S1:3035:5	O
Placebo	FANAPT.xml:S1:3046:7	O
(	FANAPT.xml:S1:3053:1	O
)	FANAPT.xml:S1:3055:1	O
FANAPT	FANAPT.xml:S1:3063:6	O
10	FANAPT.xml:S1:3070:2	O
-	FANAPT.xml:S1:3072:1	O
16	FANAPT.xml:S1:3073:2	O
mg	FANAPT.xml:S1:3076:2	O
day	FANAPT.xml:S1:3079:3	O
(	FANAPT.xml:S1:3082:1	O
)	FANAPT.xml:S1:3084:1	O
FANAPT	FANAPT.xml:S1:3091:6	O
20	FANAPT.xml:S1:3098:2	O
-	FANAPT.xml:S1:3100:1	O
24	FANAPT.xml:S1:3101:2	O
mg	FANAPT.xml:S1:3104:2	O
day	FANAPT.xml:S1:3107:3	O
(	FANAPT.xml:S1:3110:1	O
)	FANAPT.xml:S1:3112:1	O

Dictionary	FANAPT.xml:S1:3126:10	O
-	FANAPT.xml:S1:3136:1	O
derived	FANAPT.xml:S1:3137:7	O
Term	FANAPT.xml:S1:3145:4	O
(	FANAPT.xml:S1:3153:1	O
N	FANAPT.xml:S1:3154:1	O
587	FANAPT.xml:S1:3156:3	O
)	FANAPT.xml:S1:3159:1	O
(	FANAPT.xml:S1:3170:1	O
N	FANAPT.xml:S1:3171:1	O
483	FANAPT.xml:S1:3173:3	O
)	FANAPT.xml:S1:3176:1	O
(	FANAPT.xml:S1:3187:1	O
N	FANAPT.xml:S1:3188:1	O
391	FANAPT.xml:S1:3190:3	O
)	FANAPT.xml:S1:3193:1	O

Body	FANAPT.xml:S1:3207:4	O
as	FANAPT.xml:S1:3212:2	O
a	FANAPT.xml:S1:3215:1	O
Whole	FANAPT.xml:S1:3217:5	O

Arthralgia	FANAPT.xml:S1:3286:10	B-AdverseReaction
2	FANAPT.xml:S1:3298:1	O
3	FANAPT.xml:S1:3315:1	O
3	FANAPT.xml:S1:3332:1	O

Fatigue	FANAPT.xml:S1:3358:7	B-AdverseReaction
3	FANAPT.xml:S1:3369:1	O
4	FANAPT.xml:S1:3386:1	O
6	FANAPT.xml:S1:3403:1	O

Musculoskeletal	FANAPT.xml:S1:3429:15	B-AdverseReaction
Stiffness	FANAPT.xml:S1:3445:9	I-AdverseReaction
1	FANAPT.xml:S1:3456:1	O
1	FANAPT.xml:S1:3473:1	O
3	FANAPT.xml:S1:3490:1	O

Weight	FANAPT.xml:S1:3516:6	B-AdverseReaction
Increased	FANAPT.xml:S1:3523:9	I-AdverseReaction
1	FANAPT.xml:S1:3534:1	O
1	FANAPT.xml:S1:3551:1	O
9	FANAPT.xml:S1:3568:1	O

Cardiac	FANAPT.xml:S1:3590:7	O
Disorders	FANAPT.xml:S1:3598:9	O

Tachycardia	FANAPT.xml:S1:3671:11	B-AdverseReaction
1	FANAPT.xml:S1:3684:1	O
3	FANAPT.xml:S1:3701:1	O
12	FANAPT.xml:S1:3718:2	O

Eye	FANAPT.xml:S1:3740:3	O
Disorders	FANAPT.xml:S1:3744:9	O

Vision	FANAPT.xml:S1:3817:6	B-AdverseReaction
Blurred	FANAPT.xml:S1:3824:7	I-AdverseReaction
2	FANAPT.xml:S1:3833:1	O
3	FANAPT.xml:S1:3850:1	O
1	FANAPT.xml:S1:3867:1	O

Gastrointestinal	FANAPT.xml:S1:3889:16	O
Disorders	FANAPT.xml:S1:3906:9	O

Nausea	FANAPT.xml:S1:3979:6	B-AdverseReaction
8	FANAPT.xml:S1:3990:1	O
7	FANAPT.xml:S1:4007:1	O
10	FANAPT.xml:S1:4024:2	O

Dry	FANAPT.xml:S1:4050:3	B-AdverseReaction
Mouth	FANAPT.xml:S1:4054:5	I-AdverseReaction
1	FANAPT.xml:S1:4061:1	O
8	FANAPT.xml:S1:4078:1	O
10	FANAPT.xml:S1:4095:2	O

Diarrhea	FANAPT.xml:S1:4121:8	B-AdverseReaction
4	FANAPT.xml:S1:4132:1	O
5	FANAPT.xml:S1:4149:1	O
7	FANAPT.xml:S1:4166:1	O

Abdominal	FANAPT.xml:S1:4192:9	B-AdverseReaction
Discomfort	FANAPT.xml:S1:4202:10	I-AdverseReaction
1	FANAPT.xml:S1:4214:1	O
1	FANAPT.xml:S1:4231:1	O
3	FANAPT.xml:S1:4248:1	O

Infections	FANAPT.xml:S1:4270:10	O

Nasopharyngitis	FANAPT.xml:S1:4345:15	B-AdverseReaction
3	FANAPT.xml:S1:4362:1	O
4	FANAPT.xml:S1:4379:1	O
3	FANAPT.xml:S1:4396:1	O

Upper	FANAPT.xml:S1:4422:5	B-AdverseReaction
Respiratory	FANAPT.xml:S1:4428:11	I-AdverseReaction
Tract	FANAPT.xml:S1:4440:5	I-AdverseReaction
Infection	FANAPT.xml:S1:4446:9	I-AdverseReaction
1	FANAPT.xml:S1:4457:1	O
2	FANAPT.xml:S1:4474:1	O
3	FANAPT.xml:S1:4491:1	O

Nervous	FANAPT.xml:S1:4513:7	O
System	FANAPT.xml:S1:4521:6	O
Disorders	FANAPT.xml:S1:4528:9	O

Dizziness	FANAPT.xml:S1:4601:9	B-AdverseReaction
7	FANAPT.xml:S1:4612:1	O
10	FANAPT.xml:S1:4629:2	O
20	FANAPT.xml:S1:4646:2	O

Somnolence	FANAPT.xml:S1:4672:10	B-AdverseReaction
5	FANAPT.xml:S1:4684:1	O
9	FANAPT.xml:S1:4701:1	O
15	FANAPT.xml:S1:4718:2	O

Extrapyramidal	FANAPT.xml:S1:4744:14	B-AdverseReaction
Disorder	FANAPT.xml:S1:4759:8	I-AdverseReaction
4	FANAPT.xml:S1:4769:1	O
5	FANAPT.xml:S1:4786:1	O
4	FANAPT.xml:S1:4803:1	O

Tremor	FANAPT.xml:S1:4829:6	B-AdverseReaction
2	FANAPT.xml:S1:4840:1	O
3	FANAPT.xml:S1:4857:1	O
3	FANAPT.xml:S1:4874:1	O

Lethargy	FANAPT.xml:S1:4900:8	B-AdverseReaction
1	FANAPT.xml:S1:4911:1	O
3	FANAPT.xml:S1:4928:1	O
1	FANAPT.xml:S1:4945:1	O

Reproductive	FANAPT.xml:S1:4967:12	O
System	FANAPT.xml:S1:4980:6	O

Ejaculation	FANAPT.xml:S1:5050:11	B-AdverseReaction
Failure	FANAPT.xml:S1:5062:7	I-AdverseReaction
1	FANAPT.xml:S1:5072:1	O
2	FANAPT.xml:S1:5088:1	O
2	FANAPT.xml:S1:5105:1	O

Respiratory	FANAPT.xml:S1:5127:11	O

Nasal	FANAPT.xml:S1:5202:5	B-AdverseReaction
Congestion	FANAPT.xml:S1:5208:10	I-AdverseReaction
2	FANAPT.xml:S1:5220:1	O
5	FANAPT.xml:S1:5237:1	O
8	FANAPT.xml:S1:5254:1	O

Dyspnea	FANAPT.xml:S1:5280:7	B-AdverseReaction
1	FANAPT.xml:S1:5292:1	O
2	FANAPT.xml:S1:5308:1	O
2	FANAPT.xml:S1:5325:1	O

Skin	FANAPT.xml:S1:5347:4	O

Rash	FANAPT.xml:S1:5422:4	B-AdverseReaction
2	FANAPT.xml:S1:5433:1	O
3	FANAPT.xml:S1:5450:1	O
2	FANAPT.xml:S1:5467:1	O

Vascular	FANAPT.xml:S1:5489:8	O
Disorders	FANAPT.xml:S1:5498:9	O

Orthostatic	FANAPT.xml:S1:5571:11	B-AdverseReaction
Hypotension	FANAPT.xml:S1:5583:11	I-AdverseReaction
1	FANAPT.xml:S1:5596:1	O
3	FANAPT.xml:S1:5613:1	O
5	FANAPT.xml:S1:5630:1	O

Hypotension	FANAPT.xml:S1:5656:11	B-AdverseReaction
1	FANAPT.xml:S1:5670:1	O
1	FANAPT.xml:S1:5687:1	O
3	FANAPT.xml:S1:5703:1	O

Table	FANAPT.xml:S1:5734:5	O
includes	FANAPT.xml:S1:5740:8	O
adverse	FANAPT.xml:S1:5749:7	O
reactions	FANAPT.xml:S1:5757:9	O
that	FANAPT.xml:S1:5767:4	O
were	FANAPT.xml:S1:5772:4	O
reported	FANAPT.xml:S1:5777:8	O
in	FANAPT.xml:S1:5786:2	O
2%	FANAPT.xml:S1:5789:2	O
or	FANAPT.xml:S1:5792:2	O
more	FANAPT.xml:S1:5795:4	O
of	FANAPT.xml:S1:5800:2	O
patients	FANAPT.xml:S1:5803:8	O
in	FANAPT.xml:S1:5812:2	O
any	FANAPT.xml:S1:5815:3	O
of	FANAPT.xml:S1:5819:2	O
the	FANAPT.xml:S1:5822:3	O
FANAPT	FANAPT.xml:S1:5826:6	O
dose	FANAPT.xml:S1:5833:4	O
groups	FANAPT.xml:S1:5838:6	O
and	FANAPT.xml:S1:5845:3	O
which	FANAPT.xml:S1:5849:5	O
occurred	FANAPT.xml:S1:5855:8	O
at	FANAPT.xml:S1:5864:2	O
greater	FANAPT.xml:S1:5867:7	O
incidence	FANAPT.xml:S1:5875:9	O
than	FANAPT.xml:S1:5885:4	O
in	FANAPT.xml:S1:5890:2	O
the	FANAPT.xml:S1:5893:3	O
placebo	FANAPT.xml:S1:5897:7	O
-	FANAPT.xml:S1:5904:1	O
group	FANAPT.xml:S1:5905:5	O
.	FANAPT.xml:S1:5910:1	O

Figures	FANAPT.xml:S1:5912:7	O
rounded	FANAPT.xml:S1:5920:7	O
to	FANAPT.xml:S1:5928:2	O
the	FANAPT.xml:S1:5931:3	O
nearest	FANAPT.xml:S1:5935:7	O
integer	FANAPT.xml:S1:5943:7	O
.	FANAPT.xml:S1:5950:1	O

Dose	FANAPT.xml:S1:5959:4	O

-	FANAPT.xml:S1:5963:1	O
Related	FANAPT.xml:S1:5964:7	O
Adverse	FANAPT.xml:S1:5972:7	O
Reactions	FANAPT.xml:S1:5980:9	O
in	FANAPT.xml:S1:5990:2	O
Clinical	FANAPT.xml:S1:5993:8	O
Trials	FANAPT.xml:S1:6002:6	O

Based	FANAPT.xml:S1:6015:5	O
on	FANAPT.xml:S1:6021:2	O
the	FANAPT.xml:S1:6024:3	O
pooled	FANAPT.xml:S1:6028:6	O
data	FANAPT.xml:S1:6035:4	O
from	FANAPT.xml:S1:6040:4	O
4	FANAPT.xml:S1:6045:1	O
placebo	FANAPT.xml:S1:6047:7	O
-	FANAPT.xml:S1:6054:1	O
controlled	FANAPT.xml:S1:6055:10	O
,	FANAPT.xml:S1:6065:1	O
4	FANAPT.xml:S1:6067:1	O
-	FANAPT.xml:S1:6068:1	O
or	FANAPT.xml:S1:6070:2	O
6	FANAPT.xml:S1:6073:1	O
-	FANAPT.xml:S1:6074:1	O
week	FANAPT.xml:S1:6075:4	O
,	FANAPT.xml:S1:6079:1	O
fixed	FANAPT.xml:S1:6081:5	O
-	FANAPT.xml:S1:6086:1	O
or	FANAPT.xml:S1:6088:2	O
flexible	FANAPT.xml:S1:6091:8	O
-	FANAPT.xml:S1:6099:1	O
dose	FANAPT.xml:S1:6100:4	O
studies	FANAPT.xml:S1:6105:7	O
,	FANAPT.xml:S1:6112:1	O
adverse	FANAPT.xml:S1:6114:7	O
reactions	FANAPT.xml:S1:6122:9	O
that	FANAPT.xml:S1:6132:4	O
occurred	FANAPT.xml:S1:6137:8	O
with	FANAPT.xml:S1:6146:4	O
a	FANAPT.xml:S1:6151:1	O
greater	FANAPT.xml:S1:6153:7	O
than	FANAPT.xml:S1:6161:4	O
2%	FANAPT.xml:S1:6166:2	O
incidence	FANAPT.xml:S1:6169:9	O
in	FANAPT.xml:S1:6179:2	O
the	FANAPT.xml:S1:6182:3	O
patients	FANAPT.xml:S1:6186:8	O
treated	FANAPT.xml:S1:6195:7	O
with	FANAPT.xml:S1:6203:4	O
FANAPT	FANAPT.xml:S1:6208:6	O
,	FANAPT.xml:S1:6214:1	O
and	FANAPT.xml:S1:6216:3	O
for	FANAPT.xml:S1:6220:3	O
which	FANAPT.xml:S1:6224:5	O
the	FANAPT.xml:S1:6230:3	O
incidence	FANAPT.xml:S1:6234:9	O
in	FANAPT.xml:S1:6244:2	O
patients	FANAPT.xml:S1:6247:8	O
treated	FANAPT.xml:S1:6256:7	O
with	FANAPT.xml:S1:6264:4	O
FANAPT	FANAPT.xml:S1:6269:6	O
20	FANAPT.xml:S1:6280:2	O
to	FANAPT.xml:S1:6283:2	O
24	FANAPT.xml:S1:6286:2	O
mg	FANAPT.xml:S1:6289:2	O
day	FANAPT.xml:S1:6292:3	O
were	FANAPT.xml:S1:6296:4	O
twice	FANAPT.xml:S1:6301:5	O
than	FANAPT.xml:S1:6307:4	O
the	FANAPT.xml:S1:6312:3	O
incidence	FANAPT.xml:S1:6316:9	O
in	FANAPT.xml:S1:6326:2	O
patients	FANAPT.xml:S1:6329:8	O
treated	FANAPT.xml:S1:6338:7	O
with	FANAPT.xml:S1:6346:4	O
FANAPT	FANAPT.xml:S1:6351:6	O
10	FANAPT.xml:S1:6358:2	O
to	FANAPT.xml:S1:6361:2	O
16	FANAPT.xml:S1:6364:2	O
mg	FANAPT.xml:S1:6367:2	O
day	FANAPT.xml:S1:6370:3	O
were	FANAPT.xml:S1:6374:4	O
:	FANAPT.xml:S1:6378:1	O
abdominal	FANAPT.xml:S1:6380:9	B-AdverseReaction
discomfort	FANAPT.xml:S1:6390:10	I-AdverseReaction
,	FANAPT.xml:S1:6400:1	O
dizziness	FANAPT.xml:S1:6402:9	B-AdverseReaction
,	FANAPT.xml:S1:6411:1	O
hypotension	FANAPT.xml:S1:6413:11	B-AdverseReaction
,	FANAPT.xml:S1:6424:1	O
musculoskeletal	FANAPT.xml:S1:6426:15	B-AdverseReaction
stiffness	FANAPT.xml:S1:6442:9	I-AdverseReaction
,	FANAPT.xml:S1:6451:1	O
tachycardia	FANAPT.xml:S1:6453:11	B-AdverseReaction
,	FANAPT.xml:S1:6464:1	O
and	FANAPT.xml:S1:6466:3	O
weight	FANAPT.xml:S1:6470:6	B-AdverseReaction
increased	FANAPT.xml:S1:6477:9	I-AdverseReaction
.	FANAPT.xml:S1:6486:1	O

Common	FANAPT.xml:S1:6495:6	O
and	FANAPT.xml:S1:6502:3	O
Drug	FANAPT.xml:S1:6506:4	O
-	FANAPT.xml:S1:6510:1	O
Related	FANAPT.xml:S1:6511:7	O
Adverse	FANAPT.xml:S1:6519:7	O
Reactions	FANAPT.xml:S1:6527:9	O
in	FANAPT.xml:S1:6537:2	O
Clinical	FANAPT.xml:S1:6540:8	O
Trials	FANAPT.xml:S1:6549:6	O

Based	FANAPT.xml:S1:6562:5	O
on	FANAPT.xml:S1:6568:2	O
the	FANAPT.xml:S1:6571:3	O
pooled	FANAPT.xml:S1:6575:6	O
data	FANAPT.xml:S1:6582:4	O
from	FANAPT.xml:S1:6587:4	O
4	FANAPT.xml:S1:6592:1	O
placebo	FANAPT.xml:S1:6594:7	O
-	FANAPT.xml:S1:6601:1	O
controlled	FANAPT.xml:S1:6602:10	O
,	FANAPT.xml:S1:6612:1	O
4	FANAPT.xml:S1:6614:1	O
-	FANAPT.xml:S1:6615:1	O
or	FANAPT.xml:S1:6617:2	O
6	FANAPT.xml:S1:6620:1	O
-	FANAPT.xml:S1:6621:1	O
week	FANAPT.xml:S1:6622:4	O
,	FANAPT.xml:S1:6626:1	O
fixed	FANAPT.xml:S1:6628:5	O
-	FANAPT.xml:S1:6633:1	O
or	FANAPT.xml:S1:6635:2	O
flexible	FANAPT.xml:S1:6638:8	O
-	FANAPT.xml:S1:6646:1	O
dose	FANAPT.xml:S1:6647:4	O
studies	FANAPT.xml:S1:6652:7	O
,	FANAPT.xml:S1:6659:1	O
the	FANAPT.xml:S1:6661:3	O
following	FANAPT.xml:S1:6665:9	O
adverse	FANAPT.xml:S1:6675:7	O
reactions	FANAPT.xml:S1:6683:9	O
occurred	FANAPT.xml:S1:6693:8	O
in	FANAPT.xml:S1:6702:2	O
5%	FANAPT.xml:S1:6707:2	O
incidence	FANAPT.xml:S1:6710:9	O
in	FANAPT.xml:S1:6720:2	O
the	FANAPT.xml:S1:6723:3	O
patients	FANAPT.xml:S1:6727:8	O
treated	FANAPT.xml:S1:6736:7	O
with	FANAPT.xml:S1:6744:4	O
FANAPT	FANAPT.xml:S1:6749:6	O
and	FANAPT.xml:S1:6756:3	O
at	FANAPT.xml:S1:6760:2	O
least	FANAPT.xml:S1:6763:5	O
twice	FANAPT.xml:S1:6769:5	O
the	FANAPT.xml:S1:6775:3	O
placebo	FANAPT.xml:S1:6779:7	O
rate	FANAPT.xml:S1:6787:4	O
for	FANAPT.xml:S1:6792:3	O
at	FANAPT.xml:S1:6796:2	O
least	FANAPT.xml:S1:6799:5	O
1	FANAPT.xml:S1:6805:1	O
dose	FANAPT.xml:S1:6807:4	O
:	FANAPT.xml:S1:6811:1	O
dizziness	FANAPT.xml:S1:6813:9	B-AdverseReaction
,	FANAPT.xml:S1:6822:1	O
dry	FANAPT.xml:S1:6824:3	B-AdverseReaction
mouth	FANAPT.xml:S1:6828:5	I-AdverseReaction
,	FANAPT.xml:S1:6833:1	O
fatigue	FANAPT.xml:S1:6835:7	B-AdverseReaction
,	FANAPT.xml:S1:6842:1	O
nasal	FANAPT.xml:S1:6844:5	B-AdverseReaction
congestion	FANAPT.xml:S1:6850:10	I-AdverseReaction
,	FANAPT.xml:S1:6860:1	O
somnolence	FANAPT.xml:S1:6862:10	B-AdverseReaction
,	FANAPT.xml:S1:6872:1	O
tachycardia	FANAPT.xml:S1:6874:11	B-AdverseReaction
,	FANAPT.xml:S1:6885:1	O
orthostatic	FANAPT.xml:S1:6887:11	B-AdverseReaction
hypotension	FANAPT.xml:S1:6899:11	I-AdverseReaction
,	FANAPT.xml:S1:6910:1	O
and	FANAPT.xml:S1:6912:3	O
weight	FANAPT.xml:S1:6916:6	B-AdverseReaction
increased	FANAPT.xml:S1:6923:9	I-AdverseReaction
.	FANAPT.xml:S1:6932:1	O

Dizziness	FANAPT.xml:S1:6934:9	B-AdverseReaction
,	FANAPT.xml:S1:6943:1	O
tachycardia	FANAPT.xml:S1:6945:11	B-AdverseReaction
,	FANAPT.xml:S1:6956:1	O
and	FANAPT.xml:S1:6958:3	O
weight	FANAPT.xml:S1:6962:6	B-AdverseReaction
increased	FANAPT.xml:S1:6969:9	I-AdverseReaction
were	FANAPT.xml:S1:6979:4	O
at	FANAPT.xml:S1:6984:2	O
least	FANAPT.xml:S1:6987:5	O
twice	FANAPT.xml:S1:6993:5	O
as	FANAPT.xml:S1:6999:2	O
common	FANAPT.xml:S1:7002:6	O
on	FANAPT.xml:S1:7009:2	O
20	FANAPT.xml:S1:7012:2	O
to	FANAPT.xml:S1:7015:2	O
24	FANAPT.xml:S1:7018:2	O
mg	FANAPT.xml:S1:7021:2	O
day	FANAPT.xml:S1:7024:3	O
as	FANAPT.xml:S1:7028:2	O
on	FANAPT.xml:S1:7031:2	O
10	FANAPT.xml:S1:7034:2	O
to	FANAPT.xml:S1:7037:2	O
16	FANAPT.xml:S1:7040:2	O
mg	FANAPT.xml:S1:7043:2	O
day	FANAPT.xml:S1:7046:3	O
.	FANAPT.xml:S1:7049:1	O

Extrapyramidal	FANAPT.xml:S1:7057:14	O
Symptoms	FANAPT.xml:S1:7072:8	O
(	FANAPT.xml:S1:7081:1	O
EPS	FANAPT.xml:S1:7082:3	O
)	FANAPT.xml:S1:7085:1	O
in	FANAPT.xml:S1:7087:2	O
Clinical	FANAPT.xml:S1:7090:8	O
Trials	FANAPT.xml:S1:7099:6	O

Pooled	FANAPT.xml:S1:7112:6	O
data	FANAPT.xml:S1:7119:4	O
from	FANAPT.xml:S1:7124:4	O
the	FANAPT.xml:S1:7129:3	O
4	FANAPT.xml:S1:7133:1	O
placebo	FANAPT.xml:S1:7135:7	O
-	FANAPT.xml:S1:7142:1	O
controlled	FANAPT.xml:S1:7143:10	O
,	FANAPT.xml:S1:7153:1	O
4	FANAPT.xml:S1:7155:1	O
-	FANAPT.xml:S1:7156:1	O
or	FANAPT.xml:S1:7158:2	O
6	FANAPT.xml:S1:7161:1	O
-	FANAPT.xml:S1:7162:1	O
week	FANAPT.xml:S1:7163:4	O
,	FANAPT.xml:S1:7167:1	O
fixed	FANAPT.xml:S1:7169:5	O
-	FANAPT.xml:S1:7174:1	O
or	FANAPT.xml:S1:7176:2	O
flexible	FANAPT.xml:S1:7179:8	O
-	FANAPT.xml:S1:7187:1	O
dose	FANAPT.xml:S1:7188:4	O
studies	FANAPT.xml:S1:7193:7	O
provided	FANAPT.xml:S1:7201:8	O
information	FANAPT.xml:S1:7210:11	O
regarding	FANAPT.xml:S1:7222:9	O
treatment	FANAPT.xml:S1:7232:9	O
-	FANAPT.xml:S1:7241:1	O
emergent	FANAPT.xml:S1:7242:8	O
EPS	FANAPT.xml:S1:7251:3	B-AdverseReaction
.	FANAPT.xml:S1:7254:1	O

Adverse	FANAPT.xml:S1:7256:7	O
event	FANAPT.xml:S1:7264:5	O
data	FANAPT.xml:S1:7270:4	O
collected	FANAPT.xml:S1:7275:9	O
from	FANAPT.xml:S1:7285:4	O
those	FANAPT.xml:S1:7290:5	O
trials	FANAPT.xml:S1:7296:6	O
showed	FANAPT.xml:S1:7303:6	O
the	FANAPT.xml:S1:7310:3	O
following	FANAPT.xml:S1:7314:9	O
rates	FANAPT.xml:S1:7324:5	O
of	FANAPT.xml:S1:7330:2	O
EPS	FANAPT.xml:S1:7333:3	B-AdverseReaction
-	FANAPT.xml:S1:7336:1	I-AdverseReaction
related	FANAPT.xml:S1:7337:7	I-AdverseReaction
adverse	FANAPT.xml:S1:7345:7	I-AdverseReaction
events	FANAPT.xml:S1:7353:6	I-AdverseReaction
as	FANAPT.xml:S1:7360:2	O
shown	FANAPT.xml:S1:7363:5	O
in	FANAPT.xml:S1:7369:2	O
Table	FANAPT.xml:S1:7372:5	O
8	FANAPT.xml:S1:7378:1	O
.	FANAPT.xml:S1:7379:1	O

Table	FANAPT.xml:S1:7385:5	O
8	FANAPT.xml:S1:7391:1	O
:	FANAPT.xml:S1:7392:1	O
Percentage	FANAPT.xml:S1:7394:10	O
of	FANAPT.xml:S1:7405:2	O
EPS	FANAPT.xml:S1:7408:3	B-AdverseReaction
Compared	FANAPT.xml:S1:7412:8	O
to	FANAPT.xml:S1:7421:2	O
Placebo	FANAPT.xml:S1:7424:7	O

Placebo	FANAPT.xml:S1:7453:7	O
(	FANAPT.xml:S1:7460:1	O
)	FANAPT.xml:S1:7462:1	O
FANAPT	FANAPT.xml:S1:7470:6	O
10	FANAPT.xml:S1:7477:2	O
-	FANAPT.xml:S1:7479:1	O
16	FANAPT.xml:S1:7480:2	O
mg	FANAPT.xml:S1:7483:2	O
day	FANAPT.xml:S1:7486:3	O
(	FANAPT.xml:S1:7489:1	O
)	FANAPT.xml:S1:7491:1	O
FANAPT	FANAPT.xml:S1:7498:6	O
20	FANAPT.xml:S1:7505:2	O
-	FANAPT.xml:S1:7507:1	O
24	FANAPT.xml:S1:7508:2	O
mg	FANAPT.xml:S1:7511:2	O
day	FANAPT.xml:S1:7514:3	O
(	FANAPT.xml:S1:7517:1	O
)	FANAPT.xml:S1:7519:1	O

Adverse	FANAPT.xml:S1:7529:7	O
Event	FANAPT.xml:S1:7537:5	O
Term	FANAPT.xml:S1:7543:4	O
(	FANAPT.xml:S1:7553:1	O
N	FANAPT.xml:S1:7554:1	O
587	FANAPT.xml:S1:7556:3	O
)	FANAPT.xml:S1:7559:1	O
(	FANAPT.xml:S1:7570:1	O
N	FANAPT.xml:S1:7571:1	O
483	FANAPT.xml:S1:7573:3	O
)	FANAPT.xml:S1:7576:1	O
(	FANAPT.xml:S1:7587:1	O
N	FANAPT.xml:S1:7588:1	O
391	FANAPT.xml:S1:7590:3	O
)	FANAPT.xml:S1:7593:1	O

All	FANAPT.xml:S1:7607:3	O
EPS	FANAPT.xml:S1:7611:3	O
events	FANAPT.xml:S1:7615:6	O
11.6	FANAPT.xml:S1:7627:4	O
13.5	FANAPT.xml:S1:7644:4	O
15.1	FANAPT.xml:S1:7661:4	O

Akathisia	FANAPT.xml:S1:7679:9	B-AdverseReaction
2.7	FANAPT.xml:S1:7696:3	O
1.7	FANAPT.xml:S1:7713:3	O
2.3	FANAPT.xml:S1:7730:3	O

Bradykinesia	FANAPT.xml:S1:7750:12	B-AdverseReaction
0	FANAPT.xml:S1:7767:1	O
0.6	FANAPT.xml:S1:7784:3	O
0.5	FANAPT.xml:S1:7801:3	O

Dyskinesia	FANAPT.xml:S1:7821:10	B-AdverseReaction
1.5	FANAPT.xml:S1:7838:3	O
1.7	FANAPT.xml:S1:7855:3	O
1.0	FANAPT.xml:S1:7872:3	O

Dystonia	FANAPT.xml:S1:7892:8	B-AdverseReaction
0.7	FANAPT.xml:S1:7909:3	O
1.0	FANAPT.xml:S1:7926:3	O
0.8	FANAPT.xml:S1:7943:3	O

Parkinsonism	FANAPT.xml:S1:7963:12	B-AdverseReaction
0	FANAPT.xml:S1:7980:1	O
0.2	FANAPT.xml:S1:7997:3	O
0.3	FANAPT.xml:S1:8014:3	O

Tremor	FANAPT.xml:S1:8034:6	B-AdverseReaction
1.9	FANAPT.xml:S1:8051:3	O
2.5	FANAPT.xml:S1:8068:3	O
3.1	FANAPT.xml:S1:8085:3	O

Adverse	FANAPT.xml:S1:8116:7	O
Reactions	FANAPT.xml:S1:8124:9	O
Associated	FANAPT.xml:S1:8134:10	O
with	FANAPT.xml:S1:8145:4	O
Discontinuation	FANAPT.xml:S1:8150:15	O
of	FANAPT.xml:S1:8166:2	O
Treatment	FANAPT.xml:S1:8169:9	O
in	FANAPT.xml:S1:8179:2	O
Clinical	FANAPT.xml:S1:8182:8	O
Trials	FANAPT.xml:S1:8191:6	O

Based	FANAPT.xml:S1:8204:5	O

on	FANAPT.xml:S1:8210:2	O
the	FANAPT.xml:S1:8213:3	O
pooled	FANAPT.xml:S1:8217:6	O
data	FANAPT.xml:S1:8224:4	O
from	FANAPT.xml:S1:8229:4	O
4	FANAPT.xml:S1:8234:1	O
placebo	FANAPT.xml:S1:8236:7	O
-	FANAPT.xml:S1:8243:1	O
controlled	FANAPT.xml:S1:8244:10	O
,	FANAPT.xml:S1:8254:1	O
4	FANAPT.xml:S1:8256:1	O
-	FANAPT.xml:S1:8257:1	O
or	FANAPT.xml:S1:8259:2	O
6	FANAPT.xml:S1:8262:1	O
-	FANAPT.xml:S1:8263:1	O
week	FANAPT.xml:S1:8264:4	O
,	FANAPT.xml:S1:8268:1	O
fixed	FANAPT.xml:S1:8270:5	O
-	FANAPT.xml:S1:8275:1	O
or	FANAPT.xml:S1:8277:2	O
flexible	FANAPT.xml:S1:8280:8	O
-	FANAPT.xml:S1:8288:1	O
dose	FANAPT.xml:S1:8289:4	O
studies	FANAPT.xml:S1:8294:7	O
,	FANAPT.xml:S1:8301:1	O
there	FANAPT.xml:S1:8303:5	O
was	FANAPT.xml:S1:8309:3	O
no	FANAPT.xml:S1:8313:2	O
difference	FANAPT.xml:S1:8316:10	O
in	FANAPT.xml:S1:8327:2	O
the	FANAPT.xml:S1:8330:3	O
incidence	FANAPT.xml:S1:8334:9	O
of	FANAPT.xml:S1:8344:2	O
discontinuation	FANAPT.xml:S1:8347:15	O
due	FANAPT.xml:S1:8363:3	O
to	FANAPT.xml:S1:8367:2	O
adverse	FANAPT.xml:S1:8370:7	O
events	FANAPT.xml:S1:8378:6	O
between	FANAPT.xml:S1:8385:7	O
FANAPT	FANAPT.xml:S1:8393:6	O
-	FANAPT.xml:S1:8399:1	O
treated	FANAPT.xml:S1:8400:7	O
(	FANAPT.xml:S1:8408:1	O
5%	FANAPT.xml:S1:8409:2	O
)	FANAPT.xml:S1:8411:1	O
and	FANAPT.xml:S1:8413:3	O
placebo	FANAPT.xml:S1:8417:7	O
-	FANAPT.xml:S1:8424:1	O
treated	FANAPT.xml:S1:8425:7	O
(	FANAPT.xml:S1:8433:1	O
5%	FANAPT.xml:S1:8434:2	O
)	FANAPT.xml:S1:8436:1	O
patients	FANAPT.xml:S1:8438:8	O
.	FANAPT.xml:S1:8446:1	O

The	FANAPT.xml:S1:8448:3	O
types	FANAPT.xml:S1:8452:5	O
of	FANAPT.xml:S1:8458:2	O
adverse	FANAPT.xml:S1:8461:7	O
events	FANAPT.xml:S1:8469:6	O
that	FANAPT.xml:S1:8476:4	O
led	FANAPT.xml:S1:8481:3	O
to	FANAPT.xml:S1:8485:2	O
discontinuation	FANAPT.xml:S1:8488:15	O
were	FANAPT.xml:S1:8504:4	O
similar	FANAPT.xml:S1:8509:7	O
for	FANAPT.xml:S1:8517:3	O
the	FANAPT.xml:S1:8521:3	O
FANAPT	FANAPT.xml:S1:8525:6	O
-	FANAPT.xml:S1:8531:1	O
and	FANAPT.xml:S1:8533:3	O
placebo	FANAPT.xml:S1:8537:7	O
-	FANAPT.xml:S1:8544:1	O
treated	FANAPT.xml:S1:8545:7	O
patients	FANAPT.xml:S1:8553:8	O
.	FANAPT.xml:S1:8561:1	O

Demographic	FANAPT.xml:S1:8569:11	O
Differences	FANAPT.xml:S1:8581:11	O
in	FANAPT.xml:S1:8593:2	O
Adverse	FANAPT.xml:S1:8596:7	O
Reactions	FANAPT.xml:S1:8604:9	O
in	FANAPT.xml:S1:8614:2	O
Clinical	FANAPT.xml:S1:8617:8	O
Trials	FANAPT.xml:S1:8626:6	O

An	FANAPT.xml:S1:8639:2	O
examination	FANAPT.xml:S1:8642:11	O
of	FANAPT.xml:S1:8654:2	O
population	FANAPT.xml:S1:8657:10	O
subgroups	FANAPT.xml:S1:8668:9	O
in	FANAPT.xml:S1:8678:2	O
the	FANAPT.xml:S1:8681:3	O
4	FANAPT.xml:S1:8685:1	O
placebo	FANAPT.xml:S1:8687:7	O
-	FANAPT.xml:S1:8694:1	O
controlled	FANAPT.xml:S1:8695:10	O
,	FANAPT.xml:S1:8705:1	O
4	FANAPT.xml:S1:8707:1	O
-	FANAPT.xml:S1:8708:1	O
or	FANAPT.xml:S1:8710:2	O
6	FANAPT.xml:S1:8713:1	O
-	FANAPT.xml:S1:8714:1	O
week	FANAPT.xml:S1:8715:4	O
,	FANAPT.xml:S1:8719:1	O
fixed	FANAPT.xml:S1:8721:5	O
-	FANAPT.xml:S1:8726:1	O
or	FANAPT.xml:S1:8728:2	O
flexible	FANAPT.xml:S1:8731:8	O
-	FANAPT.xml:S1:8739:1	O
dose	FANAPT.xml:S1:8740:4	O
studies	FANAPT.xml:S1:8745:7	O
did	FANAPT.xml:S1:8753:3	O
not	FANAPT.xml:S1:8757:3	O
reveal	FANAPT.xml:S1:8761:6	O
any	FANAPT.xml:S1:8768:3	O
evidence	FANAPT.xml:S1:8772:8	O
of	FANAPT.xml:S1:8781:2	O
differences	FANAPT.xml:S1:8784:11	O
in	FANAPT.xml:S1:8796:2	O
safety	FANAPT.xml:S1:8799:6	O
on	FANAPT.xml:S1:8806:2	O
the	FANAPT.xml:S1:8809:3	O
basis	FANAPT.xml:S1:8813:5	O
of	FANAPT.xml:S1:8819:2	O
age	FANAPT.xml:S1:8822:3	O
,	FANAPT.xml:S1:8825:1	O
gender	FANAPT.xml:S1:8827:6	O
or	FANAPT.xml:S1:8834:2	O
race	FANAPT.xml:S1:8837:4	O
[	FANAPT.xml:S1:8843:1	O
see	FANAPT.xml:S1:8844:3	O
Warnings	FANAPT.xml:S1:8848:8	O
and	FANAPT.xml:S1:8857:3	O
Precautions	FANAPT.xml:S1:8861:11	O
(	FANAPT.xml:S1:8873:1	O
5.1	FANAPT.xml:S1:8874:3	O
)]	FANAPT.xml:S1:8877:2	O
.	FANAPT.xml:S1:8881:1	O

Laboratory	FANAPT.xml:S1:8889:10	O
Test	FANAPT.xml:S1:8900:4	O
Abnormalities	FANAPT.xml:S1:8905:13	O
in	FANAPT.xml:S1:8919:2	O
Clinical	FANAPT.xml:S1:8922:8	O
Trials	FANAPT.xml:S1:8931:6	O

There	FANAPT.xml:S1:8944:5	O
were	FANAPT.xml:S1:8950:4	O
no	FANAPT.xml:S1:8955:2	O
differences	FANAPT.xml:S1:8958:11	O
between	FANAPT.xml:S1:8970:7	O
FANAPT	FANAPT.xml:S1:8978:6	O
and	FANAPT.xml:S1:8985:3	O
placebo	FANAPT.xml:S1:8989:7	O
in	FANAPT.xml:S1:8997:2	O
the	FANAPT.xml:S1:9000:3	O
incidence	FANAPT.xml:S1:9004:9	O
of	FANAPT.xml:S1:9014:2	O
discontinuation	FANAPT.xml:S1:9017:15	O
due	FANAPT.xml:S1:9033:3	O
to	FANAPT.xml:S1:9037:2	O
changes	FANAPT.xml:S1:9040:7	O
in	FANAPT.xml:S1:9048:2	O
hematology	FANAPT.xml:S1:9051:10	O
,	FANAPT.xml:S1:9061:1	O
urinalysis	FANAPT.xml:S1:9063:10	O
,	FANAPT.xml:S1:9073:1	O
or	FANAPT.xml:S1:9075:2	O
serum	FANAPT.xml:S1:9078:5	O
chemistry	FANAPT.xml:S1:9084:9	O
.	FANAPT.xml:S1:9093:1	O

In	FANAPT.xml:S1:9099:2	O
short	FANAPT.xml:S1:9102:5	O
-	FANAPT.xml:S1:9107:1	O
term	FANAPT.xml:S1:9108:4	O
placebo	FANAPT.xml:S1:9113:7	O
-	FANAPT.xml:S1:9120:1	O
controlled	FANAPT.xml:S1:9121:10	O
trials	FANAPT.xml:S1:9132:6	O
(	FANAPT.xml:S1:9139:1	O
4	FANAPT.xml:S1:9140:1	O
-	FANAPT.xml:S1:9141:1	O
to	FANAPT.xml:S1:9143:2	O
6	FANAPT.xml:S1:9146:1	O
-	FANAPT.xml:S1:9147:1	O
weeks	FANAPT.xml:S1:9148:5	O
)	FANAPT.xml:S1:9153:1	O
,	FANAPT.xml:S1:9154:1	O
there	FANAPT.xml:S1:9156:5	O
were	FANAPT.xml:S1:9162:4	O
1.0%	FANAPT.xml:S1:9167:4	O
(	FANAPT.xml:S1:9172:1	O
13	FANAPT.xml:S1:9173:2	O
1342	FANAPT.xml:S1:9176:4	O
)	FANAPT.xml:S1:9180:1	O
iloperidone	FANAPT.xml:S1:9182:11	O
-	FANAPT.xml:S1:9193:1	O
treated	FANAPT.xml:S1:9194:7	O
patients	FANAPT.xml:S1:9202:8	O
with	FANAPT.xml:S1:9211:4	O
hematocrit	FANAPT.xml:S1:9216:10	B-AdverseReaction
at	FANAPT.xml:S1:9227:2	O
least	FANAPT.xml:S1:9230:5	O
one	FANAPT.xml:S1:9236:3	O
time	FANAPT.xml:S1:9240:4	O
below	FANAPT.xml:S1:9245:5	I-AdverseReaction
the	FANAPT.xml:S1:9251:3	I-AdverseReaction
extended	FANAPT.xml:S1:9255:8	I-AdverseReaction
normal	FANAPT.xml:S1:9264:6	I-AdverseReaction
range	FANAPT.xml:S1:9271:5	I-AdverseReaction
during	FANAPT.xml:S1:9277:6	O
post	FANAPT.xml:S1:9284:4	O
-	FANAPT.xml:S1:9288:1	O
randomization	FANAPT.xml:S1:9289:13	O
treatment	FANAPT.xml:S1:9303:9	O
,	FANAPT.xml:S1:9312:1	O
compared	FANAPT.xml:S1:9314:8	O
to	FANAPT.xml:S1:9323:2	O
0.3%	FANAPT.xml:S1:9326:4	O
(	FANAPT.xml:S1:9331:1	O
2	FANAPT.xml:S1:9332:1	O
585	FANAPT.xml:S1:9334:3	O
)	FANAPT.xml:S1:9337:1	O
on	FANAPT.xml:S1:9339:2	O
placebo	FANAPT.xml:S1:9342:7	O
.	FANAPT.xml:S1:9349:1	O

The	FANAPT.xml:S1:9351:3	O
extended	FANAPT.xml:S1:9355:8	O
normal	FANAPT.xml:S1:9364:6	O
range	FANAPT.xml:S1:9371:5	O
for	FANAPT.xml:S1:9377:3	O
lowered	FANAPT.xml:S1:9381:7	O
hematocrit	FANAPT.xml:S1:9389:10	O
was	FANAPT.xml:S1:9400:3	O
defined	FANAPT.xml:S1:9404:7	O
in	FANAPT.xml:S1:9412:2	O
each	FANAPT.xml:S1:9415:4	O
of	FANAPT.xml:S1:9420:2	O
these	FANAPT.xml:S1:9423:5	O
trials	FANAPT.xml:S1:9429:6	O
as	FANAPT.xml:S1:9436:2	O
the	FANAPT.xml:S1:9439:3	O
value	FANAPT.xml:S1:9443:5	O
15%	FANAPT.xml:S1:9449:3	O
below	FANAPT.xml:S1:9453:5	O
the	FANAPT.xml:S1:9459:3	O
normal	FANAPT.xml:S1:9463:6	O
range	FANAPT.xml:S1:9470:5	O
for	FANAPT.xml:S1:9476:3	O
the	FANAPT.xml:S1:9480:3	O
centralized	FANAPT.xml:S1:9484:11	O
laboratory	FANAPT.xml:S1:9496:10	O
that	FANAPT.xml:S1:9507:4	O
was	FANAPT.xml:S1:9512:3	O
used	FANAPT.xml:S1:9516:4	O
in	FANAPT.xml:S1:9521:2	O
the	FANAPT.xml:S1:9524:3	O
trial	FANAPT.xml:S1:9528:5	O
.	FANAPT.xml:S1:9533:1	O

Other	FANAPT.xml:S1:9542:5	O
Reactions	FANAPT.xml:S1:9548:9	O
During	FANAPT.xml:S1:9558:6	O
the	FANAPT.xml:S1:9565:3	O
Premarketing	FANAPT.xml:S1:9569:12	O
Evaluation	FANAPT.xml:S1:9582:10	O
of	FANAPT.xml:S1:9593:2	O
FANAPT	FANAPT.xml:S1:9596:6	O

The	FANAPT.xml:S1:9609:3	O
following	FANAPT.xml:S1:9613:9	O
is	FANAPT.xml:S1:9623:2	O
a	FANAPT.xml:S1:9626:1	O
list	FANAPT.xml:S1:9628:4	O
of	FANAPT.xml:S1:9633:2	O
MedDRA	FANAPT.xml:S1:9636:6	O
terms	FANAPT.xml:S1:9643:5	O
that	FANAPT.xml:S1:9649:4	O
reflect	FANAPT.xml:S1:9654:7	O
treatment	FANAPT.xml:S1:9662:9	O
-	FANAPT.xml:S1:9671:1	O
emergent	FANAPT.xml:S1:9672:8	O
adverse	FANAPT.xml:S1:9681:7	O
reactions	FANAPT.xml:S1:9689:9	O
in	FANAPT.xml:S1:9699:2	O
patients	FANAPT.xml:S1:9702:8	O
treated	FANAPT.xml:S1:9711:7	O
with	FANAPT.xml:S1:9719:4	O
FANAPT	FANAPT.xml:S1:9724:6	O
at	FANAPT.xml:S1:9731:2	O
multiple	FANAPT.xml:S1:9734:8	O
doses	FANAPT.xml:S1:9743:5	O
4	FANAPT.xml:S1:9751:1	O
mg	FANAPT.xml:S1:9753:2	O
day	FANAPT.xml:S1:9756:3	O
during	FANAPT.xml:S1:9760:6	O
any	FANAPT.xml:S1:9767:3	O
phase	FANAPT.xml:S1:9771:5	O
of	FANAPT.xml:S1:9777:2	O
a	FANAPT.xml:S1:9780:1	O
trial	FANAPT.xml:S1:9782:5	O
with	FANAPT.xml:S1:9788:4	O
the	FANAPT.xml:S1:9793:3	O
database	FANAPT.xml:S1:9797:8	O
of	FANAPT.xml:S1:9806:2	O
3210	FANAPT.xml:S1:9809:4	O
FANAPT	FANAPT.xml:S1:9814:6	O
-	FANAPT.xml:S1:9820:1	O
treated	FANAPT.xml:S1:9821:7	O
patients	FANAPT.xml:S1:9829:8	O
.	FANAPT.xml:S1:9837:1	O

All	FANAPT.xml:S1:9839:3	O
reported	FANAPT.xml:S1:9843:8	O
reactions	FANAPT.xml:S1:9852:9	O
are	FANAPT.xml:S1:9862:3	O
included	FANAPT.xml:S1:9866:8	O
except	FANAPT.xml:S1:9875:6	O
those	FANAPT.xml:S1:9882:5	O
already	FANAPT.xml:S1:9888:7	O
listed	FANAPT.xml:S1:9896:6	O
in	FANAPT.xml:S1:9903:2	O
Table	FANAPT.xml:S1:9906:5	O
7	FANAPT.xml:S1:9912:1	O
,	FANAPT.xml:S1:9913:1	O
or	FANAPT.xml:S1:9915:2	O
other	FANAPT.xml:S1:9918:5	O
parts	FANAPT.xml:S1:9924:5	O
of	FANAPT.xml:S1:9930:2	O
the	FANAPT.xml:S1:9933:3	O
Adverse	FANAPT.xml:S1:9938:7	O
Reactions	FANAPT.xml:S1:9946:9	O
(	FANAPT.xml:S1:9956:1	O
6	FANAPT.xml:S1:9957:1	O
)	FANAPT.xml:S1:9958:1	O
section	FANAPT.xml:S1:9961:7	O
,	FANAPT.xml:S1:9968:1	O
those	FANAPT.xml:S1:9970:5	O
considered	FANAPT.xml:S1:9976:10	O
in	FANAPT.xml:S1:9987:2	O
the	FANAPT.xml:S1:9990:3	O
Warnings	FANAPT.xml:S1:9995:8	O
and	FANAPT.xml:S1:10004:3	O
Precautions	FANAPT.xml:S1:10008:11	O
(	FANAPT.xml:S1:10020:1	O
5	FANAPT.xml:S1:10021:1	O
)	FANAPT.xml:S1:10022:1	O
,	FANAPT.xml:S1:10025:1	O
those	FANAPT.xml:S1:10027:5	O
reaction	FANAPT.xml:S1:10033:8	O
terms	FANAPT.xml:S1:10042:5	O
which	FANAPT.xml:S1:10048:5	O
were	FANAPT.xml:S1:10054:4	O
so	FANAPT.xml:S1:10059:2	O
general	FANAPT.xml:S1:10062:7	O
as	FANAPT.xml:S1:10070:2	O
to	FANAPT.xml:S1:10073:2	O
be	FANAPT.xml:S1:10076:2	O
uninformative	FANAPT.xml:S1:10079:13	O
,	FANAPT.xml:S1:10092:1	O
reactions	FANAPT.xml:S1:10094:9	O
reported	FANAPT.xml:S1:10104:8	O
in	FANAPT.xml:S1:10113:2	O
fewer	FANAPT.xml:S1:10116:5	O
than	FANAPT.xml:S1:10122:4	O
3	FANAPT.xml:S1:10127:1	O
patients	FANAPT.xml:S1:10129:8	O
and	FANAPT.xml:S1:10138:3	O
which	FANAPT.xml:S1:10142:5	O
were	FANAPT.xml:S1:10148:4	O
neither	FANAPT.xml:S1:10153:7	O
serious	FANAPT.xml:S1:10161:7	O
nor	FANAPT.xml:S1:10169:3	O
life	FANAPT.xml:S1:10173:4	O
-	FANAPT.xml:S1:10177:1	O
threatening	FANAPT.xml:S1:10178:11	O
,	FANAPT.xml:S1:10189:1	O
reactions	FANAPT.xml:S1:10191:9	O
that	FANAPT.xml:S1:10201:4	O
are	FANAPT.xml:S1:10206:3	O
otherwise	FANAPT.xml:S1:10210:9	O
common	FANAPT.xml:S1:10220:6	O
as	FANAPT.xml:S1:10227:2	O
background	FANAPT.xml:S1:10230:10	O
reactions	FANAPT.xml:S1:10241:9	O
,	FANAPT.xml:S1:10250:1	O
and	FANAPT.xml:S1:10252:3	O
reactions	FANAPT.xml:S1:10256:9	O
considered	FANAPT.xml:S1:10266:10	O
unlikely	FANAPT.xml:S1:10277:8	O
to	FANAPT.xml:S1:10286:2	O
be	FANAPT.xml:S1:10289:2	O
drug	FANAPT.xml:S1:10292:4	O
related	FANAPT.xml:S1:10297:7	O
.	FANAPT.xml:S1:10304:1	O

It	FANAPT.xml:S1:10306:2	O
is	FANAPT.xml:S1:10309:2	O
important	FANAPT.xml:S1:10312:9	O
to	FANAPT.xml:S1:10322:2	O
emphasize	FANAPT.xml:S1:10325:9	O
that	FANAPT.xml:S1:10335:4	O
,	FANAPT.xml:S1:10339:1	O
although	FANAPT.xml:S1:10341:8	O
the	FANAPT.xml:S1:10350:3	O
reactions	FANAPT.xml:S1:10354:9	O
reported	FANAPT.xml:S1:10364:8	O
occurred	FANAPT.xml:S1:10373:8	O
during	FANAPT.xml:S1:10382:6	O
treatment	FANAPT.xml:S1:10389:9	O
with	FANAPT.xml:S1:10399:4	O
FANAPT	FANAPT.xml:S1:10404:6	O
,	FANAPT.xml:S1:10410:1	O
they	FANAPT.xml:S1:10412:4	O
were	FANAPT.xml:S1:10417:4	O
not	FANAPT.xml:S1:10422:3	O
necessarily	FANAPT.xml:S1:10426:11	O
caused	FANAPT.xml:S1:10438:6	O
by	FANAPT.xml:S1:10445:2	O
it	FANAPT.xml:S1:10448:2	O
.	FANAPT.xml:S1:10450:1	O

Reactions	FANAPT.xml:S1:10456:9	O
are	FANAPT.xml:S1:10466:3	O
further	FANAPT.xml:S1:10470:7	O
categorized	FANAPT.xml:S1:10478:11	O
by	FANAPT.xml:S1:10490:2	O
MedDRA	FANAPT.xml:S1:10493:6	O
system	FANAPT.xml:S1:10500:6	O
organ	FANAPT.xml:S1:10507:5	O
class	FANAPT.xml:S1:10513:5	O
and	FANAPT.xml:S1:10519:3	O
listed	FANAPT.xml:S1:10523:6	O
in	FANAPT.xml:S1:10530:2	O
order	FANAPT.xml:S1:10533:5	O
of	FANAPT.xml:S1:10539:2	O
decreasing	FANAPT.xml:S1:10542:10	O
frequency	FANAPT.xml:S1:10553:9	O
according	FANAPT.xml:S1:10563:9	O
to	FANAPT.xml:S1:10573:2	O
the	FANAPT.xml:S1:10576:3	O
following	FANAPT.xml:S1:10580:9	O
definitions	FANAPT.xml:S1:10590:11	O
:	FANAPT.xml:S1:10601:1	O
frequent	FANAPT.xml:S1:10603:8	O
adverse	FANAPT.xml:S1:10612:7	O
events	FANAPT.xml:S1:10620:6	O
are	FANAPT.xml:S1:10627:3	O
those	FANAPT.xml:S1:10631:5	O
occurring	FANAPT.xml:S1:10637:9	O
in	FANAPT.xml:S1:10647:2	O
at	FANAPT.xml:S1:10650:2	O
least	FANAPT.xml:S1:10653:5	O
1	FANAPT.xml:S1:10659:1	O
100	FANAPT.xml:S1:10661:3	O
patients	FANAPT.xml:S1:10665:8	O
(	FANAPT.xml:S1:10674:1	O
only	FANAPT.xml:S1:10675:4	O
those	FANAPT.xml:S1:10680:5	O
not	FANAPT.xml:S1:10686:3	O
listed	FANAPT.xml:S1:10690:6	O
in	FANAPT.xml:S1:10697:2	O
Table	FANAPT.xml:S1:10700:5	O
7	FANAPT.xml:S1:10706:1	O
appear	FANAPT.xml:S1:10708:6	O
in	FANAPT.xml:S1:10715:2	O
this	FANAPT.xml:S1:10718:4	O
listing	FANAPT.xml:S1:10723:7	O
)	FANAPT.xml:S1:10730:1	O
;	FANAPT.xml:S1:10731:1	O
infrequent	FANAPT.xml:S1:10733:10	O
adverse	FANAPT.xml:S1:10744:7	O
reactions	FANAPT.xml:S1:10752:9	O
are	FANAPT.xml:S1:10762:3	O
those	FANAPT.xml:S1:10766:5	O
occurring	FANAPT.xml:S1:10772:9	O
in	FANAPT.xml:S1:10782:2	O
1	FANAPT.xml:S1:10785:1	O
100	FANAPT.xml:S1:10787:3	O
to	FANAPT.xml:S1:10791:2	O
1	FANAPT.xml:S1:10794:1	O
1000	FANAPT.xml:S1:10796:4	O
patients	FANAPT.xml:S1:10801:8	O
;	FANAPT.xml:S1:10809:1	O
rare	FANAPT.xml:S1:10811:4	O
events	FANAPT.xml:S1:10816:6	O
are	FANAPT.xml:S1:10823:3	O
those	FANAPT.xml:S1:10827:5	O
occurring	FANAPT.xml:S1:10833:9	O
in	FANAPT.xml:S1:10843:2	O
fewer	FANAPT.xml:S1:10846:5	O
than	FANAPT.xml:S1:10852:4	O
1	FANAPT.xml:S1:10857:1	O
1000	FANAPT.xml:S1:10859:4	O
patients	FANAPT.xml:S1:10864:8	O
.	FANAPT.xml:S1:10872:1	O

Blood	FANAPT.xml:S1:10880:5	O
and	FANAPT.xml:S1:10886:3	O
Lymphatic	FANAPT.xml:S1:10890:9	O
Disorders	FANAPT.xml:S1:10900:9	O
:	FANAPT.xml:S1:10909:1	O
Infrequent	FANAPT.xml:S1:10911:10	O
-	FANAPT.xml:S1:10923:1	O
anemia	FANAPT.xml:S1:10925:6	B-AdverseReaction
,	FANAPT.xml:S1:10931:1	O
iron	FANAPT.xml:S1:10933:4	B-AdverseReaction
deficiency	FANAPT.xml:S1:10938:10	I-AdverseReaction
anemia	FANAPT.xml:S1:10949:6	I-AdverseReaction
;	FANAPT.xml:S1:10955:1	O
Rare	FANAPT.xml:S1:10958:4	O
-	FANAPT.xml:S1:10964:1	O
leukopenia	FANAPT.xml:S1:10966:10	B-AdverseReaction

Cardiac	FANAPT.xml:S1:10983:7	O
Disorders	FANAPT.xml:S1:10991:9	O
:	FANAPT.xml:S1:11000:1	O
Frequent	FANAPT.xml:S1:11002:8	O
-	FANAPT.xml:S1:11011:1	O
palpitations	FANAPT.xml:S1:11014:12	B-AdverseReaction
;	FANAPT.xml:S1:11026:1	O
Rare	FANAPT.xml:S1:11029:4	O
-	FANAPT.xml:S1:11035:1	O
arrhythmia	FANAPT.xml:S1:11037:10	B-AdverseReaction
,	FANAPT.xml:S1:11047:1	O
atrioventricular	FANAPT.xml:S1:11049:16	B-AdverseReaction
block	FANAPT.xml:S1:11066:5	I-AdverseReaction
first	FANAPT.xml:S1:11072:5	B-Severity
degree	FANAPT.xml:S1:11078:6	I-Severity
,	FANAPT.xml:S1:11084:1	O
cardiac	FANAPT.xml:S1:11086:7	B-AdverseReaction
failure	FANAPT.xml:S1:11094:7	I-AdverseReaction
(	FANAPT.xml:S1:11102:1	O
including	FANAPT.xml:S1:11103:9	O
congestive	FANAPT.xml:S1:11113:10	I-AdverseReaction
and	FANAPT.xml:S1:11124:3	O
acute	FANAPT.xml:S1:11128:5	I-AdverseReaction
)	FANAPT.xml:S1:11133:1	O

Ear	FANAPT.xml:S1:11141:3	O
and	FANAPT.xml:S1:11145:3	O
Labyrinth	FANAPT.xml:S1:11149:9	O
Disorders	FANAPT.xml:S1:11159:9	O
:	FANAPT.xml:S1:11168:1	O
Infrequent	FANAPT.xml:S1:11170:10	O
-	FANAPT.xml:S1:11181:1	O
vertigo	FANAPT.xml:S1:11185:7	B-AdverseReaction
,	FANAPT.xml:S1:11192:1	O
tinnitus	FANAPT.xml:S1:11194:8	B-AdverseReaction

Endocrine	FANAPT.xml:S1:11209:9	O
Disorders	FANAPT.xml:S1:11219:9	O
:	FANAPT.xml:S1:11228:1	O
Infrequent	FANAPT.xml:S1:11230:10	O
-	FANAPT.xml:S1:11242:1	O
hypothyroidism	FANAPT.xml:S1:11244:14	B-AdverseReaction

Eye	FANAPT.xml:S1:11265:3	O
Disorders	FANAPT.xml:S1:11269:9	O
:	FANAPT.xml:S1:11278:1	O
Frequent	FANAPT.xml:S1:11280:8	O
-	FANAPT.xml:S1:11289:1	O
conjunctivitis	FANAPT.xml:S1:11292:14	B-AdverseReaction
(	FANAPT.xml:S1:11307:1	O
including	FANAPT.xml:S1:11308:9	O
allergic	FANAPT.xml:S1:11318:8	I-AdverseReaction
)	FANAPT.xml:S1:11326:1	O
;	FANAPT.xml:S1:11327:1	O
Infrequent	FANAPT.xml:S1:11330:10	O
-	FANAPT.xml:S1:11342:1	O
dry	FANAPT.xml:S1:11344:3	B-AdverseReaction
eye	FANAPT.xml:S1:11348:3	I-AdverseReaction
,	FANAPT.xml:S1:11351:1	O
blepharitis	FANAPT.xml:S1:11353:11	B-AdverseReaction
,	FANAPT.xml:S1:11364:1	O
eyelid	FANAPT.xml:S1:11366:6	B-AdverseReaction
edema	FANAPT.xml:S1:11373:5	I-AdverseReaction
,	FANAPT.xml:S1:11378:1	O
eye	FANAPT.xml:S1:11380:3	B-AdverseReaction
swelling	FANAPT.xml:S1:11384:8	I-AdverseReaction
,	FANAPT.xml:S1:11392:1	O
lenticular	FANAPT.xml:S1:11394:10	B-AdverseReaction
opacities	FANAPT.xml:S1:11405:9	I-AdverseReaction
,	FANAPT.xml:S1:11414:1	O
cataract	FANAPT.xml:S1:11416:8	B-AdverseReaction
,	FANAPT.xml:S1:11424:1	O
hyperemia	FANAPT.xml:S1:11426:9	B-AdverseReaction
(	FANAPT.xml:S1:11436:1	O
including	FANAPT.xml:S1:11437:9	O
conjunctival	FANAPT.xml:S1:11447:12	I-AdverseReaction
)	FANAPT.xml:S1:11459:1	O

Gastrointestinal	FANAPT.xml:S1:11467:16	O
Disorders	FANAPT.xml:S1:11484:9	O
:	FANAPT.xml:S1:11493:1	O
Infrequent	FANAPT.xml:S1:11495:10	O
-	FANAPT.xml:S1:11507:1	O
gastritis	FANAPT.xml:S1:11509:9	B-AdverseReaction
,	FANAPT.xml:S1:11518:1	O
salivary	FANAPT.xml:S1:11520:8	B-AdverseReaction
hypersecretion	FANAPT.xml:S1:11529:14	I-AdverseReaction
,	FANAPT.xml:S1:11543:1	O
fecal	FANAPT.xml:S1:11545:5	B-AdverseReaction
incontinence	FANAPT.xml:S1:11551:12	I-AdverseReaction
,	FANAPT.xml:S1:11563:1	O
mouth	FANAPT.xml:S1:11565:5	B-AdverseReaction
ulceration	FANAPT.xml:S1:11571:10	I-AdverseReaction
;	FANAPT.xml:S1:11581:1	O
Rare	FANAPT.xml:S1:11585:4	O
-	FANAPT.xml:S1:11592:1	O
aphthous	FANAPT.xml:S1:11594:8	B-AdverseReaction
stomatitis	FANAPT.xml:S1:11603:10	I-AdverseReaction
,	FANAPT.xml:S1:11613:1	O
duodenal	FANAPT.xml:S1:11615:8	B-AdverseReaction
ulcer	FANAPT.xml:S1:11624:5	I-AdverseReaction
,	FANAPT.xml:S1:11629:1	O
hiatus	FANAPT.xml:S1:11631:6	B-AdverseReaction
hernia	FANAPT.xml:S1:11638:6	I-AdverseReaction
,	FANAPT.xml:S1:11644:1	O
hyperchlorhydria	FANAPT.xml:S1:11646:16	B-AdverseReaction
,	FANAPT.xml:S1:11662:1	O
lip	FANAPT.xml:S1:11664:3	B-AdverseReaction
ulceration	FANAPT.xml:S1:11668:10	I-AdverseReaction
,	FANAPT.xml:S1:11678:1	O
reflux	FANAPT.xml:S1:11680:6	B-AdverseReaction
esophagitis	FANAPT.xml:S1:11687:11	I-AdverseReaction
,	FANAPT.xml:S1:11698:1	O
stomatitis	FANAPT.xml:S1:11700:10	B-AdverseReaction

General	FANAPT.xml:S1:11717:7	O
Disorders	FANAPT.xml:S1:11725:9	O
and	FANAPT.xml:S1:11735:3	O
Administrative	FANAPT.xml:S1:11739:14	O
Site	FANAPT.xml:S1:11754:4	O
Conditions	FANAPT.xml:S1:11759:10	O
:	FANAPT.xml:S1:11769:1	O
Infrequent	FANAPT.xml:S1:11771:10	O
-	FANAPT.xml:S1:11783:1	O
edema	FANAPT.xml:S1:11785:5	B-AdverseReaction
(	FANAPT.xml:S1:11791:1	O
general	FANAPT.xml:S1:11792:7	I-AdverseReaction
,	FANAPT.xml:S1:11799:1	O
pitting	FANAPT.xml:S1:11801:7	I-AdverseReaction
,	FANAPT.xml:S1:11808:1	O
due	FANAPT.xml:S1:11810:3	O
to	FANAPT.xml:S1:11814:2	O
cardiac	FANAPT.xml:S1:11817:7	O
disease	FANAPT.xml:S1:11825:7	O
)	FANAPT.xml:S1:11832:1	O
,	FANAPT.xml:S1:11833:1	O
difficulty	FANAPT.xml:S1:11835:10	B-AdverseReaction
in	FANAPT.xml:S1:11846:2	I-AdverseReaction
walking	FANAPT.xml:S1:11849:7	I-AdverseReaction
,	FANAPT.xml:S1:11856:1	O
thirst	FANAPT.xml:S1:11858:6	B-AdverseReaction
;	FANAPT.xml:S1:11864:1	O
Rare	FANAPT.xml:S1:11867:4	O
-	FANAPT.xml:S1:11873:1	O
hyperthermia	FANAPT.xml:S1:11875:12	B-AdverseReaction

Hepatobiliary	FANAPT.xml:S1:11894:13	O
Disorders	FANAPT.xml:S1:11908:9	O
:	FANAPT.xml:S1:11917:1	O
Infrequent	FANAPT.xml:S1:11919:10	O
-	FANAPT.xml:S1:11930:1	O
cholelithiasis	FANAPT.xml:S1:11933:14	B-AdverseReaction

Investigations	FANAPT.xml:S1:11954:14	O
:	FANAPT.xml:S1:11968:1	O
Frequent	FANAPT.xml:S1:11970:8	O
-	FANAPT.xml:S1:11979:1	O
weight	FANAPT.xml:S1:11982:6	B-AdverseReaction
decreased	FANAPT.xml:S1:11989:9	I-AdverseReaction
;	FANAPT.xml:S1:11998:1	O
Infrequent	FANAPT.xml:S1:12001:10	O
-	FANAPT.xml:S1:12013:1	O
hemoglobin	FANAPT.xml:S1:12015:10	B-AdverseReaction
decreased	FANAPT.xml:S1:12026:9	I-AdverseReaction
,	FANAPT.xml:S1:12035:1	O
neutrophil	FANAPT.xml:S1:12037:10	B-AdverseReaction
count	FANAPT.xml:S1:12048:5	I-AdverseReaction
increased	FANAPT.xml:S1:12054:9	I-AdverseReaction
,	FANAPT.xml:S1:12063:1	O
hematocrit	FANAPT.xml:S1:12065:10	B-AdverseReaction
decreased	FANAPT.xml:S1:12076:9	I-AdverseReaction

Metabolism	FANAPT.xml:S1:12092:10	O
and	FANAPT.xml:S1:12103:3	O
Nutrition	FANAPT.xml:S1:12107:9	O
Disorders	FANAPT.xml:S1:12117:9	O
:	FANAPT.xml:S1:12126:1	O
Infrequent	FANAPT.xml:S1:12132:10	O
-	FANAPT.xml:S1:12144:1	O
increased	FANAPT.xml:S1:12146:9	B-AdverseReaction
appetite	FANAPT.xml:S1:12156:8	I-AdverseReaction
,	FANAPT.xml:S1:12164:1	O
dehydration	FANAPT.xml:S1:12166:11	B-AdverseReaction
,	FANAPT.xml:S1:12177:1	O
hypokalemia	FANAPT.xml:S1:12179:11	B-AdverseReaction
,	FANAPT.xml:S1:12190:1	O
fluid	FANAPT.xml:S1:12192:5	B-AdverseReaction
retention	FANAPT.xml:S1:12198:9	I-AdverseReaction

Musculoskeletal	FANAPT.xml:S1:12214:15	O
and	FANAPT.xml:S1:12230:3	O
Connective	FANAPT.xml:S1:12234:10	O
Tissue	FANAPT.xml:S1:12245:6	O
Disorders	FANAPT.xml:S1:12252:9	O
:	FANAPT.xml:S1:12261:1	O
Frequent	FANAPT.xml:S1:12263:8	O
-	FANAPT.xml:S1:12273:1	O
myalgia	FANAPT.xml:S1:12275:7	B-AdverseReaction
,	FANAPT.xml:S1:12282:1	O
muscle	FANAPT.xml:S1:12284:6	B-AdverseReaction
spasms	FANAPT.xml:S1:12291:6	I-AdverseReaction
;	FANAPT.xml:S1:12297:1	O
Rare	FANAPT.xml:S1:12300:4	O
-	FANAPT.xml:S1:12306:1	O
torticollis	FANAPT.xml:S1:12308:11	B-AdverseReaction

Nervous	FANAPT.xml:S1:12326:7	O
System	FANAPT.xml:S1:12334:6	O
Disorders	FANAPT.xml:S1:12341:9	O
:	FANAPT.xml:S1:12350:1	O
Infrequent	FANAPT.xml:S1:12352:10	O
-	FANAPT.xml:S1:12363:1	O
paresthesia	FANAPT.xml:S1:12367:11	B-AdverseReaction
,	FANAPT.xml:S1:12378:1	O
psychomotor	FANAPT.xml:S1:12380:11	B-AdverseReaction
hyperactivity	FANAPT.xml:S1:12392:13	I-AdverseReaction
,	FANAPT.xml:S1:12405:1	O
restlessness	FANAPT.xml:S1:12407:12	B-AdverseReaction
,	FANAPT.xml:S1:12419:1	O
amnesia	FANAPT.xml:S1:12421:7	B-AdverseReaction
,	FANAPT.xml:S1:12428:1	O
nystagmus	FANAPT.xml:S1:12430:9	B-AdverseReaction
;	FANAPT.xml:S1:12439:1	O
Rare	FANAPT.xml:S1:12442:4	O
-	FANAPT.xml:S1:12448:1	O
restless	FANAPT.xml:S1:12450:8	B-AdverseReaction
legs	FANAPT.xml:S1:12459:4	I-AdverseReaction
syndrome	FANAPT.xml:S1:12464:8	I-AdverseReaction

Psychiatric	FANAPT.xml:S1:12479:11	O
Disorders	FANAPT.xml:S1:12491:9	O
:	FANAPT.xml:S1:12500:1	O
Frequent	FANAPT.xml:S1:12502:8	O
-	FANAPT.xml:S1:12512:1	O
restlessness	FANAPT.xml:S1:12514:12	B-AdverseReaction
,	FANAPT.xml:S1:12526:1	O
aggression	FANAPT.xml:S1:12528:10	B-AdverseReaction
,	FANAPT.xml:S1:12538:1	O
delusion	FANAPT.xml:S1:12540:8	B-AdverseReaction
;	FANAPT.xml:S1:12548:1	O
Infrequent	FANAPT.xml:S1:12551:10	O
-	FANAPT.xml:S1:12563:1	O
hostility	FANAPT.xml:S1:12565:9	B-AdverseReaction
,	FANAPT.xml:S1:12574:1	O
libido	FANAPT.xml:S1:12576:6	B-AdverseReaction
decreased	FANAPT.xml:S1:12583:9	I-AdverseReaction
,	FANAPT.xml:S1:12592:1	O
paranoia	FANAPT.xml:S1:12594:8	B-AdverseReaction
,	FANAPT.xml:S1:12602:1	O
anorgasmia	FANAPT.xml:S1:12604:10	B-AdverseReaction
,	FANAPT.xml:S1:12614:1	O
confusional	FANAPT.xml:S1:12616:11	B-AdverseReaction
state	FANAPT.xml:S1:12628:5	I-AdverseReaction
,	FANAPT.xml:S1:12633:1	O
mania	FANAPT.xml:S1:12635:5	B-AdverseReaction
,	FANAPT.xml:S1:12640:1	O
catatonia	FANAPT.xml:S1:12642:9	B-AdverseReaction
,	FANAPT.xml:S1:12651:1	O
mood	FANAPT.xml:S1:12653:4	B-AdverseReaction
swings	FANAPT.xml:S1:12658:6	I-AdverseReaction
,	FANAPT.xml:S1:12664:1	O
panic	FANAPT.xml:S1:12666:5	B-AdverseReaction
attack	FANAPT.xml:S1:12672:6	I-AdverseReaction
,	FANAPT.xml:S1:12678:1	O
obsessive	FANAPT.xml:S1:12680:9	B-AdverseReaction
-	FANAPT.xml:S1:12689:1	I-AdverseReaction
compulsive	FANAPT.xml:S1:12690:10	I-AdverseReaction
disorder	FANAPT.xml:S1:12701:8	I-AdverseReaction
,	FANAPT.xml:S1:12709:1	O
bulimia	FANAPT.xml:S1:12711:7	B-AdverseReaction
nervosa	FANAPT.xml:S1:12719:7	I-AdverseReaction
,	FANAPT.xml:S1:12726:1	O
delirium	FANAPT.xml:S1:12728:8	B-AdverseReaction
,	FANAPT.xml:S1:12736:1	O
polydipsia	FANAPT.xml:S1:12738:10	B-AdverseReaction
psychogenic	FANAPT.xml:S1:12749:11	I-AdverseReaction
,	FANAPT.xml:S1:12760:1	O
impulse	FANAPT.xml:S1:12762:7	B-AdverseReaction
-	FANAPT.xml:S1:12769:1	I-AdverseReaction
control	FANAPT.xml:S1:12770:7	I-AdverseReaction
disorder	FANAPT.xml:S1:12778:8	I-AdverseReaction
,	FANAPT.xml:S1:12786:1	O
major	FANAPT.xml:S1:12788:5	B-AdverseReaction
depression	FANAPT.xml:S1:12794:10	I-AdverseReaction

Renal	FANAPT.xml:S1:12811:5	O
and	FANAPT.xml:S1:12817:3	O
Urinary	FANAPT.xml:S1:12821:7	O
Disorders	FANAPT.xml:S1:12829:9	O
:	FANAPT.xml:S1:12838:1	O
Frequent	FANAPT.xml:S1:12840:8	O
-	FANAPT.xml:S1:12850:1	O
urinary	FANAPT.xml:S1:12852:7	B-AdverseReaction
incontinence	FANAPT.xml:S1:12860:12	I-AdverseReaction
;	FANAPT.xml:S1:12872:1	O
Infrequent	FANAPT.xml:S1:12875:10	O
-	FANAPT.xml:S1:12887:1	O
dysuria	FANAPT.xml:S1:12889:7	B-AdverseReaction
,	FANAPT.xml:S1:12896:1	O
pollakiuria	FANAPT.xml:S1:12898:11	B-AdverseReaction
,	FANAPT.xml:S1:12909:1	O
enuresis	FANAPT.xml:S1:12911:8	B-AdverseReaction
,	FANAPT.xml:S1:12919:1	O
nephrolithiasis	FANAPT.xml:S1:12921:15	B-AdverseReaction
;	FANAPT.xml:S1:12936:1	O
Rare	FANAPT.xml:S1:12939:4	O
-	FANAPT.xml:S1:12945:1	O
urinary	FANAPT.xml:S1:12947:7	B-AdverseReaction
retention	FANAPT.xml:S1:12955:9	I-AdverseReaction
,	FANAPT.xml:S1:12964:1	O
renal	FANAPT.xml:S1:12966:5	B-AdverseReaction
failure	FANAPT.xml:S1:12972:7	I-AdverseReaction
acute	FANAPT.xml:S1:12980:5	I-AdverseReaction

Reproductive	FANAPT.xml:S1:12992:12	O
System	FANAPT.xml:S1:13005:6	O
and	FANAPT.xml:S1:13012:3	O
Breast	FANAPT.xml:S1:13016:6	O
Disorders	FANAPT.xml:S1:13023:9	O
:	FANAPT.xml:S1:13032:1	O
Frequent	FANAPT.xml:S1:13034:8	O
-	FANAPT.xml:S1:13044:1	O
erectile	FANAPT.xml:S1:13046:8	B-AdverseReaction
dysfunction	FANAPT.xml:S1:13055:11	I-AdverseReaction
;	FANAPT.xml:S1:13066:1	O
Infrequent	FANAPT.xml:S1:13069:10	O
-	FANAPT.xml:S1:13081:1	O
testicular	FANAPT.xml:S1:13083:10	B-AdverseReaction
pain	FANAPT.xml:S1:13094:4	I-AdverseReaction
,	FANAPT.xml:S1:13098:1	O
amenorrhea	FANAPT.xml:S1:13100:10	B-AdverseReaction
,	FANAPT.xml:S1:13110:1	O
breast	FANAPT.xml:S1:13112:6	B-AdverseReaction
pain	FANAPT.xml:S1:13119:4	I-AdverseReaction
;	FANAPT.xml:S1:13123:1	O
Rare	FANAPT.xml:S1:13127:4	O
-	FANAPT.xml:S1:13133:1	O
menstruation	FANAPT.xml:S1:13135:12	B-AdverseReaction
irregular	FANAPT.xml:S1:13148:9	I-AdverseReaction
,	FANAPT.xml:S1:13157:1	O
gynecomastia	FANAPT.xml:S1:13159:12	B-AdverseReaction
,	FANAPT.xml:S1:13171:1	O
menorrhagia	FANAPT.xml:S1:13173:11	B-AdverseReaction
,	FANAPT.xml:S1:13184:1	O
metrorrhagia	FANAPT.xml:S1:13186:12	B-AdverseReaction
,	FANAPT.xml:S1:13198:1	O
postmenopausal	FANAPT.xml:S1:13200:14	B-AdverseReaction
hemorrhage	FANAPT.xml:S1:13215:10	I-AdverseReaction
,	FANAPT.xml:S1:13225:1	O
prostatitis	FANAPT.xml:S1:13227:11	B-AdverseReaction
.	FANAPT.xml:S1:13238:1	O

Respiratory	FANAPT.xml:S1:13246:11	O
,	FANAPT.xml:S1:13257:1	O
Thoracic	FANAPT.xml:S1:13259:8	O
and	FANAPT.xml:S1:13268:3	O
Mediastinal	FANAPT.xml:S1:13272:11	O
Disorders	FANAPT.xml:S1:13284:9	O
:	FANAPT.xml:S1:13293:1	O
Infrequent	FANAPT.xml:S1:13295:10	O
-	FANAPT.xml:S1:13307:1	O
epistaxis	FANAPT.xml:S1:13309:9	B-AdverseReaction
,	FANAPT.xml:S1:13318:1	O
asthma	FANAPT.xml:S1:13320:6	B-AdverseReaction
,	FANAPT.xml:S1:13326:1	O
rhinorrhea	FANAPT.xml:S1:13328:10	B-AdverseReaction
,	FANAPT.xml:S1:13338:1	O
sinus	FANAPT.xml:S1:13340:5	B-AdverseReaction
congestion	FANAPT.xml:S1:13346:10	I-AdverseReaction
,	FANAPT.xml:S1:13356:1	O
nasal	FANAPT.xml:S1:13358:5	B-AdverseReaction
dryness	FANAPT.xml:S1:13364:7	I-AdverseReaction
;	FANAPT.xml:S1:13371:1	O
Rare	FANAPT.xml:S1:13374:4	O
-	FANAPT.xml:S1:13380:1	O
dry	FANAPT.xml:S1:13382:3	B-AdverseReaction
throat	FANAPT.xml:S1:13386:6	I-AdverseReaction
,	FANAPT.xml:S1:13392:1	O
sleep	FANAPT.xml:S1:13394:5	B-AdverseReaction
apnea	FANAPT.xml:S1:13400:5	I-AdverseReaction
syndrome	FANAPT.xml:S1:13406:8	I-AdverseReaction
,	FANAPT.xml:S1:13414:1	O
dyspnea	FANAPT.xml:S1:13416:7	B-AdverseReaction
exertional	FANAPT.xml:S1:13424:10	I-AdverseReaction

6.2	FANAPT.xml:S1:13441:3	O
Postmarketing	FANAPT.xml:S1:13449:13	O
Experience	FANAPT.xml:S1:13463:10	O

The	FANAPT.xml:S1:13477:3	O
following	FANAPT.xml:S1:13481:9	O
adverse	FANAPT.xml:S1:13491:7	O
reactions	FANAPT.xml:S1:13499:9	O
have	FANAPT.xml:S1:13509:4	O
been	FANAPT.xml:S1:13514:4	O
identified	FANAPT.xml:S1:13519:10	O
during	FANAPT.xml:S1:13530:6	O
post	FANAPT.xml:S1:13537:4	O
-	FANAPT.xml:S1:13541:1	O
approval	FANAPT.xml:S1:13542:8	O
use	FANAPT.xml:S1:13551:3	O
of	FANAPT.xml:S1:13555:2	O
FANAPT	FANAPT.xml:S1:13558:6	O
:	FANAPT.xml:S1:13564:1	O
retrograde	FANAPT.xml:S1:13566:10	B-AdverseReaction
ejaculation	FANAPT.xml:S1:13577:11	I-AdverseReaction
.	FANAPT.xml:S1:13588:1	O

Because	FANAPT.xml:S1:13590:7	O
these	FANAPT.xml:S1:13598:5	O
reactions	FANAPT.xml:S1:13604:9	O
were	FANAPT.xml:S1:13614:4	O
reported	FANAPT.xml:S1:13619:8	O
voluntarily	FANAPT.xml:S1:13628:11	O
from	FANAPT.xml:S1:13640:4	O
a	FANAPT.xml:S1:13645:1	O
population	FANAPT.xml:S1:13647:10	O
of	FANAPT.xml:S1:13658:2	O
uncertain	FANAPT.xml:S1:13661:9	O
size	FANAPT.xml:S1:13671:4	O
,	FANAPT.xml:S1:13675:1	O
it	FANAPT.xml:S1:13677:2	O
is	FANAPT.xml:S1:13680:2	O
not	FANAPT.xml:S1:13683:3	O
possible	FANAPT.xml:S1:13687:8	O
to	FANAPT.xml:S1:13696:2	O
reliably	FANAPT.xml:S1:13699:8	O
estimate	FANAPT.xml:S1:13708:8	O
their	FANAPT.xml:S1:13717:5	O
frequency	FANAPT.xml:S1:13723:9	O
or	FANAPT.xml:S1:13733:2	O
establish	FANAPT.xml:S1:13736:9	O
a	FANAPT.xml:S1:13746:1	O
causal	FANAPT.xml:S1:13748:6	O
relationship	FANAPT.xml:S1:13755:12	O
to	FANAPT.xml:S1:13768:2	O
drug	FANAPT.xml:S1:13771:4	O
exposure	FANAPT.xml:S1:13776:8	O
.	FANAPT.xml:S1:13784:1	O
\n\n	FANAPT.xml:S2:0:2	O
BOXED	FANAPT.xml:S2:6:5	O
WARNING	FANAPT.xml:S2:12:7	O
:	FANAPT.xml:S2:19:1	O
WARNING	FANAPT.xml:S2:21:7	O
:	FANAPT.xml:S2:28:1	O
INCREASED	FANAPT.xml:S2:30:9	O
MORTALITY	FANAPT.xml:S2:40:9	B-AdverseReaction
IN	FANAPT.xml:S2:50:2	O
ELDERLY	FANAPT.xml:S2:53:7	O
PATIENTS	FANAPT.xml:S2:61:8	O
WITH	FANAPT.xml:S2:70:4	O
DEMENTIA	FANAPT.xml:S2:75:8	O
-	FANAPT.xml:S2:83:1	O
RELATED	FANAPT.xml:S2:84:7	O
PSYCHOSIS	FANAPT.xml:S2:92:9	O
\n\n	FANAPT.xml:S2:101:2	O
WARNING	FANAPT.xml:S2:107:7	O
:	FANAPT.xml:S2:114:1	O
INCREASED	FANAPT.xml:S2:116:9	O
MORTALITY	FANAPT.xml:S2:126:9	B-AdverseReaction
IN	FANAPT.xml:S2:136:2	O
ELDERLY	FANAPT.xml:S2:139:7	O
PATIENTS	FANAPT.xml:S2:147:8	O
WITH	FANAPT.xml:S2:156:4	O
DEMENTIA	FANAPT.xml:S2:161:8	O
-	FANAPT.xml:S2:169:1	O
RELATED	FANAPT.xml:S2:170:7	O
PSYCHOSIS	FANAPT.xml:S2:178:9	O
\n\n	FANAPT.xml:S2:189:2	O
Elderly	FANAPT.xml:S2:195:7	O
patients	FANAPT.xml:S2:203:8	O
with	FANAPT.xml:S2:212:4	O
dementia	FANAPT.xml:S2:217:8	O
-	FANAPT.xml:S2:225:1	O
related	FANAPT.xml:S2:226:7	O
psychosis	FANAPT.xml:S2:234:9	O
treated	FANAPT.xml:S2:244:7	O
with	FANAPT.xml:S2:252:4	O
antipsychotic	FANAPT.xml:S2:257:13	B-DrugClass
drugs	FANAPT.xml:S2:271:5	I-DrugClass
are	FANAPT.xml:S2:277:3	O
at	FANAPT.xml:S2:281:2	O
an	FANAPT.xml:S2:284:2	O
increased	FANAPT.xml:S2:287:9	O
risk	FANAPT.xml:S2:297:4	O
of	FANAPT.xml:S2:302:2	O
death	FANAPT.xml:S2:305:5	B-AdverseReaction
.	FANAPT.xml:S2:310:1	O

Analysis	FANAPT.xml:S2:312:8	O
of	FANAPT.xml:S2:321:2	O
seventeen	FANAPT.xml:S2:324:9	O
placebo	FANAPT.xml:S2:334:7	O
-	FANAPT.xml:S2:341:1	O
controlled	FANAPT.xml:S2:342:10	O
trials	FANAPT.xml:S2:353:6	O
(	FANAPT.xml:S2:360:1	O
modal	FANAPT.xml:S2:361:5	O
duration	FANAPT.xml:S2:367:8	O
10	FANAPT.xml:S2:376:2	O
weeks	FANAPT.xml:S2:379:5	O
)	FANAPT.xml:S2:384:1	O
,	FANAPT.xml:S2:385:1	O
largely	FANAPT.xml:S2:387:7	O
in	FANAPT.xml:S2:395:2	O
patients	FANAPT.xml:S2:398:8	O
taking	FANAPT.xml:S2:407:6	O
atypical	FANAPT.xml:S2:414:8	O
antipsychotic	FANAPT.xml:S2:423:13	O
drugs	FANAPT.xml:S2:437:5	O
,	FANAPT.xml:S2:442:1	O
revealed	FANAPT.xml:S2:444:8	O
a	FANAPT.xml:S2:453:1	O
risk	FANAPT.xml:S2:455:4	B-Factor
of	FANAPT.xml:S2:460:2	O
death	FANAPT.xml:S2:463:5	B-AdverseReaction
in	FANAPT.xml:S2:469:2	O
the	FANAPT.xml:S2:472:3	O
drug	FANAPT.xml:S2:476:4	O
-	FANAPT.xml:S2:480:1	O
treated	FANAPT.xml:S2:481:7	O
patients	FANAPT.xml:S2:489:8	O
of	FANAPT.xml:S2:498:2	O
between	FANAPT.xml:S2:501:7	O
1.6	FANAPT.xml:S2:509:3	O
to	FANAPT.xml:S2:513:2	O
1.7	FANAPT.xml:S2:516:3	O
times	FANAPT.xml:S2:520:5	O
the	FANAPT.xml:S2:526:3	O
risk	FANAPT.xml:S2:530:4	O
of	FANAPT.xml:S2:535:2	O
death	FANAPT.xml:S2:538:5	O
in	FANAPT.xml:S2:544:2	O
placebo	FANAPT.xml:S2:547:7	O
-	FANAPT.xml:S2:554:1	O
treated	FANAPT.xml:S2:555:7	O
patients	FANAPT.xml:S2:563:8	O
.	FANAPT.xml:S2:571:1	O

Over	FANAPT.xml:S2:573:4	O
the	FANAPT.xml:S2:578:3	O
course	FANAPT.xml:S2:582:6	O
of	FANAPT.xml:S2:589:2	O
a	FANAPT.xml:S2:592:1	O
typical	FANAPT.xml:S2:594:7	O
10	FANAPT.xml:S2:602:2	O
-	FANAPT.xml:S2:604:1	O
week	FANAPT.xml:S2:605:4	O
controlled	FANAPT.xml:S2:610:10	O
trial	FANAPT.xml:S2:621:5	O
,	FANAPT.xml:S2:626:1	O
the	FANAPT.xml:S2:628:3	O
rate	FANAPT.xml:S2:632:4	O
of	FANAPT.xml:S2:637:2	O
death	FANAPT.xml:S2:640:5	B-AdverseReaction
in	FANAPT.xml:S2:646:2	O
drug	FANAPT.xml:S2:649:4	O
-	FANAPT.xml:S2:653:1	O
treated	FANAPT.xml:S2:654:7	O
patients	FANAPT.xml:S2:662:8	O
was	FANAPT.xml:S2:671:3	O
about	FANAPT.xml:S2:675:5	O
4.5%	FANAPT.xml:S2:681:4	O
,	FANAPT.xml:S2:685:1	O
compared	FANAPT.xml:S2:687:8	O
to	FANAPT.xml:S2:696:2	O
a	FANAPT.xml:S2:699:1	O
rate	FANAPT.xml:S2:701:4	O
of	FANAPT.xml:S2:706:2	O
about	FANAPT.xml:S2:709:5	O
2.6%	FANAPT.xml:S2:715:4	O
in	FANAPT.xml:S2:720:2	O
the	FANAPT.xml:S2:723:3	O
placebo	FANAPT.xml:S2:727:7	O
group	FANAPT.xml:S2:735:5	O
.	FANAPT.xml:S2:740:1	O

Although	FANAPT.xml:S2:742:8	O
the	FANAPT.xml:S2:751:3	O
causes	FANAPT.xml:S2:755:6	O
of	FANAPT.xml:S2:762:2	O
death	FANAPT.xml:S2:765:5	B-AdverseReaction
were	FANAPT.xml:S2:771:4	O
varied	FANAPT.xml:S2:776:6	O
,	FANAPT.xml:S2:782:1	O
most	FANAPT.xml:S2:784:4	O
of	FANAPT.xml:S2:789:2	O
the	FANAPT.xml:S2:792:3	O
deaths	FANAPT.xml:S2:796:6	B-AdverseReaction
appeared	FANAPT.xml:S2:803:8	O
to	FANAPT.xml:S2:812:2	O
be	FANAPT.xml:S2:815:2	O
either	FANAPT.xml:S2:818:6	O
cardiovascular	FANAPT.xml:S2:825:14	O
(	FANAPT.xml:S2:840:1	O
e	FANAPT.xml:S2:841:1	O
.	FANAPT.xml:S2:842:1	O
g	FANAPT.xml:S2:843:1	O
.	FANAPT.xml:S2:844:1	O
,	FANAPT.xml:S2:845:1	O
heart	FANAPT.xml:S2:847:5	B-AdverseReaction
failure	FANAPT.xml:S2:853:7	I-AdverseReaction
,	FANAPT.xml:S2:860:1	O
sudden	FANAPT.xml:S2:862:6	B-AdverseReaction
death	FANAPT.xml:S2:869:5	I-AdverseReaction
)	FANAPT.xml:S2:874:1	O
or	FANAPT.xml:S2:876:2	O
infectious	FANAPT.xml:S2:879:10	O
(	FANAPT.xml:S2:890:1	O
e	FANAPT.xml:S2:891:1	O
.	FANAPT.xml:S2:892:1	O
g	FANAPT.xml:S2:893:1	O
.	FANAPT.xml:S2:894:1	O
,	FANAPT.xml:S2:895:1	O
pneumonia	FANAPT.xml:S2:897:9	B-AdverseReaction
)	FANAPT.xml:S2:906:1	O
in	FANAPT.xml:S2:908:2	O
nature	FANAPT.xml:S2:911:6	O
.	FANAPT.xml:S2:917:1	O

Observational	FANAPT.xml:S2:927:13	O
studies	FANAPT.xml:S2:941:7	O
suggest	FANAPT.xml:S2:949:7	O
that	FANAPT.xml:S2:957:4	O
,	FANAPT.xml:S2:961:1	O
similar	FANAPT.xml:S2:963:7	O
to	FANAPT.xml:S2:971:2	O
atypical	FANAPT.xml:S2:974:8	O
antipsychotic	FANAPT.xml:S2:983:13	O
drugs	FANAPT.xml:S2:997:5	O
,	FANAPT.xml:S2:1002:1	O
treatment	FANAPT.xml:S2:1004:9	O
with	FANAPT.xml:S2:1014:4	O
conventional	FANAPT.xml:S2:1019:12	O
antipsychotic	FANAPT.xml:S2:1032:13	O
drugs	FANAPT.xml:S2:1046:5	O
may	FANAPT.xml:S2:1052:3	O
increase	FANAPT.xml:S2:1056:8	O
mortality	FANAPT.xml:S2:1065:9	O
.	FANAPT.xml:S2:1074:1	O

The	FANAPT.xml:S2:1076:3	O
extent	FANAPT.xml:S2:1080:6	O
to	FANAPT.xml:S2:1087:2	O
which	FANAPT.xml:S2:1090:5	O
the	FANAPT.xml:S2:1096:3	O
findings	FANAPT.xml:S2:1100:8	O
of	FANAPT.xml:S2:1109:2	O
increased	FANAPT.xml:S2:1112:9	O
mortality	FANAPT.xml:S2:1122:9	O
in	FANAPT.xml:S2:1132:2	O
observational	FANAPT.xml:S2:1135:13	O
studies	FANAPT.xml:S2:1149:7	O
may	FANAPT.xml:S2:1157:3	O
be	FANAPT.xml:S2:1161:2	O
attributed	FANAPT.xml:S2:1164:10	O
to	FANAPT.xml:S2:1175:2	O
the	FANAPT.xml:S2:1178:3	O
antipsychotic	FANAPT.xml:S2:1182:13	O
drug	FANAPT.xml:S2:1196:4	O
as	FANAPT.xml:S2:1201:2	O
opposed	FANAPT.xml:S2:1204:7	O
to	FANAPT.xml:S2:1212:2	O
some	FANAPT.xml:S2:1215:4	O
characteristic	FANAPT.xml:S2:1220:14	O
(	FANAPT.xml:S2:1234:1	O
s	FANAPT.xml:S2:1235:1	O
)	FANAPT.xml:S2:1236:1	O
of	FANAPT.xml:S2:1238:2	O
the	FANAPT.xml:S2:1241:3	O
patients	FANAPT.xml:S2:1245:8	O
is	FANAPT.xml:S2:1254:2	O
not	FANAPT.xml:S2:1257:3	O
clear	FANAPT.xml:S2:1261:5	O
.	FANAPT.xml:S2:1266:1	O

FANAPT	FANAPT.xml:S2:1268:6	O
is	FANAPT.xml:S2:1275:2	O
not	FANAPT.xml:S2:1278:3	O
approved	FANAPT.xml:S2:1282:8	O
for	FANAPT.xml:S2:1291:3	O
the	FANAPT.xml:S2:1295:3	O
treatment	FANAPT.xml:S2:1299:9	O
of	FANAPT.xml:S2:1309:2	O
patients	FANAPT.xml:S2:1312:8	O
with	FANAPT.xml:S2:1321:4	O
Dementia	FANAPT.xml:S2:1326:8	O
-	FANAPT.xml:S2:1334:1	O
Related	FANAPT.xml:S2:1335:7	O
Psychosis	FANAPT.xml:S2:1343:9	O
.	FANAPT.xml:S2:1352:1	O

[	FANAPT.xml:S2:1358:1	O
See	FANAPT.xml:S2:1359:3	O
Warnings	FANAPT.xml:S2:1363:8	O
and	FANAPT.xml:S2:1372:3	O
Precautions	FANAPT.xml:S2:1376:11	O
(	FANAPT.xml:S2:1388:1	O
5.1	FANAPT.xml:S2:1389:3	O
)]	FANAPT.xml:S2:1392:2	O
\n\n\n\n	FANAPT.xml:S2:1396:4	O
EXCERPT	FANAPT.xml:S2:1403:7	O
:	FANAPT.xml:S2:1410:1	O
WARNING	FANAPT.xml:S2:1416:7	O
:	FANAPT.xml:S2:1423:1	O
INCREASED	FANAPT.xml:S2:1425:9	O
MORTALITY	FANAPT.xml:S2:1435:9	B-AdverseReaction
IN	FANAPT.xml:S2:1445:2	O
ELDERLY	FANAPT.xml:S2:1448:7	O
PATIENTS	FANAPT.xml:S2:1456:8	O
WITH	FANAPT.xml:S2:1465:4	O
DEMENTIA	FANAPT.xml:S2:1470:8	O
-	FANAPT.xml:S2:1478:1	O
RELATED	FANAPT.xml:S2:1479:7	O
PSYCHOSIS	FANAPT.xml:S2:1487:9	O
\n\n\n\n	FANAPT.xml:S2:1503:4	O
See	FANAPT.xml:S2:1510:3	O
full	FANAPT.xml:S2:1514:4	O
prescribing	FANAPT.xml:S2:1519:11	O
information	FANAPT.xml:S2:1531:11	O
for	FANAPT.xml:S2:1543:3	O
complete	FANAPT.xml:S2:1547:8	O
boxed	FANAPT.xml:S2:1556:5	O
warning	FANAPT.xml:S2:1562:7	O
.	FANAPT.xml:S2:1569:1	O

Elderly	FANAPT.xml:S2:1579:7	O
patients	FANAPT.xml:S2:1587:8	O
with	FANAPT.xml:S2:1596:4	O
dementia	FANAPT.xml:S2:1601:8	O
-	FANAPT.xml:S2:1609:1	O
related	FANAPT.xml:S2:1610:7	O
psychosis	FANAPT.xml:S2:1618:9	O
treated	FANAPT.xml:S2:1628:7	O
with	FANAPT.xml:S2:1636:4	O
antipsychotic	FANAPT.xml:S2:1641:13	B-DrugClass
drugs	FANAPT.xml:S2:1655:5	I-DrugClass
are	FANAPT.xml:S2:1661:3	O
at	FANAPT.xml:S2:1665:2	O
an	FANAPT.xml:S2:1668:2	O
increased	FANAPT.xml:S2:1671:9	O
risk	FANAPT.xml:S2:1681:4	O
of	FANAPT.xml:S2:1686:2	O
death	FANAPT.xml:S2:1689:5	B-AdverseReaction
.	FANAPT.xml:S2:1694:1	O

FANAPT	FANAPT.xml:S2:1696:6	O
is	FANAPT.xml:S2:1703:2	O
not	FANAPT.xml:S2:1706:3	O
approved	FANAPT.xml:S2:1710:8	O
for	FANAPT.xml:S2:1719:3	O
use	FANAPT.xml:S2:1723:3	O
in	FANAPT.xml:S2:1727:2	O
patients	FANAPT.xml:S2:1730:8	O
with	FANAPT.xml:S2:1739:4	O
dementia	FANAPT.xml:S2:1744:8	O
-	FANAPT.xml:S2:1752:1	O
related	FANAPT.xml:S2:1753:7	O
psychosis	FANAPT.xml:S2:1761:9	O
.	FANAPT.xml:S2:1770:1	O

(	FANAPT.xml:S2:1772:1	O
5.1	FANAPT.xml:S2:1775:3	O
)	FANAPT.xml:S2:1780:1	O
\n	FANAPT.xml:S2:1783:1	O
5	FANAPT.xml:S3:4:1	O
WARNINGS	FANAPT.xml:S3:10:8	O
AND	FANAPT.xml:S3:19:3	O
PRECAUTIONS	FANAPT.xml:S3:23:11	O

EXCERPT	FANAPT.xml:S3:41:7	O
:	FANAPT.xml:S3:48:1	O
Elderly	FANAPT.xml:S3:57:7	O
patients	FANAPT.xml:S3:65:8	O
with	FANAPT.xml:S3:74:4	O
dementia	FANAPT.xml:S3:79:8	O
-	FANAPT.xml:S3:87:1	O
related	FANAPT.xml:S3:88:7	O
psychosis	FANAPT.xml:S3:96:9	O
who	FANAPT.xml:S3:106:3	O
are	FANAPT.xml:S3:110:3	O
treated	FANAPT.xml:S3:114:7	O
with	FANAPT.xml:S3:122:4	O
atypical	FANAPT.xml:S3:127:8	B-DrugClass
antipsychotic	FANAPT.xml:S3:136:13	I-DrugClass
drugs	FANAPT.xml:S3:150:5	I-DrugClass
are	FANAPT.xml:S3:156:3	O
at	FANAPT.xml:S3:160:2	O
an	FANAPT.xml:S3:163:2	O
increased	FANAPT.xml:S3:166:9	O
risk	FANAPT.xml:S3:176:4	O
of	FANAPT.xml:S3:181:2	O
death	FANAPT.xml:S3:184:5	B-AdverseReaction
and	FANAPT.xml:S3:190:3	O
cerebrovascular	FANAPT.xml:S3:194:15	B-AdverseReaction
-	FANAPT.xml:S3:209:1	I-AdverseReaction
related	FANAPT.xml:S3:210:7	I-AdverseReaction
adverse	FANAPT.xml:S3:218:7	I-AdverseReaction
events	FANAPT.xml:S3:226:6	I-AdverseReaction
,	FANAPT.xml:S3:232:1	O
including	FANAPT.xml:S3:234:9	O
stroke	FANAPT.xml:S3:244:6	B-AdverseReaction
.	FANAPT.xml:S3:250:1	O

(	FANAPT.xml:S3:252:1	O
5.1	FANAPT.xml:S3:255:3	O
)	FANAPT.xml:S3:260:1	O

QT	FANAPT.xml:S3:268:2	B-AdverseReaction
prolongation	FANAPT.xml:S3:271:12	I-AdverseReaction
:	FANAPT.xml:S3:283:1	O
Prolongs	FANAPT.xml:S3:285:8	B-AdverseReaction
QT	FANAPT.xml:S3:294:2	I-AdverseReaction
interval	FANAPT.xml:S3:297:8	I-AdverseReaction
and	FANAPT.xml:S3:306:3	O
may	FANAPT.xml:S3:310:3	B-Factor
be	FANAPT.xml:S3:314:2	O
associated	FANAPT.xml:S3:317:10	O
with	FANAPT.xml:S3:328:4	O
arrhythmia	FANAPT.xml:S3:333:10	B-AdverseReaction
and	FANAPT.xml:S3:344:3	O
sudden	FANAPT.xml:S3:348:6	B-AdverseReaction
death	FANAPT.xml:S3:355:5	I-AdverseReaction
-	FANAPT.xml:S3:360:1	O
consider	FANAPT.xml:S3:361:8	O
using	FANAPT.xml:S3:370:5	O
other	FANAPT.xml:S3:376:5	O
antipsychotics	FANAPT.xml:S3:382:14	O
first	FANAPT.xml:S3:397:5	O
.	FANAPT.xml:S3:402:1	O

Avoid	FANAPT.xml:S3:404:5	O
use	FANAPT.xml:S3:410:3	O
of	FANAPT.xml:S3:414:2	O
FANAPT	FANAPT.xml:S3:417:6	O
in	FANAPT.xml:S3:424:2	O
combination	FANAPT.xml:S3:427:11	O
with	FANAPT.xml:S3:439:4	O
other	FANAPT.xml:S3:444:5	O
drugs	FANAPT.xml:S3:450:5	O
that	FANAPT.xml:S3:456:4	O
are	FANAPT.xml:S3:461:3	O
known	FANAPT.xml:S3:465:5	O
to	FANAPT.xml:S3:471:2	O
prolong	FANAPT.xml:S3:474:7	O
QTc	FANAPT.xml:S3:482:3	O
;	FANAPT.xml:S3:485:1	O
use	FANAPT.xml:S3:487:3	O
caution	FANAPT.xml:S3:491:7	O
and	FANAPT.xml:S3:499:3	O
consider	FANAPT.xml:S3:503:8	O
dose	FANAPT.xml:S3:512:4	O
modification	FANAPT.xml:S3:517:12	O
when	FANAPT.xml:S3:530:4	O
prescribing	FANAPT.xml:S3:535:11	O
FANAPT	FANAPT.xml:S3:547:6	O
with	FANAPT.xml:S3:554:4	O
other	FANAPT.xml:S3:559:5	O
drugs	FANAPT.xml:S3:565:5	O
that	FANAPT.xml:S3:571:4	O
inhibit	FANAPT.xml:S3:576:7	O
FANAPT	FANAPT.xml:S3:584:6	O
metabolism	FANAPT.xml:S3:591:10	O
.	FANAPT.xml:S3:601:1	O

Monitor	FANAPT.xml:S3:603:7	O
serum	FANAPT.xml:S3:611:5	O
potassium	FANAPT.xml:S3:617:9	O
and	FANAPT.xml:S3:627:3	O
magnesium	FANAPT.xml:S3:631:9	O
in	FANAPT.xml:S3:641:2	O
patients	FANAPT.xml:S3:644:8	O
at	FANAPT.xml:S3:653:2	O
risk	FANAPT.xml:S3:656:4	O
for	FANAPT.xml:S3:661:3	O
electrolyte	FANAPT.xml:S3:665:11	O
disturbances	FANAPT.xml:S3:677:12	O
.	FANAPT.xml:S3:689:1	O

(	FANAPT.xml:S3:691:1	O
1	FANAPT.xml:S3:694:1	O
,	FANAPT.xml:S3:697:1	O
5.2	FANAPT.xml:S3:700:3	O
,	FANAPT.xml:S3:705:1	O
7.1	FANAPT.xml:S3:708:3	O
,	FANAPT.xml:S3:713:1	O
7.3	FANAPT.xml:S3:716:3	O
,	FANAPT.xml:S3:721:1	O
12.3	FANAPT.xml:S3:724:4	O
)	FANAPT.xml:S3:730:1	O

Neuroleptic	FANAPT.xml:S3:738:11	B-AdverseReaction
Malignant	FANAPT.xml:S3:750:9	I-AdverseReaction
Syndrome	FANAPT.xml:S3:760:8	I-AdverseReaction
:	FANAPT.xml:S3:768:1	O
Manage	FANAPT.xml:S3:770:6	O
with	FANAPT.xml:S3:777:4	O
immediate	FANAPT.xml:S3:782:9	O
discontinuation	FANAPT.xml:S3:792:15	O
of	FANAPT.xml:S3:808:2	O
drug	FANAPT.xml:S3:811:4	O
and	FANAPT.xml:S3:816:3	O
close	FANAPT.xml:S3:820:5	O
monitoring	FANAPT.xml:S3:826:10	O
.	FANAPT.xml:S3:836:1	O

(	FANAPT.xml:S3:838:1	O
5.3	FANAPT.xml:S3:841:3	O
)	FANAPT.xml:S3:846:1	O

Tardive	FANAPT.xml:S3:854:7	B-AdverseReaction
dyskinesia	FANAPT.xml:S3:862:10	I-AdverseReaction
:	FANAPT.xml:S3:872:1	O
Discontinue	FANAPT.xml:S3:874:11	O
if	FANAPT.xml:S3:886:2	O
clinically	FANAPT.xml:S3:889:10	O
appropriate	FANAPT.xml:S3:900:11	O
.	FANAPT.xml:S3:911:1	O

(	FANAPT.xml:S3:913:1	O
5.4	FANAPT.xml:S3:916:3	O
)	FANAPT.xml:S3:921:1	O

Hyperglycemia	FANAPT.xml:S3:932:13	B-AdverseReaction
and	FANAPT.xml:S3:946:3	O
diabetes	FANAPT.xml:S3:950:8	B-AdverseReaction
mellitus	FANAPT.xml:S3:959:8	I-AdverseReaction
:	FANAPT.xml:S3:967:1	O
Monitor	FANAPT.xml:S3:969:7	O
patients	FANAPT.xml:S3:977:8	O
for	FANAPT.xml:S3:986:3	O
symptoms	FANAPT.xml:S3:990:8	O
of	FANAPT.xml:S3:999:2	O
hyperglycemia	FANAPT.xml:S3:1002:13	O
including	FANAPT.xml:S3:1016:9	O
polydipsia	FANAPT.xml:S3:1026:10	O
,	FANAPT.xml:S3:1036:1	O
polyuria	FANAPT.xml:S3:1038:8	O
,	FANAPT.xml:S3:1046:1	O
polyphagia	FANAPT.xml:S3:1048:10	O
,	FANAPT.xml:S3:1058:1	O
and	FANAPT.xml:S3:1060:3	O
weakness	FANAPT.xml:S3:1064:8	O
.	FANAPT.xml:S3:1072:1	O

Monitor	FANAPT.xml:S3:1074:7	O
glucose	FANAPT.xml:S3:1082:7	O
regularly	FANAPT.xml:S3:1090:9	O
in	FANAPT.xml:S3:1100:2	O
patients	FANAPT.xml:S3:1103:8	O
at	FANAPT.xml:S3:1112:2	O
risk	FANAPT.xml:S3:1115:4	O
for	FANAPT.xml:S3:1120:3	O
diabetes	FANAPT.xml:S3:1124:8	O
.	FANAPT.xml:S3:1132:1	O

(	FANAPT.xml:S3:1134:1	O
5.5	FANAPT.xml:S3:1137:3	O
)	FANAPT.xml:S3:1142:1	O

Dyslipidemia	FANAPT.xml:S3:1150:12	B-AdverseReaction
:	FANAPT.xml:S3:1162:1	O
Undesirable	FANAPT.xml:S3:1164:11	O
alterations	FANAPT.xml:S3:1176:11	O
have	FANAPT.xml:S3:1188:4	O
been	FANAPT.xml:S3:1193:4	O
observed	FANAPT.xml:S3:1198:8	O
in	FANAPT.xml:S3:1207:2	O
patients	FANAPT.xml:S3:1210:8	O
treated	FANAPT.xml:S3:1219:7	O
with	FANAPT.xml:S3:1227:4	O
atypical	FANAPT.xml:S3:1232:8	O
antipsychotics	FANAPT.xml:S3:1241:14	O
.	FANAPT.xml:S3:1255:1	O

(	FANAPT.xml:S3:1257:1	O
5.5	FANAPT.xml:S3:1260:3	O
)	FANAPT.xml:S3:1265:1	O

Weight	FANAPT.xml:S3:1273:6	B-AdverseReaction
Gain	FANAPT.xml:S3:1280:4	I-AdverseReaction
:	FANAPT.xml:S3:1284:1	O
Weight	FANAPT.xml:S3:1286:6	O
gain	FANAPT.xml:S3:1293:4	O
has	FANAPT.xml:S3:1298:3	O
been	FANAPT.xml:S3:1302:4	O
reported	FANAPT.xml:S3:1307:8	O
.	FANAPT.xml:S3:1315:1	O

Monitor	FANAPT.xml:S3:1317:7	O
weight	FANAPT.xml:S3:1325:6	O
.	FANAPT.xml:S3:1331:1	O

(	FANAPT.xml:S3:1333:1	O
5.5	FANAPT.xml:S3:1336:3	O
)	FANAPT.xml:S3:1341:1	O

Metabolic	FANAPT.xml:S3:1348:9	B-AdverseReaction
Changes	FANAPT.xml:S3:1358:7	I-AdverseReaction
:	FANAPT.xml:S3:1365:1	O
Atypical	FANAPT.xml:S3:1367:8	B-DrugClass
antipsychotic	FANAPT.xml:S3:1376:13	I-DrugClass
drugs	FANAPT.xml:S3:1390:5	I-DrugClass
have	FANAPT.xml:S3:1396:4	O
been	FANAPT.xml:S3:1401:4	O
associated	FANAPT.xml:S3:1406:10	O
with	FANAPT.xml:S3:1417:4	O
metabolic	FANAPT.xml:S3:1422:9	O
changes	FANAPT.xml:S3:1432:7	O
that	FANAPT.xml:S3:1440:4	O
may	FANAPT.xml:S3:1445:3	O
increase	FANAPT.xml:S3:1449:8	O
cardiovascular	FANAPT.xml:S3:1458:14	B-AdverseReaction
cerebrovascular	FANAPT.xml:S3:1473:15	B-AdverseReaction
risk	FANAPT.xml:S3:1489:4	I-AdverseReaction
.	FANAPT.xml:S3:1493:1	O

These	FANAPT.xml:S3:1495:5	O
metabolic	FANAPT.xml:S3:1501:9	B-AdverseReaction
changes	FANAPT.xml:S3:1511:7	I-AdverseReaction
include	FANAPT.xml:S3:1519:7	O
hyperglycemia	FANAPT.xml:S3:1527:13	B-AdverseReaction
,	FANAPT.xml:S3:1540:1	O
dyslipidemia	FANAPT.xml:S3:1542:12	B-AdverseReaction
,	FANAPT.xml:S3:1554:1	O
and	FANAPT.xml:S3:1556:3	O
weight	FANAPT.xml:S3:1560:6	B-AdverseReaction
gain	FANAPT.xml:S3:1567:4	I-AdverseReaction
.	FANAPT.xml:S3:1571:1	O

(	FANAPT.xml:S3:1573:1	O
5.5	FANAPT.xml:S3:1576:3	O
)	FANAPT.xml:S3:1581:1	O

Seizures	FANAPT.xml:S3:1589:8	B-AdverseReaction
:	FANAPT.xml:S3:1597:1	O
Use	FANAPT.xml:S3:1599:3	O
cautiously	FANAPT.xml:S3:1603:10	O
in	FANAPT.xml:S3:1614:2	O
patients	FANAPT.xml:S3:1617:8	O
with	FANAPT.xml:S3:1626:4	O
a	FANAPT.xml:S3:1631:1	O
history	FANAPT.xml:S3:1633:7	O
of	FANAPT.xml:S3:1641:2	O
seizures	FANAPT.xml:S3:1644:8	O
or	FANAPT.xml:S3:1653:2	O
with	FANAPT.xml:S3:1656:4	O
conditions	FANAPT.xml:S3:1661:10	O
that	FANAPT.xml:S3:1672:4	O
lower	FANAPT.xml:S3:1677:5	O
seizure	FANAPT.xml:S3:1683:7	O
threshold	FANAPT.xml:S3:1691:9	O
.	FANAPT.xml:S3:1700:1	O

(	FANAPT.xml:S3:1702:1	O
5.6	FANAPT.xml:S3:1705:3	O
)	FANAPT.xml:S3:1710:1	O

Orthostatic	FANAPT.xml:S3:1718:11	B-AdverseReaction
hypotension	FANAPT.xml:S3:1730:11	I-AdverseReaction
:	FANAPT.xml:S3:1741:1	O
Dizziness	FANAPT.xml:S3:1743:9	B-AdverseReaction
,	FANAPT.xml:S3:1752:1	O
tachycardia	FANAPT.xml:S3:1754:11	B-AdverseReaction
,	FANAPT.xml:S3:1765:1	O
and	FANAPT.xml:S3:1767:3	O
syncope	FANAPT.xml:S3:1771:7	B-AdverseReaction
can	FANAPT.xml:S3:1779:3	B-Factor
occur	FANAPT.xml:S3:1783:5	O
with	FANAPT.xml:S3:1789:4	O
standing	FANAPT.xml:S3:1794:8	O
.	FANAPT.xml:S3:1802:1	O

(	FANAPT.xml:S3:1804:1	O
5.7	FANAPT.xml:S3:1807:3	O
)	FANAPT.xml:S3:1812:1	O

Leukopenia	FANAPT.xml:S3:1820:10	B-AdverseReaction
,	FANAPT.xml:S3:1830:1	O
Neutropenia	FANAPT.xml:S3:1832:11	B-AdverseReaction
,	FANAPT.xml:S3:1843:1	O
and	FANAPT.xml:S3:1845:3	O
Agranulocytosis	FANAPT.xml:S3:1849:15	B-AdverseReaction
have	FANAPT.xml:S3:1865:4	O
been	FANAPT.xml:S3:1870:4	O
reported	FANAPT.xml:S3:1875:8	O
with	FANAPT.xml:S3:1884:4	O
antipsychotics	FANAPT.xml:S3:1889:14	B-DrugClass
.	FANAPT.xml:S3:1903:1	O

Patients	FANAPT.xml:S3:1905:8	O
with	FANAPT.xml:S3:1914:4	O
a	FANAPT.xml:S3:1919:1	O
pre	FANAPT.xml:S3:1921:3	O
-	FANAPT.xml:S3:1924:1	O
existing	FANAPT.xml:S3:1925:8	O
low	FANAPT.xml:S3:1934:3	O
white	FANAPT.xml:S3:1938:5	O
blood	FANAPT.xml:S3:1944:5	O
cell	FANAPT.xml:S3:1950:4	O
count	FANAPT.xml:S3:1955:5	O
(	FANAPT.xml:S3:1961:1	O
WBC	FANAPT.xml:S3:1962:3	O
)	FANAPT.xml:S3:1965:1	O
or	FANAPT.xml:S3:1967:2	O
a	FANAPT.xml:S3:1970:1	O
history	FANAPT.xml:S3:1972:7	O
of	FANAPT.xml:S3:1980:2	O
leukopenia	FANAPT.xml:S3:1983:10	O
neutropenia	FANAPT.xml:S3:1994:11	O
should	FANAPT.xml:S3:2006:6	O
have	FANAPT.xml:S3:2013:4	O
their	FANAPT.xml:S3:2018:5	O
complete	FANAPT.xml:S3:2024:8	O
blood	FANAPT.xml:S3:2033:5	O
count	FANAPT.xml:S3:2039:5	O
(	FANAPT.xml:S3:2045:1	O
CBC	FANAPT.xml:S3:2046:3	O
)	FANAPT.xml:S3:2049:1	O
monitored	FANAPT.xml:S3:2051:9	O
frequently	FANAPT.xml:S3:2061:10	O
during	FANAPT.xml:S3:2072:6	O
the	FANAPT.xml:S3:2079:3	O
first	FANAPT.xml:S3:2083:5	O
few	FANAPT.xml:S3:2089:3	O
months	FANAPT.xml:S3:2093:6	O
of	FANAPT.xml:S3:2100:2	O
therapy	FANAPT.xml:S3:2103:7	O
and	FANAPT.xml:S3:2111:3	O
should	FANAPT.xml:S3:2115:6	O
discontinue	FANAPT.xml:S3:2122:11	O
FANAPT	FANAPT.xml:S3:2134:6	O
at	FANAPT.xml:S3:2141:2	O
the	FANAPT.xml:S3:2144:3	O
first	FANAPT.xml:S3:2148:5	O
sign	FANAPT.xml:S3:2154:4	O
of	FANAPT.xml:S3:2159:2	O
a	FANAPT.xml:S3:2162:1	O
decline	FANAPT.xml:S3:2164:7	O
in	FANAPT.xml:S3:2172:2	O
WBC	FANAPT.xml:S3:2175:3	O
in	FANAPT.xml:S3:2179:2	O
the	FANAPT.xml:S3:2182:3	O
absence	FANAPT.xml:S3:2186:7	O
of	FANAPT.xml:S3:2194:2	O
other	FANAPT.xml:S3:2197:5	O
causative	FANAPT.xml:S3:2203:9	O
factors	FANAPT.xml:S3:2213:7	O
.	FANAPT.xml:S3:2220:1	O

(	FANAPT.xml:S3:2222:1	O
5.8	FANAPT.xml:S3:2225:3	O
)	FANAPT.xml:S3:2230:1	O

Suicide	FANAPT.xml:S3:2238:7	B-AdverseReaction
:	FANAPT.xml:S3:2245:1	O
Close	FANAPT.xml:S3:2247:5	O
supervision	FANAPT.xml:S3:2253:11	O
of	FANAPT.xml:S3:2265:2	O
high	FANAPT.xml:S3:2268:4	O
risk	FANAPT.xml:S3:2273:4	O
patients	FANAPT.xml:S3:2278:8	O
.	FANAPT.xml:S3:2286:1	O

(	FANAPT.xml:S3:2288:1	O
5.12	FANAPT.xml:S3:2291:4	O
)	FANAPT.xml:S3:2297:1	O

Priapism	FANAPT.xml:S3:2305:8	B-AdverseReaction
:	FANAPT.xml:S3:2313:1	O
Cases	FANAPT.xml:S3:2315:5	O
have	FANAPT.xml:S3:2321:4	O
been	FANAPT.xml:S3:2326:4	O
reported	FANAPT.xml:S3:2331:8	O
in	FANAPT.xml:S3:2340:2	O
association	FANAPT.xml:S3:2343:11	O
with	FANAPT.xml:S3:2355:4	O
FANAPT	FANAPT.xml:S3:2360:6	O
treatment	FANAPT.xml:S3:2367:9	O
.	FANAPT.xml:S3:2376:1	O

(	FANAPT.xml:S3:2378:1	O
5.13	FANAPT.xml:S3:2381:4	O
)	FANAPT.xml:S3:2387:1	O

Potential	FANAPT.xml:S3:2395:9	B-Factor
for	FANAPT.xml:S3:2405:3	O
cognitive	FANAPT.xml:S3:2409:9	B-AdverseReaction
and	FANAPT.xml:S3:2419:3	O
motor	FANAPT.xml:S3:2423:5	B-AdverseReaction
impairment	FANAPT.xml:S3:2429:10	I-AdverseReaction
:	FANAPT.xml:S3:2439:1	O
Use	FANAPT.xml:S3:2441:3	O
caution	FANAPT.xml:S3:2445:7	O
when	FANAPT.xml:S3:2453:4	O
operating	FANAPT.xml:S3:2458:9	O
machinery	FANAPT.xml:S3:2468:9	O
.	FANAPT.xml:S3:2477:1	O

(	FANAPT.xml:S3:2479:1	O
5.14	FANAPT.xml:S3:2482:4	O
)	FANAPT.xml:S3:2488:1	O

See	FANAPT.xml:S3:2495:3	O
Full	FANAPT.xml:S3:2499:4	O
Prescribing	FANAPT.xml:S3:2504:11	O
Information	FANAPT.xml:S3:2516:11	O
for	FANAPT.xml:S3:2528:3	O
additional	FANAPT.xml:S3:2532:10	O
WARNINGS	FANAPT.xml:S3:2543:8	O
and	FANAPT.xml:S3:2552:3	O
PRECAUTIONS	FANAPT.xml:S3:2556:11	O
.	FANAPT.xml:S3:2567:1	O

5.1	FANAPT.xml:S3:2582:3	O

Increased	FANAPT.xml:S3:2590:9	O

Risks	FANAPT.xml:S3:2600:5	O
in	FANAPT.xml:S3:2606:2	O
Elderly	FANAPT.xml:S3:2609:7	O
Patients	FANAPT.xml:S3:2617:8	O
with	FANAPT.xml:S3:2626:4	O
Dementia	FANAPT.xml:S3:2631:8	O
-	FANAPT.xml:S3:2639:1	O
Related	FANAPT.xml:S3:2640:7	O
Psychosis	FANAPT.xml:S3:2648:9	O

Increased	FANAPT.xml:S3:2664:9	O
Mortality	FANAPT.xml:S3:2674:9	O

Elderly	FANAPT.xml:S3:2691:7	O
patients	FANAPT.xml:S3:2699:8	O
with	FANAPT.xml:S3:2708:4	O
dementia	FANAPT.xml:S3:2713:8	O
-	FANAPT.xml:S3:2721:1	O
related	FANAPT.xml:S3:2722:7	O
psychosis	FANAPT.xml:S3:2730:9	O
treated	FANAPT.xml:S3:2740:7	O
with	FANAPT.xml:S3:2748:4	O
atypical	FANAPT.xml:S3:2753:8	B-DrugClass
antipsychotic	FANAPT.xml:S3:2762:13	I-DrugClass
drugs	FANAPT.xml:S3:2776:5	I-DrugClass
are	FANAPT.xml:S3:2782:3	O
at	FANAPT.xml:S3:2786:2	O
an	FANAPT.xml:S3:2789:2	O
increased	FANAPT.xml:S3:2792:9	O
risk	FANAPT.xml:S3:2802:4	O
of	FANAPT.xml:S3:2807:2	O
death	FANAPT.xml:S3:2810:5	B-AdverseReaction
compared	FANAPT.xml:S3:2816:8	O
to	FANAPT.xml:S3:2825:2	O
placebo	FANAPT.xml:S3:2828:7	O
.	FANAPT.xml:S3:2835:1	O

FANAPT	FANAPT.xml:S3:2839:6	O
is	FANAPT.xml:S3:2848:2	O
not	FANAPT.xml:S3:2851:3	O
approved	FANAPT.xml:S3:2855:8	O
for	FANAPT.xml:S3:2864:3	O
the	FANAPT.xml:S3:2868:3	O
treatment	FANAPT.xml:S3:2872:9	O
of	FANAPT.xml:S3:2882:2	O
patients	FANAPT.xml:S3:2885:8	O
with	FANAPT.xml:S3:2894:4	O
dementia	FANAPT.xml:S3:2899:8	O
-	FANAPT.xml:S3:2907:1	O
related	FANAPT.xml:S3:2908:7	O
psychosis	FANAPT.xml:S3:2916:9	O
[	FANAPT.xml:S3:2932:1	O
s	FANAPT.xml:S3:2933:1	O
ee	FANAPT.xml:S3:2937:2	O
Boxed	FANAPT.xml:S3:2940:5	O
Warning	FANAPT.xml:S3:2946:7	O
]	FANAPT.xml:S3:2956:1	O
.	FANAPT.xml:S3:2960:1	O

Cerebrovascular	FANAPT.xml:S3:2969:15	O
Adverse	FANAPT.xml:S3:2985:7	O
Events	FANAPT.xml:S3:2993:6	O
,	FANAPT.xml:S3:2999:1	O
Including	FANAPT.xml:S3:3001:9	O
Stroke	FANAPT.xml:S3:3011:6	O

In	FANAPT.xml:S3:3024:2	O
placebo	FANAPT.xml:S3:3027:7	O
-	FANAPT.xml:S3:3034:1	O
controlled	FANAPT.xml:S3:3035:10	O
trials	FANAPT.xml:S3:3046:6	O
with	FANAPT.xml:S3:3053:4	O
risperidone	FANAPT.xml:S3:3058:11	O
,	FANAPT.xml:S3:3069:1	O
aripiprazole	FANAPT.xml:S3:3071:12	O
,	FANAPT.xml:S3:3083:1	O
and	FANAPT.xml:S3:3085:3	O
olanzapine	FANAPT.xml:S3:3089:10	O
in	FANAPT.xml:S3:3100:2	O
elderly	FANAPT.xml:S3:3103:7	O
patients	FANAPT.xml:S3:3111:8	O
with	FANAPT.xml:S3:3120:4	O
dementia	FANAPT.xml:S3:3125:8	O
,	FANAPT.xml:S3:3133:1	O
there	FANAPT.xml:S3:3135:5	O
was	FANAPT.xml:S3:3141:3	O
a	FANAPT.xml:S3:3145:1	O
higher	FANAPT.xml:S3:3147:6	O
incidence	FANAPT.xml:S3:3154:9	O
of	FANAPT.xml:S3:3164:2	O
cerebrovascular	FANAPT.xml:S3:3167:15	B-AdverseReaction
adverse	FANAPT.xml:S3:3183:7	I-AdverseReaction
events	FANAPT.xml:S3:3191:6	I-AdverseReaction
(	FANAPT.xml:S3:3198:1	O
cerebrovascular	FANAPT.xml:S3:3199:15	B-AdverseReaction
accidents	FANAPT.xml:S3:3215:9	I-AdverseReaction
and	FANAPT.xml:S3:3225:3	O
transient	FANAPT.xml:S3:3229:9	B-AdverseReaction
ischemic	FANAPT.xml:S3:3239:8	I-AdverseReaction
attacks	FANAPT.xml:S3:3248:7	I-AdverseReaction
)	FANAPT.xml:S3:3255:1	O
including	FANAPT.xml:S3:3257:9	O
fatalities	FANAPT.xml:S3:3267:10	B-AdverseReaction
compared	FANAPT.xml:S3:3278:8	O
to	FANAPT.xml:S3:3287:2	O
placebo	FANAPT.xml:S3:3290:7	O
-	FANAPT.xml:S3:3297:1	O
treated	FANAPT.xml:S3:3298:7	O
patients	FANAPT.xml:S3:3306:8	O
.	FANAPT.xml:S3:3314:1	O

FANAPT	FANAPT.xml:S3:3316:6	O
is	FANAPT.xml:S3:3323:2	O
not	FANAPT.xml:S3:3326:3	O
approved	FANAPT.xml:S3:3330:8	O
for	FANAPT.xml:S3:3339:3	O
the	FANAPT.xml:S3:3343:3	O
treatment	FANAPT.xml:S3:3347:9	O
of	FANAPT.xml:S3:3357:2	O
patients	FANAPT.xml:S3:3360:8	O
with	FANAPT.xml:S3:3369:4	O
dementia	FANAPT.xml:S3:3374:8	O
-	FANAPT.xml:S3:3382:1	O
related	FANAPT.xml:S3:3383:7	O
psychosis	FANAPT.xml:S3:3391:9	O
[	FANAPT.xml:S3:3402:1	O
s	FANAPT.xml:S3:3403:1	O
ee	FANAPT.xml:S3:3407:2	O
Boxed	FANAPT.xml:S3:3410:5	O
Warning	FANAPT.xml:S3:3416:7	O
]	FANAPT.xml:S3:3426:1	O
.	FANAPT.xml:S3:3429:1	O

5.2	FANAPT.xml:S3:3438:3	O
QT	FANAPT.xml:S3:3446:2	O
Prolongation	FANAPT.xml:S3:3449:12	O

In	FANAPT.xml:S3:3467:2	O
an	FANAPT.xml:S3:3470:2	O
open	FANAPT.xml:S3:3473:4	O
-	FANAPT.xml:S3:3477:1	O
label	FANAPT.xml:S3:3478:5	O
QTc	FANAPT.xml:S3:3484:3	O
study	FANAPT.xml:S3:3488:5	O
in	FANAPT.xml:S3:3494:2	O
patients	FANAPT.xml:S3:3497:8	O
with	FANAPT.xml:S3:3506:4	O
schizophrenia	FANAPT.xml:S3:3511:13	O
or	FANAPT.xml:S3:3525:2	O
schizoaffective	FANAPT.xml:S3:3528:15	O
disorder	FANAPT.xml:S3:3544:8	O
(	FANAPT.xml:S3:3553:1	O
n	FANAPT.xml:S3:3554:1	O
160	FANAPT.xml:S3:3556:3	O
)	FANAPT.xml:S3:3559:1	O
,	FANAPT.xml:S3:3560:1	O
FANAPT	FANAPT.xml:S3:3562:6	O
was	FANAPT.xml:S3:3569:3	O
associated	FANAPT.xml:S3:3573:10	O
with	FANAPT.xml:S3:3584:4	O
QTc	FANAPT.xml:S3:3589:3	B-AdverseReaction
prolongation	FANAPT.xml:S3:3593:12	I-AdverseReaction
of	FANAPT.xml:S3:3606:2	O
9	FANAPT.xml:S3:3609:1	O
msec	FANAPT.xml:S3:3611:4	O
at	FANAPT.xml:S3:3616:2	O
an	FANAPT.xml:S3:3619:2	O
iloperidone	FANAPT.xml:S3:3622:11	O
dose	FANAPT.xml:S3:3634:4	O
of	FANAPT.xml:S3:3639:2	O
12	FANAPT.xml:S3:3642:2	O
mg	FANAPT.xml:S3:3645:2	O
twice	FANAPT.xml:S3:3648:5	O
daily	FANAPT.xml:S3:3654:5	O
.	FANAPT.xml:S3:3659:1	O

The	FANAPT.xml:S3:3661:3	O
effect	FANAPT.xml:S3:3665:6	O
of	FANAPT.xml:S3:3672:2	O
FANAPT	FANAPT.xml:S3:3675:6	O
on	FANAPT.xml:S3:3682:2	O
the	FANAPT.xml:S3:3685:3	O
QT	FANAPT.xml:S3:3689:2	O
interval	FANAPT.xml:S3:3692:8	O
was	FANAPT.xml:S3:3701:3	O
augmented	FANAPT.xml:S3:3705:9	O
by	FANAPT.xml:S3:3715:2	O
the	FANAPT.xml:S3:3718:3	O
presence	FANAPT.xml:S3:3722:8	O
of	FANAPT.xml:S3:3731:2	O
CYP450	FANAPT.xml:S3:3734:6	O
2	FANAPT.xml:S3:3741:1	O
D6	FANAPT.xml:S3:3742:2	O
or	FANAPT.xml:S3:3745:2	O
3	FANAPT.xml:S3:3748:1	O
A4	FANAPT.xml:S3:3749:2	O
metabolic	FANAPT.xml:S3:3752:9	O
inhibition	FANAPT.xml:S3:3762:10	O
(	FANAPT.xml:S3:3773:1	O
paroxetine	FANAPT.xml:S3:3774:10	O
20	FANAPT.xml:S3:3785:2	O
mg	FANAPT.xml:S3:3788:2	O
once	FANAPT.xml:S3:3791:4	O
daily	FANAPT.xml:S3:3796:5	O
and	FANAPT.xml:S3:3802:3	O
ketoconazole	FANAPT.xml:S3:3806:12	O
200	FANAPT.xml:S3:3819:3	O
mg	FANAPT.xml:S3:3823:2	O
twice	FANAPT.xml:S3:3826:5	O
daily	FANAPT.xml:S3:3832:5	O
,	FANAPT.xml:S3:3837:1	O
respectively	FANAPT.xml:S3:3839:12	O
)	FANAPT.xml:S3:3851:1	O
.	FANAPT.xml:S3:3852:1	O

Under	FANAPT.xml:S3:3854:5	O
conditions	FANAPT.xml:S3:3860:10	O
of	FANAPT.xml:S3:3871:2	O
metabolic	FANAPT.xml:S3:3874:9	O
inhibition	FANAPT.xml:S3:3884:10	O
for	FANAPT.xml:S3:3895:3	O
both	FANAPT.xml:S3:3899:4	O
2	FANAPT.xml:S3:3904:1	O
D6	FANAPT.xml:S3:3905:2	O
and	FANAPT.xml:S3:3908:3	O
3	FANAPT.xml:S3:3912:1	O
A4	FANAPT.xml:S3:3913:2	O
,	FANAPT.xml:S3:3915:1	O
FANAPT	FANAPT.xml:S3:3917:6	O
12	FANAPT.xml:S3:3924:2	O
mg	FANAPT.xml:S3:3927:2	O
twice	FANAPT.xml:S3:3930:5	O
daily	FANAPT.xml:S3:3936:5	O
was	FANAPT.xml:S3:3942:3	O
associated	FANAPT.xml:S3:3946:10	O
with	FANAPT.xml:S3:3957:4	O
a	FANAPT.xml:S3:3962:1	O
mean	FANAPT.xml:S3:3964:4	O
QTcF	FANAPT.xml:S3:3969:4	B-AdverseReaction
increase	FANAPT.xml:S3:3974:8	I-AdverseReaction
from	FANAPT.xml:S3:3983:4	O
baseline	FANAPT.xml:S3:3988:8	O
of	FANAPT.xml:S3:3997:2	O
about	FANAPT.xml:S3:4000:5	O
19	FANAPT.xml:S3:4006:2	O
msec	FANAPT.xml:S3:4009:4	O
.	FANAPT.xml:S3:4013:1	O

No	FANAPT.xml:S3:4019:2	B-Negation
cases	FANAPT.xml:S3:4022:5	O
of	FANAPT.xml:S3:4028:2	O
torsade	FANAPT.xml:S3:4031:7	B-AdverseReaction
de	FANAPT.xml:S3:4039:2	I-AdverseReaction
pointes	FANAPT.xml:S3:4042:7	I-AdverseReaction
or	FANAPT.xml:S3:4050:2	O
other	FANAPT.xml:S3:4053:5	O
severe	FANAPT.xml:S3:4059:6	B-Severity
cardiac	FANAPT.xml:S3:4066:7	B-AdverseReaction
arrhythmias	FANAPT.xml:S3:4074:11	I-AdverseReaction
were	FANAPT.xml:S3:4086:4	O
observed	FANAPT.xml:S3:4091:8	O
during	FANAPT.xml:S3:4100:6	O
the	FANAPT.xml:S3:4107:3	O
pre	FANAPT.xml:S3:4111:3	O
-	FANAPT.xml:S3:4114:1	O
marketing	FANAPT.xml:S3:4115:9	O
clinical	FANAPT.xml:S3:4125:8	O
program	FANAPT.xml:S3:4134:7	O
.	FANAPT.xml:S3:4141:1	O

The	FANAPT.xml:S3:4147:3	O
use	FANAPT.xml:S3:4151:3	O
of	FANAPT.xml:S3:4155:2	O
FANAPT	FANAPT.xml:S3:4158:6	O
should	FANAPT.xml:S3:4165:6	O
be	FANAPT.xml:S3:4172:2	O
avoided	FANAPT.xml:S3:4175:7	O
in	FANAPT.xml:S3:4183:2	O
combination	FANAPT.xml:S3:4186:11	O
with	FANAPT.xml:S3:4198:4	O
other	FANAPT.xml:S3:4203:5	O
drugs	FANAPT.xml:S3:4209:5	O
that	FANAPT.xml:S3:4215:4	O
are	FANAPT.xml:S3:4220:3	O
known	FANAPT.xml:S3:4224:5	O
to	FANAPT.xml:S3:4230:2	O
prolong	FANAPT.xml:S3:4233:7	O
QTc	FANAPT.xml:S3:4241:3	O
including	FANAPT.xml:S3:4245:9	O
Class	FANAPT.xml:S3:4255:5	O
1	FANAPT.xml:S3:4261:1	O
A	FANAPT.xml:S3:4262:1	O
(	FANAPT.xml:S3:4264:1	O
e	FANAPT.xml:S3:4265:1	O
.	FANAPT.xml:S3:4266:1	O
g	FANAPT.xml:S3:4267:1	O
.	FANAPT.xml:S3:4268:1	O
,	FANAPT.xml:S3:4269:1	O
quinidine	FANAPT.xml:S3:4271:9	O
,	FANAPT.xml:S3:4280:1	O
procainamide	FANAPT.xml:S3:4282:12	O
)	FANAPT.xml:S3:4294:1	O
or	FANAPT.xml:S3:4296:2	O
Class	FANAPT.xml:S3:4299:5	O
III	FANAPT.xml:S3:4305:3	O
(	FANAPT.xml:S3:4309:1	O
e	FANAPT.xml:S3:4310:1	O
.	FANAPT.xml:S3:4311:1	O
g	FANAPT.xml:S3:4312:1	O
.	FANAPT.xml:S3:4313:1	O
,	FANAPT.xml:S3:4314:1	O
amiodarone	FANAPT.xml:S3:4316:10	O
,	FANAPT.xml:S3:4326:1	O
sotalol	FANAPT.xml:S3:4328:7	O
)	FANAPT.xml:S3:4335:1	O
antiarrhythmic	FANAPT.xml:S3:4337:14	O
medications	FANAPT.xml:S3:4352:11	O
,	FANAPT.xml:S3:4363:1	O
antipsychotic	FANAPT.xml:S3:4365:13	O
medications	FANAPT.xml:S3:4379:11	O
(	FANAPT.xml:S3:4391:1	O
e	FANAPT.xml:S3:4392:1	O
.	FANAPT.xml:S3:4393:1	O
g	FANAPT.xml:S3:4394:1	O
.	FANAPT.xml:S3:4395:1	O
,	FANAPT.xml:S3:4396:1	O
chlorpromazine	FANAPT.xml:S3:4398:14	O
,	FANAPT.xml:S3:4412:1	O
thioridazine	FANAPT.xml:S3:4414:12	O
)	FANAPT.xml:S3:4426:1	O
,	FANAPT.xml:S3:4427:1	O
antibiotics	FANAPT.xml:S3:4429:11	O
(	FANAPT.xml:S3:4441:1	O
e	FANAPT.xml:S3:4442:1	O
.	FANAPT.xml:S3:4443:1	O
g	FANAPT.xml:S3:4444:1	O
.	FANAPT.xml:S3:4445:1	O
,	FANAPT.xml:S3:4446:1	O
gatifloxacin	FANAPT.xml:S3:4448:12	O
,	FANAPT.xml:S3:4460:1	O
moxifloxacin	FANAPT.xml:S3:4462:12	O
)	FANAPT.xml:S3:4474:1	O
,	FANAPT.xml:S3:4475:1	O
or	FANAPT.xml:S3:4477:2	O
any	FANAPT.xml:S3:4480:3	O
other	FANAPT.xml:S3:4484:5	O
class	FANAPT.xml:S3:4490:5	O
of	FANAPT.xml:S3:4496:2	O
medications	FANAPT.xml:S3:4499:11	O
known	FANAPT.xml:S3:4511:5	O
to	FANAPT.xml:S3:4517:2	O
prolong	FANAPT.xml:S3:4520:7	O
the	FANAPT.xml:S3:4528:3	O
QTc	FANAPT.xml:S3:4532:3	O
interval	FANAPT.xml:S3:4536:8	O
(	FANAPT.xml:S3:4545:1	O
e	FANAPT.xml:S3:4546:1	O
.	FANAPT.xml:S3:4547:1	O
g	FANAPT.xml:S3:4548:1	O
.	FANAPT.xml:S3:4549:1	O
,	FANAPT.xml:S3:4550:1	O
pentamidine	FANAPT.xml:S3:4552:11	O
,	FANAPT.xml:S3:4563:1	O
levomethadyl	FANAPT.xml:S3:4565:12	O
acetate	FANAPT.xml:S3:4578:7	O
,	FANAPT.xml:S3:4585:1	O
methadone	FANAPT.xml:S3:4587:9	O
)	FANAPT.xml:S3:4596:1	O
.	FANAPT.xml:S3:4597:1	O

FANAPT	FANAPT.xml:S3:4599:6	O
should	FANAPT.xml:S3:4606:6	O
also	FANAPT.xml:S3:4613:4	O
be	FANAPT.xml:S3:4618:2	O
avoided	FANAPT.xml:S3:4621:7	O
in	FANAPT.xml:S3:4629:2	O
patients	FANAPT.xml:S3:4632:8	O
with	FANAPT.xml:S3:4641:4	O
congenital	FANAPT.xml:S3:4646:10	O
long	FANAPT.xml:S3:4657:4	O
QT	FANAPT.xml:S3:4662:2	O
syndrome	FANAPT.xml:S3:4665:8	O
and	FANAPT.xml:S3:4674:3	O
in	FANAPT.xml:S3:4678:2	O
patients	FANAPT.xml:S3:4681:8	O
with	FANAPT.xml:S3:4690:4	O
a	FANAPT.xml:S3:4695:1	O
history	FANAPT.xml:S3:4697:7	O
of	FANAPT.xml:S3:4705:2	O
cardiac	FANAPT.xml:S3:4708:7	O
arrhythmias	FANAPT.xml:S3:4716:11	O
.	FANAPT.xml:S3:4727:1	O

Certain	FANAPT.xml:S3:4733:7	O
circumstances	FANAPT.xml:S3:4741:13	O
may	FANAPT.xml:S3:4755:3	O
increase	FANAPT.xml:S3:4759:8	O
the	FANAPT.xml:S3:4768:3	O
risk	FANAPT.xml:S3:4772:4	O
of	FANAPT.xml:S3:4777:2	O
torsade	FANAPT.xml:S3:4780:7	O
de	FANAPT.xml:S3:4788:2	O
pointes	FANAPT.xml:S3:4791:7	O
and	FANAPT.xml:S3:4799:3	O
or	FANAPT.xml:S3:4803:2	O
sudden	FANAPT.xml:S3:4806:6	O
death	FANAPT.xml:S3:4813:5	O
in	FANAPT.xml:S3:4819:2	O
association	FANAPT.xml:S3:4822:11	O
with	FANAPT.xml:S3:4834:4	O
the	FANAPT.xml:S3:4839:3	O
use	FANAPT.xml:S3:4843:3	O
of	FANAPT.xml:S3:4847:2	O
drugs	FANAPT.xml:S3:4850:5	O
that	FANAPT.xml:S3:4856:4	O
prolong	FANAPT.xml:S3:4861:7	O
the	FANAPT.xml:S3:4869:3	O
QTc	FANAPT.xml:S3:4873:3	O
interval	FANAPT.xml:S3:4877:8	O
,	FANAPT.xml:S3:4885:1	O
including	FANAPT.xml:S3:4887:9	O
(	FANAPT.xml:S3:4897:1	O
1	FANAPT.xml:S3:4898:1	O
)	FANAPT.xml:S3:4899:1	O
bradycardia	FANAPT.xml:S3:4901:11	O
;	FANAPT.xml:S3:4912:1	O
(	FANAPT.xml:S3:4914:1	O
2	FANAPT.xml:S3:4915:1	O
)	FANAPT.xml:S3:4916:1	O
hypokalemia	FANAPT.xml:S3:4918:11	O
or	FANAPT.xml:S3:4930:2	O
hypomagnesemia	FANAPT.xml:S3:4933:14	O
;	FANAPT.xml:S3:4947:1	O
(	FANAPT.xml:S3:4949:1	O
3	FANAPT.xml:S3:4950:1	O
)	FANAPT.xml:S3:4951:1	O
concomitant	FANAPT.xml:S3:4953:11	O
use	FANAPT.xml:S3:4965:3	O
of	FANAPT.xml:S3:4969:2	O
other	FANAPT.xml:S3:4972:5	O
drugs	FANAPT.xml:S3:4978:5	O
that	FANAPT.xml:S3:4984:4	O
prolong	FANAPT.xml:S3:4989:7	O
the	FANAPT.xml:S3:4997:3	O
QTc	FANAPT.xml:S3:5001:3	O
interval	FANAPT.xml:S3:5005:8	O
;	FANAPT.xml:S3:5013:1	O
and	FANAPT.xml:S3:5015:3	O
(	FANAPT.xml:S3:5019:1	O
4	FANAPT.xml:S3:5020:1	O
)	FANAPT.xml:S3:5021:1	O
presence	FANAPT.xml:S3:5023:8	O
of	FANAPT.xml:S3:5032:2	O
congenital	FANAPT.xml:S3:5035:10	O
prolongation	FANAPT.xml:S3:5046:12	O
of	FANAPT.xml:S3:5059:2	O
the	FANAPT.xml:S3:5062:3	O
QT	FANAPT.xml:S3:5066:2	O
interval	FANAPT.xml:S3:5069:8	O
;	FANAPT.xml:S3:5077:1	O
(	FANAPT.xml:S3:5079:1	O
5	FANAPT.xml:S3:5080:1	O
)	FANAPT.xml:S3:5081:1	O
recent	FANAPT.xml:S3:5083:6	O
acute	FANAPT.xml:S3:5090:5	O
myocardial	FANAPT.xml:S3:5096:10	O
infarction	FANAPT.xml:S3:5107:10	O
;	FANAPT.xml:S3:5117:1	O
and	FANAPT.xml:S3:5119:3	O
or	FANAPT.xml:S3:5123:2	O
(	FANAPT.xml:S3:5126:1	O
6	FANAPT.xml:S3:5127:1	O
)	FANAPT.xml:S3:5128:1	O
uncompensated	FANAPT.xml:S3:5130:13	O
heart	FANAPT.xml:S3:5144:5	O
failure	FANAPT.xml:S3:5150:7	O
.	FANAPT.xml:S3:5157:1	O

Caution	FANAPT.xml:S3:5164:7	O
is	FANAPT.xml:S3:5172:2	O
warranted	FANAPT.xml:S3:5175:9	O
when	FANAPT.xml:S3:5185:4	O
prescribing	FANAPT.xml:S3:5190:11	O
FANAPT	FANAPT.xml:S3:5202:6	O
with	FANAPT.xml:S3:5209:4	O
drugs	FANAPT.xml:S3:5214:5	O
that	FANAPT.xml:S3:5220:4	O
inhibit	FANAPT.xml:S3:5225:7	O
FANAPT	FANAPT.xml:S3:5233:6	O
metabolism	FANAPT.xml:S3:5240:10	O
[	FANAPT.xml:S3:5251:1	O
see	FANAPT.xml:S3:5252:3	O
Drug	FANAPT.xml:S3:5256:4	O
Interaction	FANAPT.xml:S3:5261:11	O
s	FANAPT.xml:S3:5275:1	O
(	FANAPT.xml:S3:5279:1	O
7.1	FANAPT.xml:S3:5280:3	O
)]	FANAPT.xml:S3:5283:2	O
,	FANAPT.xml:S3:5287:1	O
and	FANAPT.xml:S3:5289:3	O
in	FANAPT.xml:S3:5293:2	O
patients	FANAPT.xml:S3:5296:8	O
with	FANAPT.xml:S3:5305:4	O
reduced	FANAPT.xml:S3:5310:7	O
activity	FANAPT.xml:S3:5318:8	O
of	FANAPT.xml:S3:5327:2	O
CYP2D6	FANAPT.xml:S3:5330:6	O
[	FANAPT.xml:S3:5337:1	O
see	FANAPT.xml:S3:5338:3	O
Clinical	FANAPT.xml:S3:5342:8	O
Pharmacology	FANAPT.xml:S3:5351:12	O
(	FANAPT.xml:S3:5364:1	O
12.3	FANAPT.xml:S3:5365:4	O
)]	FANAPT.xml:S3:5369:2	O
.	FANAPT.xml:S3:5373:1	O

It	FANAPT.xml:S3:5379:2	O
is	FANAPT.xml:S3:5382:2	O
recommended	FANAPT.xml:S3:5385:11	O
that	FANAPT.xml:S3:5397:4	O
patients	FANAPT.xml:S3:5402:8	O
being	FANAPT.xml:S3:5411:5	O
considered	FANAPT.xml:S3:5417:10	O
for	FANAPT.xml:S3:5428:3	O
FANAPT	FANAPT.xml:S3:5432:6	O
treatment	FANAPT.xml:S3:5439:9	O
who	FANAPT.xml:S3:5449:3	O
are	FANAPT.xml:S3:5453:3	O
at	FANAPT.xml:S3:5457:2	O
risk	FANAPT.xml:S3:5460:4	O
for	FANAPT.xml:S3:5465:3	O
significant	FANAPT.xml:S3:5469:11	O
electrolyte	FANAPT.xml:S3:5481:11	O
disturbances	FANAPT.xml:S3:5493:12	O
have	FANAPT.xml:S3:5506:4	O
baseline	FANAPT.xml:S3:5511:8	O
serum	FANAPT.xml:S3:5520:5	O
potassium	FANAPT.xml:S3:5526:9	O
and	FANAPT.xml:S3:5536:3	O
magnesium	FANAPT.xml:S3:5540:9	O
measurements	FANAPT.xml:S3:5550:12	O
with	FANAPT.xml:S3:5563:4	O
periodic	FANAPT.xml:S3:5568:8	O
monitoring	FANAPT.xml:S3:5577:10	O
.	FANAPT.xml:S3:5587:1	O

Hypokalemia	FANAPT.xml:S3:5589:11	O
(	FANAPT.xml:S3:5601:1	O
and	FANAPT.xml:S3:5602:3	O
or	FANAPT.xml:S3:5606:2	O
hypomagnesemia	FANAPT.xml:S3:5609:14	O
)	FANAPT.xml:S3:5623:1	O
may	FANAPT.xml:S3:5625:3	O
increase	FANAPT.xml:S3:5629:8	O
the	FANAPT.xml:S3:5638:3	O
risk	FANAPT.xml:S3:5642:4	O
of	FANAPT.xml:S3:5647:2	O
QT	FANAPT.xml:S3:5650:2	O
prolongation	FANAPT.xml:S3:5653:12	O
and	FANAPT.xml:S3:5666:3	O
arrhythmia	FANAPT.xml:S3:5670:10	O
.	FANAPT.xml:S3:5680:1	O

FANAPT	FANAPT.xml:S3:5682:6	O
should	FANAPT.xml:S3:5689:6	O
be	FANAPT.xml:S3:5696:2	O
avoided	FANAPT.xml:S3:5699:7	O
in	FANAPT.xml:S3:5707:2	O
patients	FANAPT.xml:S3:5710:8	O
with	FANAPT.xml:S3:5719:4	O
histories	FANAPT.xml:S3:5724:9	O
of	FANAPT.xml:S3:5734:2	O
significant	FANAPT.xml:S3:5737:11	O
cardiovascular	FANAPT.xml:S3:5749:14	O
illness	FANAPT.xml:S3:5764:7	O
,	FANAPT.xml:S3:5771:1	O
e	FANAPT.xml:S3:5773:1	O
.	FANAPT.xml:S3:5774:1	O
g	FANAPT.xml:S3:5775:1	O
.	FANAPT.xml:S3:5776:1	O
,	FANAPT.xml:S3:5777:1	O
QT	FANAPT.xml:S3:5779:2	O
prolongation	FANAPT.xml:S3:5782:12	O
,	FANAPT.xml:S3:5794:1	O
recent	FANAPT.xml:S3:5796:6	O
acute	FANAPT.xml:S3:5803:5	O
myocardial	FANAPT.xml:S3:5809:10	O
infarction	FANAPT.xml:S3:5820:10	O
,	FANAPT.xml:S3:5830:1	O
uncompensated	FANAPT.xml:S3:5832:13	O
heart	FANAPT.xml:S3:5846:5	O
failure	FANAPT.xml:S3:5852:7	O
,	FANAPT.xml:S3:5859:1	O
or	FANAPT.xml:S3:5861:2	O
cardiac	FANAPT.xml:S3:5864:7	O
arrhythmia	FANAPT.xml:S3:5872:10	O
.	FANAPT.xml:S3:5882:1	O

FANAPT	FANAPT.xml:S3:5884:6	O
should	FANAPT.xml:S3:5891:6	O
be	FANAPT.xml:S3:5898:2	O
discontinued	FANAPT.xml:S3:5901:12	O
in	FANAPT.xml:S3:5914:2	O
patients	FANAPT.xml:S3:5917:8	O
who	FANAPT.xml:S3:5926:3	O
are	FANAPT.xml:S3:5930:3	O
found	FANAPT.xml:S3:5934:5	O
to	FANAPT.xml:S3:5940:2	O
have	FANAPT.xml:S3:5943:4	O
persistent	FANAPT.xml:S3:5948:10	O
QTc	FANAPT.xml:S3:5959:3	O
measurements	FANAPT.xml:S3:5963:12	O
500	FANAPT.xml:S3:5977:3	O
msec	FANAPT.xml:S3:5981:4	O
.	FANAPT.xml:S3:5985:1	O

If	FANAPT.xml:S3:5991:2	O
patients	FANAPT.xml:S3:5994:8	O
taking	FANAPT.xml:S3:6003:6	O
FANAPT	FANAPT.xml:S3:6010:6	O
experience	FANAPT.xml:S3:6017:10	O
symptoms	FANAPT.xml:S3:6028:8	O
that	FANAPT.xml:S3:6037:4	O
could	FANAPT.xml:S3:6042:5	O
indicate	FANAPT.xml:S3:6048:8	O
the	FANAPT.xml:S3:6057:3	O
occurrence	FANAPT.xml:S3:6061:10	O
of	FANAPT.xml:S3:6072:2	O
cardiac	FANAPT.xml:S3:6075:7	O
arrhythmias	FANAPT.xml:S3:6083:11	O
,	FANAPT.xml:S3:6094:1	O
e	FANAPT.xml:S3:6096:1	O
.	FANAPT.xml:S3:6097:1	O
g	FANAPT.xml:S3:6098:1	O
.	FANAPT.xml:S3:6099:1	O
,	FANAPT.xml:S3:6100:1	O
dizziness	FANAPT.xml:S3:6102:9	O
,	FANAPT.xml:S3:6111:1	O
palpitations	FANAPT.xml:S3:6113:12	O
,	FANAPT.xml:S3:6125:1	O
or	FANAPT.xml:S3:6127:2	O
syncope	FANAPT.xml:S3:6130:7	O
,	FANAPT.xml:S3:6137:1	O
the	FANAPT.xml:S3:6139:3	O
prescriber	FANAPT.xml:S3:6143:10	O
should	FANAPT.xml:S3:6154:6	O
initiate	FANAPT.xml:S3:6161:8	O
further	FANAPT.xml:S3:6170:7	O
evaluation	FANAPT.xml:S3:6178:10	O
,	FANAPT.xml:S3:6188:1	O
including	FANAPT.xml:S3:6190:9	O
cardiac	FANAPT.xml:S3:6200:7	O
monitoring	FANAPT.xml:S3:6208:10	O
.	FANAPT.xml:S3:6218:1	O

5.3	FANAPT.xml:S3:6228:3	O
Neuroleptic	FANAPT.xml:S3:6236:11	O
Malignant	FANAPT.xml:S3:6248:9	O
Syndrome	FANAPT.xml:S3:6258:8	O
(	FANAPT.xml:S3:6267:1	O
NMS	FANAPT.xml:S3:6268:3	O
)	FANAPT.xml:S3:6271:1	O

A	FANAPT.xml:S3:6278:1	O
potentially	FANAPT.xml:S3:6280:11	O
fatal	FANAPT.xml:S3:6292:5	O
symptom	FANAPT.xml:S3:6298:7	O
complex	FANAPT.xml:S3:6306:7	O
sometimes	FANAPT.xml:S3:6314:9	O
referred	FANAPT.xml:S3:6324:8	O
to	FANAPT.xml:S3:6333:2	O
as	FANAPT.xml:S3:6336:2	O
Neuroleptic	FANAPT.xml:S3:6339:11	B-AdverseReaction
Malignant	FANAPT.xml:S3:6351:9	I-AdverseReaction
Syndrome	FANAPT.xml:S3:6361:8	I-AdverseReaction
(	FANAPT.xml:S3:6370:1	O
NMS	FANAPT.xml:S3:6371:3	B-AdverseReaction
)	FANAPT.xml:S3:6374:1	O
has	FANAPT.xml:S3:6376:3	O
been	FANAPT.xml:S3:6380:4	O
reported	FANAPT.xml:S3:6385:8	O
in	FANAPT.xml:S3:6394:2	O
association	FANAPT.xml:S3:6397:11	O
with	FANAPT.xml:S3:6409:4	O
administration	FANAPT.xml:S3:6414:14	O
of	FANAPT.xml:S3:6429:2	O
antipsychotic	FANAPT.xml:S3:6432:13	O
drugs	FANAPT.xml:S3:6446:5	O
,	FANAPT.xml:S3:6451:1	O
including	FANAPT.xml:S3:6453:9	O
FANAPT	FANAPT.xml:S3:6463:6	O
.	FANAPT.xml:S3:6469:1	O

Clinical	FANAPT.xml:S3:6471:8	O
manifestations	FANAPT.xml:S3:6480:14	O
include	FANAPT.xml:S3:6495:7	O
hyperpyrexia	FANAPT.xml:S3:6503:12	B-AdverseReaction
,	FANAPT.xml:S3:6515:1	O
muscle	FANAPT.xml:S3:6517:6	B-AdverseReaction
rigidity	FANAPT.xml:S3:6524:8	I-AdverseReaction
,	FANAPT.xml:S3:6532:1	O
altered	FANAPT.xml:S3:6534:7	B-AdverseReaction
mental	FANAPT.xml:S3:6542:6	I-AdverseReaction
status	FANAPT.xml:S3:6549:6	I-AdverseReaction
(	FANAPT.xml:S3:6556:1	O
including	FANAPT.xml:S3:6557:9	O
catatonic	FANAPT.xml:S3:6567:9	B-AdverseReaction
signs	FANAPT.xml:S3:6577:5	I-AdverseReaction
)	FANAPT.xml:S3:6582:1	O
and	FANAPT.xml:S3:6584:3	O
evidence	FANAPT.xml:S3:6588:8	O
of	FANAPT.xml:S3:6597:2	O
autonomic	FANAPT.xml:S3:6600:9	B-AdverseReaction
instability	FANAPT.xml:S3:6610:11	I-AdverseReaction
(	FANAPT.xml:S3:6622:1	O
irregular	FANAPT.xml:S3:6623:9	B-AdverseReaction
pulse	FANAPT.xml:S3:6633:5	I-AdverseReaction
or	FANAPT.xml:S3:6639:2	O
blood	FANAPT.xml:S3:6642:5	I-AdverseReaction
pressure	FANAPT.xml:S3:6648:8	I-AdverseReaction
,	FANAPT.xml:S3:6656:1	O
tachycardia	FANAPT.xml:S3:6658:11	B-AdverseReaction
,	FANAPT.xml:S3:6669:1	O
diaphoresis	FANAPT.xml:S3:6671:11	B-AdverseReaction
,	FANAPT.xml:S3:6682:1	O
and	FANAPT.xml:S3:6684:3	O
cardiac	FANAPT.xml:S3:6688:7	B-AdverseReaction
dysrhythmia	FANAPT.xml:S3:6696:11	I-AdverseReaction
)	FANAPT.xml:S3:6707:1	O
.	FANAPT.xml:S3:6708:1	O

Additional	FANAPT.xml:S3:6710:10	O
signs	FANAPT.xml:S3:6721:5	O
may	FANAPT.xml:S3:6727:3	B-Factor
include	FANAPT.xml:S3:6731:7	O
elevated	FANAPT.xml:S3:6739:8	B-AdverseReaction
creatine	FANAPT.xml:S3:6748:8	I-AdverseReaction
phosphokinase	FANAPT.xml:S3:6757:13	I-AdverseReaction
,	FANAPT.xml:S3:6770:1	O
myoglobinuria	FANAPT.xml:S3:6772:13	B-AdverseReaction
(	FANAPT.xml:S3:6786:1	O
rhabdomyolysis	FANAPT.xml:S3:6787:14	B-AdverseReaction
)	FANAPT.xml:S3:6801:1	O
,	FANAPT.xml:S3:6802:1	O
and	FANAPT.xml:S3:6804:3	O
acute	FANAPT.xml:S3:6808:5	B-AdverseReaction
renal	FANAPT.xml:S3:6814:5	I-AdverseReaction
failure	FANAPT.xml:S3:6820:7	I-AdverseReaction
.	FANAPT.xml:S3:6827:1	O

The	FANAPT.xml:S3:6833:3	O
diagnostic	FANAPT.xml:S3:6837:10	O
evaluation	FANAPT.xml:S3:6848:10	O
of	FANAPT.xml:S3:6859:2	O
patients	FANAPT.xml:S3:6862:8	O
with	FANAPT.xml:S3:6871:4	O
this	FANAPT.xml:S3:6876:4	O
syndrome	FANAPT.xml:S3:6881:8	O
is	FANAPT.xml:S3:6890:2	O
complicated	FANAPT.xml:S3:6893:11	O
.	FANAPT.xml:S3:6904:1	O

In	FANAPT.xml:S3:6906:2	O
arriving	FANAPT.xml:S3:6909:8	O
at	FANAPT.xml:S3:6918:2	O
a	FANAPT.xml:S3:6921:1	O
diagnosis	FANAPT.xml:S3:6923:9	O
,	FANAPT.xml:S3:6932:1	O
it	FANAPT.xml:S3:6934:2	O
is	FANAPT.xml:S3:6937:2	O
important	FANAPT.xml:S3:6940:9	O
to	FANAPT.xml:S3:6950:2	O
identify	FANAPT.xml:S3:6953:8	O
cases	FANAPT.xml:S3:6962:5	O
in	FANAPT.xml:S3:6968:2	O
which	FANAPT.xml:S3:6971:5	O
the	FANAPT.xml:S3:6977:3	O
clinical	FANAPT.xml:S3:6981:8	O
presentation	FANAPT.xml:S3:6990:12	O
includes	FANAPT.xml:S3:7003:8	O
both	FANAPT.xml:S3:7012:4	O
serious	FANAPT.xml:S3:7017:7	O
medical	FANAPT.xml:S3:7025:7	O
illness	FANAPT.xml:S3:7033:7	O
(	FANAPT.xml:S3:7041:1	O
e	FANAPT.xml:S3:7042:1	O
.	FANAPT.xml:S3:7043:1	O
g	FANAPT.xml:S3:7044:1	O
.	FANAPT.xml:S3:7045:1	O
,	FANAPT.xml:S3:7046:1	O
pneumonia	FANAPT.xml:S3:7048:9	O
,	FANAPT.xml:S3:7057:1	O
systemic	FANAPT.xml:S3:7059:8	O
infection	FANAPT.xml:S3:7068:9	O
,	FANAPT.xml:S3:7077:1	O
etc	FANAPT.xml:S3:7079:3	O
.	FANAPT.xml:S3:7082:1	O
)	FANAPT.xml:S3:7083:1	O

and	FANAPT.xml:S3:7085:3	O
untreated	FANAPT.xml:S3:7089:9	O
or	FANAPT.xml:S3:7099:2	O
inadequately	FANAPT.xml:S3:7102:12	O
treated	FANAPT.xml:S3:7115:7	O
extrapyramidal	FANAPT.xml:S3:7123:14	O
signs	FANAPT.xml:S3:7138:5	O
and	FANAPT.xml:S3:7144:3	O
symptoms	FANAPT.xml:S3:7148:8	O
(	FANAPT.xml:S3:7157:1	O
EPS	FANAPT.xml:S3:7158:3	O
)	FANAPT.xml:S3:7161:1	O
.	FANAPT.xml:S3:7162:1	O

Other	FANAPT.xml:S3:7164:5	O
important	FANAPT.xml:S3:7170:9	O
considerations	FANAPT.xml:S3:7180:14	O
in	FANAPT.xml:S3:7195:2	O
the	FANAPT.xml:S3:7198:3	O
differential	FANAPT.xml:S3:7202:12	O
diagnosis	FANAPT.xml:S3:7215:9	O
include	FANAPT.xml:S3:7225:7	O
central	FANAPT.xml:S3:7233:7	O
anticholinergic	FANAPT.xml:S3:7241:15	O
toxicity	FANAPT.xml:S3:7257:8	O
,	FANAPT.xml:S3:7265:1	O
heat	FANAPT.xml:S3:7267:4	O
stroke	FANAPT.xml:S3:7272:6	O
,	FANAPT.xml:S3:7278:1	O
drug	FANAPT.xml:S3:7280:4	O
fever	FANAPT.xml:S3:7285:5	O
,	FANAPT.xml:S3:7290:1	O
and	FANAPT.xml:S3:7292:3	O
primary	FANAPT.xml:S3:7296:7	O
central	FANAPT.xml:S3:7304:7	O
nervous	FANAPT.xml:S3:7312:7	O
system	FANAPT.xml:S3:7320:6	O
(	FANAPT.xml:S3:7327:1	O
CNS	FANAPT.xml:S3:7328:3	O
)	FANAPT.xml:S3:7331:1	O
pathology	FANAPT.xml:S3:7333:9	O
.	FANAPT.xml:S3:7342:1	O

The	FANAPT.xml:S3:7348:3	O
management	FANAPT.xml:S3:7352:10	O
of	FANAPT.xml:S3:7363:2	O
this	FANAPT.xml:S3:7366:4	O
syndrome	FANAPT.xml:S3:7371:8	O
should	FANAPT.xml:S3:7380:6	O
include	FANAPT.xml:S3:7387:7	O
:	FANAPT.xml:S3:7394:1	O
(	FANAPT.xml:S3:7396:1	O
1	FANAPT.xml:S3:7397:1	O
)	FANAPT.xml:S3:7398:1	O
immediate	FANAPT.xml:S3:7400:9	O
discontinuation	FANAPT.xml:S3:7410:15	O
of	FANAPT.xml:S3:7426:2	O
the	FANAPT.xml:S3:7429:3	O
antipsychotic	FANAPT.xml:S3:7433:13	O
drugs	FANAPT.xml:S3:7447:5	O
and	FANAPT.xml:S3:7453:3	O
other	FANAPT.xml:S3:7457:5	O
drugs	FANAPT.xml:S3:7463:5	O
not	FANAPT.xml:S3:7469:3	O
essential	FANAPT.xml:S3:7473:9	O
to	FANAPT.xml:S3:7483:2	O
concurrent	FANAPT.xml:S3:7486:10	O
therapy	FANAPT.xml:S3:7497:7	O
,	FANAPT.xml:S3:7504:1	O
(	FANAPT.xml:S3:7506:1	O
2	FANAPT.xml:S3:7507:1	O
)	FANAPT.xml:S3:7508:1	O
intensive	FANAPT.xml:S3:7510:9	O
symptomatic	FANAPT.xml:S3:7520:11	O
treatment	FANAPT.xml:S3:7532:9	O
and	FANAPT.xml:S3:7542:3	O
medical	FANAPT.xml:S3:7546:7	O
monitoring	FANAPT.xml:S3:7554:10	O
,	FANAPT.xml:S3:7564:1	O
and	FANAPT.xml:S3:7566:3	O
(	FANAPT.xml:S3:7570:1	O
3	FANAPT.xml:S3:7571:1	O
)	FANAPT.xml:S3:7572:1	O
treatment	FANAPT.xml:S3:7574:9	O
of	FANAPT.xml:S3:7584:2	O
any	FANAPT.xml:S3:7587:3	O
concomitant	FANAPT.xml:S3:7591:11	O
serious	FANAPT.xml:S3:7603:7	O
medical	FANAPT.xml:S3:7611:7	O
problems	FANAPT.xml:S3:7619:8	O
for	FANAPT.xml:S3:7628:3	O
which	FANAPT.xml:S3:7632:5	O
specific	FANAPT.xml:S3:7638:8	O
treatments	FANAPT.xml:S3:7647:10	O
are	FANAPT.xml:S3:7658:3	O
available	FANAPT.xml:S3:7662:9	O
.	FANAPT.xml:S3:7671:1	O

There	FANAPT.xml:S3:7673:5	O
is	FANAPT.xml:S3:7679:2	O
no	FANAPT.xml:S3:7682:2	O
general	FANAPT.xml:S3:7685:7	O
agreement	FANAPT.xml:S3:7693:9	O
about	FANAPT.xml:S3:7703:5	O
specific	FANAPT.xml:S3:7709:8	O
pharmacological	FANAPT.xml:S3:7718:15	O
treatment	FANAPT.xml:S3:7734:9	O
regimens	FANAPT.xml:S3:7744:8	O
for	FANAPT.xml:S3:7753:3	O
NMS	FANAPT.xml:S3:7757:3	O
.	FANAPT.xml:S3:7760:1	O

If	FANAPT.xml:S3:7766:2	O
a	FANAPT.xml:S3:7769:1	O
patient	FANAPT.xml:S3:7771:7	O
requires	FANAPT.xml:S3:7779:8	O
antipsychotic	FANAPT.xml:S3:7788:13	O
drug	FANAPT.xml:S3:7802:4	O
treatment	FANAPT.xml:S3:7807:9	O
after	FANAPT.xml:S3:7817:5	O
recovery	FANAPT.xml:S3:7823:8	O
from	FANAPT.xml:S3:7832:4	O
NMS	FANAPT.xml:S3:7837:3	O
,	FANAPT.xml:S3:7840:1	O
the	FANAPT.xml:S3:7842:3	O
potential	FANAPT.xml:S3:7846:9	O
reintroduction	FANAPT.xml:S3:7856:14	O
of	FANAPT.xml:S3:7871:2	O
drug	FANAPT.xml:S3:7874:4	O
therapy	FANAPT.xml:S3:7879:7	O
should	FANAPT.xml:S3:7887:6	O
be	FANAPT.xml:S3:7894:2	O
carefully	FANAPT.xml:S3:7897:9	O
considered	FANAPT.xml:S3:7907:10	O
.	FANAPT.xml:S3:7917:1	O

The	FANAPT.xml:S3:7919:3	O
patient	FANAPT.xml:S3:7923:7	O
should	FANAPT.xml:S3:7931:6	O
be	FANAPT.xml:S3:7938:2	O
carefully	FANAPT.xml:S3:7941:9	O
monitored	FANAPT.xml:S3:7951:9	O
,	FANAPT.xml:S3:7960:1	O
since	FANAPT.xml:S3:7962:5	O
recurrences	FANAPT.xml:S3:7968:11	O
of	FANAPT.xml:S3:7980:2	O
NMS	FANAPT.xml:S3:7983:3	O
have	FANAPT.xml:S3:7987:4	O
been	FANAPT.xml:S3:7992:4	O
reported	FANAPT.xml:S3:7997:8	O
.	FANAPT.xml:S3:8005:1	O

5.4	FANAPT.xml:S3:8014:3	O
Tardive	FANAPT.xml:S3:8022:7	O
Dyskinesia	FANAPT.xml:S3:8030:10	O

Tardive	FANAPT.xml:S3:8046:7	B-AdverseReaction
dyskinesia	FANAPT.xml:S3:8054:10	I-AdverseReaction
is	FANAPT.xml:S3:8065:2	O
a	FANAPT.xml:S3:8068:1	O
syndrome	FANAPT.xml:S3:8070:8	O
consisting	FANAPT.xml:S3:8079:10	O
of	FANAPT.xml:S3:8090:2	O
potentially	FANAPT.xml:S3:8093:11	O
irreversible	FANAPT.xml:S3:8105:12	O
,	FANAPT.xml:S3:8117:1	O
involuntary	FANAPT.xml:S3:8119:11	B-AdverseReaction
,	FANAPT.xml:S3:8130:1	I-AdverseReaction
dyskinetic	FANAPT.xml:S3:8132:10	I-AdverseReaction
movements	FANAPT.xml:S3:8143:9	I-AdverseReaction
,	FANAPT.xml:S3:8152:1	O
which	FANAPT.xml:S3:8154:5	O
may	FANAPT.xml:S3:8160:3	O
develop	FANAPT.xml:S3:8164:7	O
in	FANAPT.xml:S3:8172:2	O
patients	FANAPT.xml:S3:8175:8	O
treated	FANAPT.xml:S3:8184:7	O
with	FANAPT.xml:S3:8192:4	O
antipsychotic	FANAPT.xml:S3:8197:13	B-DrugClass
drugs	FANAPT.xml:S3:8211:5	I-DrugClass
.	FANAPT.xml:S3:8216:1	O

Although	FANAPT.xml:S3:8218:8	O
the	FANAPT.xml:S3:8227:3	O
prevalence	FANAPT.xml:S3:8231:10	O
of	FANAPT.xml:S3:8242:2	O
the	FANAPT.xml:S3:8245:3	O
syndrome	FANAPT.xml:S3:8249:8	O
appears	FANAPT.xml:S3:8258:7	O
to	FANAPT.xml:S3:8266:2	O
be	FANAPT.xml:S3:8269:2	O
highest	FANAPT.xml:S3:8272:7	O
among	FANAPT.xml:S3:8280:5	O
the	FANAPT.xml:S3:8286:3	O
elderly	FANAPT.xml:S3:8290:7	O
,	FANAPT.xml:S3:8297:1	O
especially	FANAPT.xml:S3:8299:10	O
elderly	FANAPT.xml:S3:8310:7	O
women	FANAPT.xml:S3:8318:5	O
,	FANAPT.xml:S3:8323:1	O
it	FANAPT.xml:S3:8325:2	O
is	FANAPT.xml:S3:8328:2	O
impossible	FANAPT.xml:S3:8331:10	O
to	FANAPT.xml:S3:8342:2	O
rely	FANAPT.xml:S3:8345:4	O
on	FANAPT.xml:S3:8350:2	O
prevalence	FANAPT.xml:S3:8353:10	O
estimates	FANAPT.xml:S3:8364:9	O
to	FANAPT.xml:S3:8374:2	O
predict	FANAPT.xml:S3:8377:7	O
,	FANAPT.xml:S3:8384:1	O
at	FANAPT.xml:S3:8386:2	O
the	FANAPT.xml:S3:8389:3	O
inception	FANAPT.xml:S3:8393:9	O
of	FANAPT.xml:S3:8403:2	O
antipsychotic	FANAPT.xml:S3:8406:13	O
treatment	FANAPT.xml:S3:8420:9	O
,	FANAPT.xml:S3:8429:1	O
which	FANAPT.xml:S3:8431:5	O
patients	FANAPT.xml:S3:8437:8	O
are	FANAPT.xml:S3:8446:3	O
likely	FANAPT.xml:S3:8450:6	O
to	FANAPT.xml:S3:8457:2	O
develop	FANAPT.xml:S3:8460:7	O
the	FANAPT.xml:S3:8468:3	O
syndrome	FANAPT.xml:S3:8472:8	O
.	FANAPT.xml:S3:8480:1	O

Whether	FANAPT.xml:S3:8482:7	O
antipsychotic	FANAPT.xml:S3:8490:13	O
drug	FANAPT.xml:S3:8504:4	O
products	FANAPT.xml:S3:8509:8	O
differ	FANAPT.xml:S3:8518:6	O
in	FANAPT.xml:S3:8525:2	O
their	FANAPT.xml:S3:8528:5	O
potential	FANAPT.xml:S3:8534:9	O
to	FANAPT.xml:S3:8544:2	O
cause	FANAPT.xml:S3:8547:5	O
tardive	FANAPT.xml:S3:8553:7	O
dyskinesia	FANAPT.xml:S3:8561:10	O
is	FANAPT.xml:S3:8572:2	O
unknown	FANAPT.xml:S3:8575:7	O
.	FANAPT.xml:S3:8582:1	O

The	FANAPT.xml:S3:8588:3	O
risk	FANAPT.xml:S3:8592:4	O
of	FANAPT.xml:S3:8597:2	O
developing	FANAPT.xml:S3:8600:10	O
tardive	FANAPT.xml:S3:8611:7	O
dyskinesia	FANAPT.xml:S3:8619:10	O
and	FANAPT.xml:S3:8630:3	O
the	FANAPT.xml:S3:8634:3	O
likelihood	FANAPT.xml:S3:8638:10	O
that	FANAPT.xml:S3:8649:4	O
it	FANAPT.xml:S3:8654:2	O
will	FANAPT.xml:S3:8657:4	O
become	FANAPT.xml:S3:8662:6	O
irreversible	FANAPT.xml:S3:8669:12	O
are	FANAPT.xml:S3:8682:3	O
believed	FANAPT.xml:S3:8686:8	O
to	FANAPT.xml:S3:8695:2	O
increase	FANAPT.xml:S3:8698:8	O
as	FANAPT.xml:S3:8707:2	O
the	FANAPT.xml:S3:8710:3	O
duration	FANAPT.xml:S3:8714:8	O
of	FANAPT.xml:S3:8723:2	O
treatment	FANAPT.xml:S3:8726:9	O
and	FANAPT.xml:S3:8736:3	O
the	FANAPT.xml:S3:8740:3	O
total	FANAPT.xml:S3:8744:5	O
cumulative	FANAPT.xml:S3:8750:10	O
dose	FANAPT.xml:S3:8761:4	O
of	FANAPT.xml:S3:8766:2	O
antipsychotic	FANAPT.xml:S3:8769:13	O
administered	FANAPT.xml:S3:8783:12	O
increases	FANAPT.xml:S3:8796:9	O
.	FANAPT.xml:S3:8805:1	O

However	FANAPT.xml:S3:8807:7	O
,	FANAPT.xml:S3:8814:1	O
the	FANAPT.xml:S3:8816:3	O
syndrome	FANAPT.xml:S3:8820:8	O
can	FANAPT.xml:S3:8829:3	O
develop	FANAPT.xml:S3:8833:7	O
,	FANAPT.xml:S3:8840:1	O
although	FANAPT.xml:S3:8842:8	O
much	FANAPT.xml:S3:8851:4	O
less	FANAPT.xml:S3:8856:4	O
commonly	FANAPT.xml:S3:8861:8	O
,	FANAPT.xml:S3:8869:1	O
after	FANAPT.xml:S3:8871:5	O
relatively	FANAPT.xml:S3:8877:10	O
brief	FANAPT.xml:S3:8888:5	O
treatment	FANAPT.xml:S3:8894:9	O
periods	FANAPT.xml:S3:8904:7	O
at	FANAPT.xml:S3:8912:2	O
low	FANAPT.xml:S3:8915:3	O
doses	FANAPT.xml:S3:8919:5	O
.	FANAPT.xml:S3:8924:1	O

There	FANAPT.xml:S3:8930:5	O
is	FANAPT.xml:S3:8936:2	O
no	FANAPT.xml:S3:8939:2	O
known	FANAPT.xml:S3:8942:5	O
treatment	FANAPT.xml:S3:8948:9	O
for	FANAPT.xml:S3:8958:3	O
established	FANAPT.xml:S3:8962:11	O
cases	FANAPT.xml:S3:8974:5	O
of	FANAPT.xml:S3:8980:2	O
tardive	FANAPT.xml:S3:8983:7	O
dyskinesia	FANAPT.xml:S3:8991:10	O
,	FANAPT.xml:S3:9001:1	O
although	FANAPT.xml:S3:9003:8	O
the	FANAPT.xml:S3:9012:3	O
syndrome	FANAPT.xml:S3:9016:8	O
may	FANAPT.xml:S3:9025:3	O
remit	FANAPT.xml:S3:9029:5	O
,	FANAPT.xml:S3:9034:1	O
partially	FANAPT.xml:S3:9036:9	O
or	FANAPT.xml:S3:9046:2	O
completely	FANAPT.xml:S3:9049:10	O
,	FANAPT.xml:S3:9059:1	O
if	FANAPT.xml:S3:9061:2	O
antipsychotic	FANAPT.xml:S3:9064:13	O
treatment	FANAPT.xml:S3:9078:9	O
is	FANAPT.xml:S3:9088:2	O
withdrawn	FANAPT.xml:S3:9091:9	O
.	FANAPT.xml:S3:9100:1	O

Antipsychotic	FANAPT.xml:S3:9102:13	O
treatment	FANAPT.xml:S3:9116:9	O
itself	FANAPT.xml:S3:9126:6	O
,	FANAPT.xml:S3:9132:1	O
however	FANAPT.xml:S3:9134:7	O
,	FANAPT.xml:S3:9141:1	O
may	FANAPT.xml:S3:9143:3	O
suppress	FANAPT.xml:S3:9147:8	O
(	FANAPT.xml:S3:9156:1	O
or	FANAPT.xml:S3:9157:2	O
partially	FANAPT.xml:S3:9160:9	O
suppress	FANAPT.xml:S3:9170:8	O
)	FANAPT.xml:S3:9178:1	O
the	FANAPT.xml:S3:9180:3	O
signs	FANAPT.xml:S3:9184:5	O
and	FANAPT.xml:S3:9190:3	O
symptoms	FANAPT.xml:S3:9194:8	O
of	FANAPT.xml:S3:9203:2	O
the	FANAPT.xml:S3:9206:3	O
syndrome	FANAPT.xml:S3:9210:8	O
and	FANAPT.xml:S3:9219:3	O
thereby	FANAPT.xml:S3:9223:7	O
may	FANAPT.xml:S3:9231:3	O
possibly	FANAPT.xml:S3:9235:8	O
mask	FANAPT.xml:S3:9244:4	O
the	FANAPT.xml:S3:9249:3	O
underlying	FANAPT.xml:S3:9253:10	O
process	FANAPT.xml:S3:9264:7	O
.	FANAPT.xml:S3:9271:1	O

The	FANAPT.xml:S3:9273:3	O
effect	FANAPT.xml:S3:9277:6	O
that	FANAPT.xml:S3:9284:4	O
symptomatic	FANAPT.xml:S3:9289:11	O
suppression	FANAPT.xml:S3:9301:11	O
has	FANAPT.xml:S3:9313:3	O
upon	FANAPT.xml:S3:9317:4	O
the	FANAPT.xml:S3:9322:3	O
long	FANAPT.xml:S3:9326:4	O
-	FANAPT.xml:S3:9330:1	O
term	FANAPT.xml:S3:9331:4	O
course	FANAPT.xml:S3:9336:6	O
of	FANAPT.xml:S3:9343:2	O
the	FANAPT.xml:S3:9346:3	O
syndrome	FANAPT.xml:S3:9350:8	O
is	FANAPT.xml:S3:9359:2	O
unknown	FANAPT.xml:S3:9362:7	O
.	FANAPT.xml:S3:9369:1	O

Given	FANAPT.xml:S3:9375:5	O
these	FANAPT.xml:S3:9381:5	O
considerations	FANAPT.xml:S3:9387:14	O
,	FANAPT.xml:S3:9401:1	O
FANAPT	FANAPT.xml:S3:9403:6	O
should	FANAPT.xml:S3:9410:6	O
be	FANAPT.xml:S3:9417:2	O
prescribed	FANAPT.xml:S3:9420:10	O
in	FANAPT.xml:S3:9431:2	O
a	FANAPT.xml:S3:9434:1	O
manner	FANAPT.xml:S3:9436:6	O
that	FANAPT.xml:S3:9443:4	O
is	FANAPT.xml:S3:9448:2	O
most	FANAPT.xml:S3:9451:4	O
likely	FANAPT.xml:S3:9456:6	O
to	FANAPT.xml:S3:9463:2	O
minimize	FANAPT.xml:S3:9466:8	O
the	FANAPT.xml:S3:9475:3	O
occurrence	FANAPT.xml:S3:9479:10	O
of	FANAPT.xml:S3:9490:2	O
tardive	FANAPT.xml:S3:9493:7	O
dyskinesia	FANAPT.xml:S3:9501:10	O
.	FANAPT.xml:S3:9511:1	O

Chronic	FANAPT.xml:S3:9513:7	O
antipsychotic	FANAPT.xml:S3:9521:13	O
treatment	FANAPT.xml:S3:9535:9	O
should	FANAPT.xml:S3:9545:6	O
generally	FANAPT.xml:S3:9552:9	O
be	FANAPT.xml:S3:9562:2	O
reserved	FANAPT.xml:S3:9565:8	O
for	FANAPT.xml:S3:9574:3	O
patients	FANAPT.xml:S3:9578:8	O
who	FANAPT.xml:S3:9587:3	O
suffer	FANAPT.xml:S3:9591:6	O
from	FANAPT.xml:S3:9598:4	O
a	FANAPT.xml:S3:9603:1	O
chronic	FANAPT.xml:S3:9605:7	O
illness	FANAPT.xml:S3:9613:7	O
that	FANAPT.xml:S3:9621:4	O
(	FANAPT.xml:S3:9626:1	O
1	FANAPT.xml:S3:9627:1	O
)	FANAPT.xml:S3:9628:1	O
is	FANAPT.xml:S3:9630:2	O
known	FANAPT.xml:S3:9633:5	O
to	FANAPT.xml:S3:9639:2	O
respond	FANAPT.xml:S3:9642:7	O
to	FANAPT.xml:S3:9650:2	O
antipsychotic	FANAPT.xml:S3:9653:13	O
drugs	FANAPT.xml:S3:9667:5	O
,	FANAPT.xml:S3:9672:1	O
and	FANAPT.xml:S3:9674:3	O
(	FANAPT.xml:S3:9678:1	O
2	FANAPT.xml:S3:9679:1	O
)	FANAPT.xml:S3:9680:1	O
for	FANAPT.xml:S3:9682:3	O
whom	FANAPT.xml:S3:9686:4	O
alternative	FANAPT.xml:S3:9691:11	O
,	FANAPT.xml:S3:9702:1	O
equally	FANAPT.xml:S3:9704:7	O
effective	FANAPT.xml:S3:9712:9	O
,	FANAPT.xml:S3:9721:1	O
but	FANAPT.xml:S3:9723:3	O
potentially	FANAPT.xml:S3:9727:11	O
less	FANAPT.xml:S3:9739:4	O
harmful	FANAPT.xml:S3:9744:7	O
treatments	FANAPT.xml:S3:9752:10	O
are	FANAPT.xml:S3:9763:3	O
not	FANAPT.xml:S3:9767:3	O
available	FANAPT.xml:S3:9771:9	O
or	FANAPT.xml:S3:9781:2	O
appropriate	FANAPT.xml:S3:9784:11	O
.	FANAPT.xml:S3:9795:1	O

In	FANAPT.xml:S3:9797:2	O
patients	FANAPT.xml:S3:9800:8	O
who	FANAPT.xml:S3:9809:3	O
do	FANAPT.xml:S3:9813:2	O
require	FANAPT.xml:S3:9816:7	O
chronic	FANAPT.xml:S3:9824:7	O
treatment	FANAPT.xml:S3:9832:9	O
,	FANAPT.xml:S3:9841:1	O
the	FANAPT.xml:S3:9843:3	O
smallest	FANAPT.xml:S3:9847:8	O
dose	FANAPT.xml:S3:9856:4	O
and	FANAPT.xml:S3:9861:3	O
the	FANAPT.xml:S3:9865:3	O
shortest	FANAPT.xml:S3:9869:8	O
duration	FANAPT.xml:S3:9878:8	O
of	FANAPT.xml:S3:9887:2	O
treatment	FANAPT.xml:S3:9890:9	O
producing	FANAPT.xml:S3:9900:9	O
a	FANAPT.xml:S3:9910:1	O
satisfactory	FANAPT.xml:S3:9912:12	O
clinical	FANAPT.xml:S3:9925:8	O
response	FANAPT.xml:S3:9934:8	O
should	FANAPT.xml:S3:9943:6	O
be	FANAPT.xml:S3:9950:2	O
sought	FANAPT.xml:S3:9953:6	O
.	FANAPT.xml:S3:9959:1	O

The	FANAPT.xml:S3:9961:3	O
need	FANAPT.xml:S3:9965:4	O
for	FANAPT.xml:S3:9970:3	O
continued	FANAPT.xml:S3:9974:9	O
treatment	FANAPT.xml:S3:9984:9	O
should	FANAPT.xml:S3:9994:6	O
be	FANAPT.xml:S3:10001:2	O
reassessed	FANAPT.xml:S3:10004:10	O
periodically	FANAPT.xml:S3:10015:12	O
.	FANAPT.xml:S3:10027:1	O

If	FANAPT.xml:S3:10033:2	O
signs	FANAPT.xml:S3:10036:5	O
and	FANAPT.xml:S3:10042:3	O
symptoms	FANAPT.xml:S3:10046:8	O
of	FANAPT.xml:S3:10055:2	O
tardive	FANAPT.xml:S3:10058:7	O
dyskinesia	FANAPT.xml:S3:10066:10	O
appear	FANAPT.xml:S3:10077:6	O
in	FANAPT.xml:S3:10084:2	O
a	FANAPT.xml:S3:10087:1	O
patient	FANAPT.xml:S3:10089:7	O
on	FANAPT.xml:S3:10097:2	O
FANAPT	FANAPT.xml:S3:10100:6	O
,	FANAPT.xml:S3:10106:1	O
drug	FANAPT.xml:S3:10108:4	O
discontinuation	FANAPT.xml:S3:10113:15	O
should	FANAPT.xml:S3:10129:6	O
be	FANAPT.xml:S3:10136:2	O
considered	FANAPT.xml:S3:10139:10	O
.	FANAPT.xml:S3:10149:1	O

However	FANAPT.xml:S3:10151:7	O
,	FANAPT.xml:S3:10158:1	O
some	FANAPT.xml:S3:10160:4	O
patients	FANAPT.xml:S3:10165:8	O
may	FANAPT.xml:S3:10174:3	O
require	FANAPT.xml:S3:10178:7	O
treatment	FANAPT.xml:S3:10186:9	O
with	FANAPT.xml:S3:10196:4	O
FANAPT	FANAPT.xml:S3:10201:6	O
despite	FANAPT.xml:S3:10208:7	O
the	FANAPT.xml:S3:10216:3	O
presence	FANAPT.xml:S3:10220:8	O
of	FANAPT.xml:S3:10229:2	O
the	FANAPT.xml:S3:10232:3	O
syndrome	FANAPT.xml:S3:10236:8	O
.	FANAPT.xml:S3:10244:1	O

5.5	FANAPT.xml:S3:10253:3	O
Metabolic	FANAPT.xml:S3:10261:9	O
Changes	FANAPT.xml:S3:10271:7	O

Atypical	FANAPT.xml:S3:10284:8	B-DrugClass
antipsychotic	FANAPT.xml:S3:10293:13	I-DrugClass
drugs	FANAPT.xml:S3:10307:5	I-DrugClass
have	FANAPT.xml:S3:10313:4	O
been	FANAPT.xml:S3:10318:4	O
associated	FANAPT.xml:S3:10323:10	O
with	FANAPT.xml:S3:10334:4	O
metabolic	FANAPT.xml:S3:10339:9	O
changes	FANAPT.xml:S3:10349:7	O
that	FANAPT.xml:S3:10357:4	O
may	FANAPT.xml:S3:10362:3	O
increase	FANAPT.xml:S3:10366:8	B-AdverseReaction
cardiovascular	FANAPT.xml:S3:10375:14	I-AdverseReaction
cerebrovascular	FANAPT.xml:S3:10390:15	I-AdverseReaction
risk	FANAPT.xml:S3:10406:4	I-AdverseReaction
.	FANAPT.xml:S3:10410:1	O

These	FANAPT.xml:S3:10412:5	O
metabolic	FANAPT.xml:S3:10418:9	O
changes	FANAPT.xml:S3:10428:7	O
include	FANAPT.xml:S3:10436:7	O
hyperglycemia	FANAPT.xml:S3:10444:13	B-AdverseReaction
,	FANAPT.xml:S3:10457:1	O
dyslipidemia	FANAPT.xml:S3:10459:12	B-AdverseReaction
,	FANAPT.xml:S3:10471:1	O
and	FANAPT.xml:S3:10473:3	O
body	FANAPT.xml:S3:10477:4	B-AdverseReaction
weight	FANAPT.xml:S3:10482:6	I-AdverseReaction
gain	FANAPT.xml:S3:10489:4	I-AdverseReaction
[	FANAPT.xml:S3:10494:1	O
see	FANAPT.xml:S3:10495:3	O
Patient	FANAPT.xml:S3:10499:7	O
Counseling	FANAPT.xml:S3:10507:10	O
Information	FANAPT.xml:S3:10518:11	O
(	FANAPT.xml:S3:10530:1	O
17.3	FANAPT.xml:S3:10531:4	O
)]	FANAPT.xml:S3:10535:2	O
.	FANAPT.xml:S3:10539:1	O

While	FANAPT.xml:S3:10541:5	O
all	FANAPT.xml:S3:10547:3	O
atypical	FANAPT.xml:S3:10551:8	O
antipsychotic	FANAPT.xml:S3:10560:13	O
drugs	FANAPT.xml:S3:10574:5	O
have	FANAPT.xml:S3:10580:4	O
been	FANAPT.xml:S3:10585:4	O
shown	FANAPT.xml:S3:10590:5	O
to	FANAPT.xml:S3:10596:2	O
produce	FANAPT.xml:S3:10599:7	O
some	FANAPT.xml:S3:10607:4	O
metabolic	FANAPT.xml:S3:10612:9	O
changes	FANAPT.xml:S3:10622:7	O
,	FANAPT.xml:S3:10629:1	O
each	FANAPT.xml:S3:10631:4	O
drug	FANAPT.xml:S3:10636:4	O
in	FANAPT.xml:S3:10641:2	O
the	FANAPT.xml:S3:10644:3	O
class	FANAPT.xml:S3:10648:5	O
has	FANAPT.xml:S3:10654:3	O
its	FANAPT.xml:S3:10658:3	O
own	FANAPT.xml:S3:10662:3	O
specific	FANAPT.xml:S3:10666:8	O
risk	FANAPT.xml:S3:10675:4	O
profile	FANAPT.xml:S3:10680:7	O
.	FANAPT.xml:S3:10687:1	O

Hyperglycemia	FANAPT.xml:S3:10694:13	O
and	FANAPT.xml:S3:10708:3	O
Diabetes	FANAPT.xml:S3:10712:8	O
Mellitus	FANAPT.xml:S3:10721:8	O

Hyperglycemia	FANAPT.xml:S3:10736:13	B-AdverseReaction
,	FANAPT.xml:S3:10749:1	O
in	FANAPT.xml:S3:10751:2	O
some	FANAPT.xml:S3:10754:4	O
cases	FANAPT.xml:S3:10759:5	O
extreme	FANAPT.xml:S3:10765:7	B-Severity
and	FANAPT.xml:S3:10773:3	O
associated	FANAPT.xml:S3:10777:10	O
with	FANAPT.xml:S3:10788:4	O
ketoacidosis	FANAPT.xml:S3:10793:12	B-AdverseReaction
or	FANAPT.xml:S3:10806:2	O
hyperosmolar	FANAPT.xml:S3:10809:12	B-AdverseReaction
coma	FANAPT.xml:S3:10822:4	I-AdverseReaction
or	FANAPT.xml:S3:10827:2	O
death	FANAPT.xml:S3:10830:5	B-AdverseReaction
,	FANAPT.xml:S3:10835:1	O
has	FANAPT.xml:S3:10837:3	O
been	FANAPT.xml:S3:10841:4	O
reported	FANAPT.xml:S3:10846:8	O
in	FANAPT.xml:S3:10855:2	O
patients	FANAPT.xml:S3:10858:8	O
treated	FANAPT.xml:S3:10867:7	O
with	FANAPT.xml:S3:10875:4	O
atypical	FANAPT.xml:S3:10880:8	O
antipsychotics	FANAPT.xml:S3:10889:14	O
including	FANAPT.xml:S3:10904:9	O
FANAPT	FANAPT.xml:S3:10914:6	O
.	FANAPT.xml:S3:10920:1	O

Assessment	FANAPT.xml:S3:10922:10	O
of	FANAPT.xml:S3:10933:2	O
the	FANAPT.xml:S3:10936:3	O
relationship	FANAPT.xml:S3:10940:12	O
between	FANAPT.xml:S3:10953:7	O
atypical	FANAPT.xml:S3:10961:8	O
antipsychotic	FANAPT.xml:S3:10970:13	O
use	FANAPT.xml:S3:10984:3	O
and	FANAPT.xml:S3:10988:3	O
glucose	FANAPT.xml:S3:10992:7	O
abnormalities	FANAPT.xml:S3:11000:13	O
is	FANAPT.xml:S3:11014:2	O
complicated	FANAPT.xml:S3:11017:11	O
by	FANAPT.xml:S3:11029:2	O
the	FANAPT.xml:S3:11032:3	O
possibility	FANAPT.xml:S3:11036:11	O
of	FANAPT.xml:S3:11048:2	O
an	FANAPT.xml:S3:11051:2	O
increased	FANAPT.xml:S3:11054:9	O
background	FANAPT.xml:S3:11064:10	O
risk	FANAPT.xml:S3:11075:4	O
of	FANAPT.xml:S3:11080:2	O
diabetes	FANAPT.xml:S3:11083:8	O
mellitus	FANAPT.xml:S3:11092:8	O
in	FANAPT.xml:S3:11101:2	O
patients	FANAPT.xml:S3:11104:8	O
with	FANAPT.xml:S3:11113:4	O
schizophrenia	FANAPT.xml:S3:11118:13	O
and	FANAPT.xml:S3:11132:3	O
the	FANAPT.xml:S3:11136:3	O
increasing	FANAPT.xml:S3:11140:10	O
incidence	FANAPT.xml:S3:11151:9	O
of	FANAPT.xml:S3:11161:2	O
diabetes	FANAPT.xml:S3:11164:8	O
mellitus	FANAPT.xml:S3:11173:8	O
in	FANAPT.xml:S3:11182:2	O
the	FANAPT.xml:S3:11185:3	O
general	FANAPT.xml:S3:11189:7	O
population	FANAPT.xml:S3:11197:10	O
.	FANAPT.xml:S3:11207:1	O

Given	FANAPT.xml:S3:11209:5	O
these	FANAPT.xml:S3:11215:5	O
confounders	FANAPT.xml:S3:11221:11	O
,	FANAPT.xml:S3:11232:1	O
the	FANAPT.xml:S3:11234:3	O
relationship	FANAPT.xml:S3:11238:12	O
between	FANAPT.xml:S3:11251:7	O
atypical	FANAPT.xml:S3:11259:8	O
antipsychotic	FANAPT.xml:S3:11268:13	O
use	FANAPT.xml:S3:11282:3	O
and	FANAPT.xml:S3:11286:3	O
hyperglycemia	FANAPT.xml:S3:11290:13	O
-	FANAPT.xml:S3:11303:1	O
related	FANAPT.xml:S3:11304:7	O
adverse	FANAPT.xml:S3:11312:7	O
events	FANAPT.xml:S3:11320:6	O
is	FANAPT.xml:S3:11327:2	O
not	FANAPT.xml:S3:11330:3	O
completely	FANAPT.xml:S3:11334:10	O
understood	FANAPT.xml:S3:11345:10	O
.	FANAPT.xml:S3:11355:1	O

However	FANAPT.xml:S3:11357:7	O
,	FANAPT.xml:S3:11364:1	O
epidemiological	FANAPT.xml:S3:11366:15	O
studies	FANAPT.xml:S3:11382:7	O
suggest	FANAPT.xml:S3:11390:7	O
an	FANAPT.xml:S3:11398:2	O
increased	FANAPT.xml:S3:11401:9	O
risk	FANAPT.xml:S3:11411:4	O
of	FANAPT.xml:S3:11416:2	O
treatment	FANAPT.xml:S3:11419:9	O
-	FANAPT.xml:S3:11428:1	O
emergent	FANAPT.xml:S3:11429:8	O
hyperglycemia	FANAPT.xml:S3:11438:13	B-AdverseReaction
-	FANAPT.xml:S3:11451:1	I-AdverseReaction
related	FANAPT.xml:S3:11452:7	I-AdverseReaction
adverse	FANAPT.xml:S3:11460:7	I-AdverseReaction
events	FANAPT.xml:S3:11468:6	I-AdverseReaction
in	FANAPT.xml:S3:11475:2	O
patients	FANAPT.xml:S3:11478:8	O
treated	FANAPT.xml:S3:11487:7	O
with	FANAPT.xml:S3:11495:4	O
the	FANAPT.xml:S3:11500:3	O
atypical	FANAPT.xml:S3:11504:8	B-DrugClass
antipsychotics	FANAPT.xml:S3:11513:14	I-DrugClass
included	FANAPT.xml:S3:11528:8	O
in	FANAPT.xml:S3:11537:2	O
these	FANAPT.xml:S3:11540:5	O
studies	FANAPT.xml:S3:11546:7	O
.	FANAPT.xml:S3:11553:1	O

Because	FANAPT.xml:S3:11555:7	O
FANAPT	FANAPT.xml:S3:11563:6	O
was	FANAPT.xml:S3:11570:3	O
not	FANAPT.xml:S3:11574:3	O
marketed	FANAPT.xml:S3:11578:8	O
at	FANAPT.xml:S3:11587:2	O
the	FANAPT.xml:S3:11590:3	O
time	FANAPT.xml:S3:11594:4	O
these	FANAPT.xml:S3:11599:5	O
studies	FANAPT.xml:S3:11605:7	O
were	FANAPT.xml:S3:11613:4	O
performed	FANAPT.xml:S3:11618:9	O
,	FANAPT.xml:S3:11627:1	O
it	FANAPT.xml:S3:11629:2	O
is	FANAPT.xml:S3:11632:2	O
not	FANAPT.xml:S3:11635:3	O
known	FANAPT.xml:S3:11639:5	O
if	FANAPT.xml:S3:11645:2	O
FANAPT	FANAPT.xml:S3:11648:6	O
is	FANAPT.xml:S3:11655:2	O
associated	FANAPT.xml:S3:11658:10	O
with	FANAPT.xml:S3:11669:4	O
this	FANAPT.xml:S3:11674:4	O
increased	FANAPT.xml:S3:11679:9	O
risk	FANAPT.xml:S3:11689:4	O
.	FANAPT.xml:S3:11693:1	O

Patients	FANAPT.xml:S3:11699:8	O
with	FANAPT.xml:S3:11708:4	O
an	FANAPT.xml:S3:11713:2	O
established	FANAPT.xml:S3:11716:11	O
diagnosis	FANAPT.xml:S3:11728:9	O
of	FANAPT.xml:S3:11738:2	O
diabetes	FANAPT.xml:S3:11741:8	O
mellitus	FANAPT.xml:S3:11750:8	O
who	FANAPT.xml:S3:11759:3	O
are	FANAPT.xml:S3:11763:3	O
started	FANAPT.xml:S3:11767:7	O
on	FANAPT.xml:S3:11775:2	O
atypical	FANAPT.xml:S3:11778:8	O
antipsychotics	FANAPT.xml:S3:11787:14	O
should	FANAPT.xml:S3:11802:6	O
be	FANAPT.xml:S3:11809:2	O
monitored	FANAPT.xml:S3:11812:9	O
regularly	FANAPT.xml:S3:11822:9	O
for	FANAPT.xml:S3:11832:3	O
worsening	FANAPT.xml:S3:11836:9	O
of	FANAPT.xml:S3:11846:2	O
glucose	FANAPT.xml:S3:11849:7	O
control	FANAPT.xml:S3:11857:7	O
.	FANAPT.xml:S3:11864:1	O

Patients	FANAPT.xml:S3:11866:8	O
with	FANAPT.xml:S3:11875:4	O
risk	FANAPT.xml:S3:11880:4	O
factors	FANAPT.xml:S3:11885:7	O
for	FANAPT.xml:S3:11893:3	O
diabetes	FANAPT.xml:S3:11897:8	O
mellitus	FANAPT.xml:S3:11906:8	O
(	FANAPT.xml:S3:11915:1	O
e	FANAPT.xml:S3:11916:1	O
.	FANAPT.xml:S3:11917:1	O
g	FANAPT.xml:S3:11918:1	O
.	FANAPT.xml:S3:11919:1	O
,	FANAPT.xml:S3:11920:1	O
obesity	FANAPT.xml:S3:11922:7	O
,	FANAPT.xml:S3:11929:1	O
family	FANAPT.xml:S3:11931:6	O
history	FANAPT.xml:S3:11938:7	O
of	FANAPT.xml:S3:11946:2	O
diabetes	FANAPT.xml:S3:11949:8	O
)	FANAPT.xml:S3:11957:1	O
who	FANAPT.xml:S3:11959:3	O
are	FANAPT.xml:S3:11963:3	O
starting	FANAPT.xml:S3:11967:8	O
treatment	FANAPT.xml:S3:11976:9	O
with	FANAPT.xml:S3:11986:4	O
atypical	FANAPT.xml:S3:11991:8	O
antipsychotics	FANAPT.xml:S3:12000:14	O
should	FANAPT.xml:S3:12015:6	O
undergo	FANAPT.xml:S3:12022:7	O
fasting	FANAPT.xml:S3:12030:7	O
blood	FANAPT.xml:S3:12038:5	O
glucose	FANAPT.xml:S3:12044:7	O
testing	FANAPT.xml:S3:12052:7	O
at	FANAPT.xml:S3:12060:2	O
the	FANAPT.xml:S3:12063:3	O
beginning	FANAPT.xml:S3:12067:9	O
of	FANAPT.xml:S3:12077:2	O
treatment	FANAPT.xml:S3:12080:9	O
and	FANAPT.xml:S3:12090:3	O
periodically	FANAPT.xml:S3:12094:12	O
during	FANAPT.xml:S3:12107:6	O
treatment	FANAPT.xml:S3:12114:9	O
.	FANAPT.xml:S3:12123:1	O

Any	FANAPT.xml:S3:12125:3	O
patient	FANAPT.xml:S3:12129:7	O
treated	FANAPT.xml:S3:12137:7	O
with	FANAPT.xml:S3:12145:4	O
atypical	FANAPT.xml:S3:12150:8	O
antipsychotics	FANAPT.xml:S3:12159:14	O
should	FANAPT.xml:S3:12174:6	O
be	FANAPT.xml:S3:12181:2	O
monitored	FANAPT.xml:S3:12184:9	O
for	FANAPT.xml:S3:12194:3	O
symptoms	FANAPT.xml:S3:12198:8	O
of	FANAPT.xml:S3:12207:2	O
hyperglycemia	FANAPT.xml:S3:12210:13	O
including	FANAPT.xml:S3:12224:9	O
polydipsia	FANAPT.xml:S3:12234:10	O
,	FANAPT.xml:S3:12244:1	O
polyuria	FANAPT.xml:S3:12246:8	O
,	FANAPT.xml:S3:12254:1	O
polyphagia	FANAPT.xml:S3:12256:10	O
,	FANAPT.xml:S3:12266:1	O
and	FANAPT.xml:S3:12268:3	O
weakness	FANAPT.xml:S3:12272:8	O
.	FANAPT.xml:S3:12280:1	O

Patients	FANAPT.xml:S3:12282:8	O
who	FANAPT.xml:S3:12291:3	O
develop	FANAPT.xml:S3:12295:7	O
symptoms	FANAPT.xml:S3:12303:8	O
of	FANAPT.xml:S3:12312:2	O
hyperglycemia	FANAPT.xml:S3:12315:13	O
during	FANAPT.xml:S3:12329:6	O
treatment	FANAPT.xml:S3:12336:9	O
with	FANAPT.xml:S3:12346:4	O
atypical	FANAPT.xml:S3:12351:8	O
antipsychotics	FANAPT.xml:S3:12360:14	O
should	FANAPT.xml:S3:12375:6	O
undergo	FANAPT.xml:S3:12382:7	O
fasting	FANAPT.xml:S3:12390:7	O
blood	FANAPT.xml:S3:12398:5	O
glucose	FANAPT.xml:S3:12404:7	O
testing	FANAPT.xml:S3:12412:7	O
.	FANAPT.xml:S3:12419:1	O

In	FANAPT.xml:S3:12421:2	O
some	FANAPT.xml:S3:12424:4	O
cases	FANAPT.xml:S3:12429:5	O
,	FANAPT.xml:S3:12434:1	O
hyperglycemia	FANAPT.xml:S3:12436:13	O
has	FANAPT.xml:S3:12450:3	O
resolved	FANAPT.xml:S3:12454:8	O
when	FANAPT.xml:S3:12463:4	O
the	FANAPT.xml:S3:12468:3	O
atypical	FANAPT.xml:S3:12472:8	O
antipsychotic	FANAPT.xml:S3:12481:13	O
was	FANAPT.xml:S3:12495:3	O
discontinued	FANAPT.xml:S3:12499:12	O
;	FANAPT.xml:S3:12511:1	O
however	FANAPT.xml:S3:12513:7	O
,	FANAPT.xml:S3:12520:1	O
some	FANAPT.xml:S3:12522:4	O
patients	FANAPT.xml:S3:12527:8	O
required	FANAPT.xml:S3:12536:8	O
continuation	FANAPT.xml:S3:12545:12	O
of	FANAPT.xml:S3:12558:2	O
antidiabetic	FANAPT.xml:S3:12561:12	O
treatment	FANAPT.xml:S3:12574:9	O
despite	FANAPT.xml:S3:12584:7	O
discontinuation	FANAPT.xml:S3:12592:15	O
of	FANAPT.xml:S3:12608:2	O
the	FANAPT.xml:S3:12611:3	O
suspect	FANAPT.xml:S3:12615:7	O
drug	FANAPT.xml:S3:12623:4	O
.	FANAPT.xml:S3:12627:1	O

Data	FANAPT.xml:S3:12633:4	O
from	FANAPT.xml:S3:12638:4	O
a	FANAPT.xml:S3:12643:1	O
4	FANAPT.xml:S3:12645:1	O
-	FANAPT.xml:S3:12646:1	O
week	FANAPT.xml:S3:12647:4	O
,	FANAPT.xml:S3:12651:1	O
fixed	FANAPT.xml:S3:12653:5	O
-	FANAPT.xml:S3:12658:1	O
dose	FANAPT.xml:S3:12659:4	O
study	FANAPT.xml:S3:12664:5	O
in	FANAPT.xml:S3:12670:2	O
adult	FANAPT.xml:S3:12673:5	O
subjects	FANAPT.xml:S3:12679:8	O
with	FANAPT.xml:S3:12688:4	O
schizophrenia	FANAPT.xml:S3:12693:13	O
,	FANAPT.xml:S3:12706:1	O
in	FANAPT.xml:S3:12708:2	O
which	FANAPT.xml:S3:12711:5	O
fasting	FANAPT.xml:S3:12717:7	O
blood	FANAPT.xml:S3:12725:5	O
samples	FANAPT.xml:S3:12731:7	O
were	FANAPT.xml:S3:12739:4	O
drawn	FANAPT.xml:S3:12744:5	O
,	FANAPT.xml:S3:12749:1	O
are	FANAPT.xml:S3:12751:3	O
presented	FANAPT.xml:S3:12755:9	O
in	FANAPT.xml:S3:12765:2	O
Table	FANAPT.xml:S3:12768:5	O
1	FANAPT.xml:S3:12774:1	O
.	FANAPT.xml:S3:12775:1	O

Table	FANAPT.xml:S3:12781:5	O
1	FANAPT.xml:S3:12787:1	O
:	FANAPT.xml:S3:12788:1	O
Change	FANAPT.xml:S3:12790:6	O
in	FANAPT.xml:S3:12797:2	O
Fasting	FANAPT.xml:S3:12800:7	O
Glucose	FANAPT.xml:S3:12808:7	O

FANAPT	FANAPT.xml:S3:12853:6	O

Placebo	FANAPT.xml:S3:12890:7	O
24	FANAPT.xml:S3:12907:2	O
mg	FANAPT.xml:S3:12910:2	O
day	FANAPT.xml:S3:12913:3	O

Mean	FANAPT.xml:S3:12944:4	O
Change	FANAPT.xml:S3:12949:6	O
from	FANAPT.xml:S3:12956:4	O
Baseline	FANAPT.xml:S3:12961:8	O
(	FANAPT.xml:S3:12969:1	O
mg	FANAPT.xml:S3:12970:2	O
dL	FANAPT.xml:S3:12973:2	O
)	FANAPT.xml:S3:12975:1	O

n	FANAPT.xml:S3:13001:1	O
114	FANAPT.xml:S3:13003:3	O
n	FANAPT.xml:S3:13018:1	O
228	FANAPT.xml:S3:13020:3	O

Serum	FANAPT.xml:S3:13038:5	O
Glucose	FANAPT.xml:S3:13044:7	O
Change	FANAPT.xml:S3:13052:6	O
from	FANAPT.xml:S3:13059:4	O
Baseline	FANAPT.xml:S3:13064:8	O
-	FANAPT.xml:S3:13076:1	O
0.5	FANAPT.xml:S3:13077:3	O
6.6	FANAPT.xml:S3:13093:3	O

Proportion	FANAPT.xml:S3:13131:10	O
of	FANAPT.xml:S3:13142:2	O
Patients	FANAPT.xml:S3:13145:8	O
with	FANAPT.xml:S3:13154:4	O
Shifts	FANAPT.xml:S3:13159:6	O

Serum	FANAPT.xml:S3:13173:5	O
Glucose	FANAPT.xml:S3:13179:7	O
Normal	FANAPT.xml:S3:13187:6	O
to	FANAPT.xml:S3:13194:2	O
High	FANAPT.xml:S3:13197:4	O
2.5	FANAPT.xml:S3:13205:3	O
10.7	FANAPT.xml:S3:13222:4	O

(	FANAPT.xml:S3:13242:1	O
100	FANAPT.xml:S3:13244:3	O
mg	FANAPT.xml:S3:13248:2	O
dL	FANAPT.xml:S3:13251:2	O
to	FANAPT.xml:S3:13254:2	O
126	FANAPT.xml:S3:13259:3	O
mg	FANAPT.xml:S3:13263:2	O
dL	FANAPT.xml:S3:13266:2	O
)	FANAPT.xml:S3:13268:1	O
(	FANAPT.xml:S3:13271:1	O
2	FANAPT.xml:S3:13272:1	O
80	FANAPT.xml:S3:13274:2	O
)	FANAPT.xml:S3:13276:1	O
(	FANAPT.xml:S3:13288:1	O
18	FANAPT.xml:S3:13289:2	O
169	FANAPT.xml:S3:13292:3	O
)	FANAPT.xml:S3:13295:1	O

Pooled	FANAPT.xml:S3:13316:6	O
analyses	FANAPT.xml:S3:13323:8	O
of	FANAPT.xml:S3:13332:2	O
glucose	FANAPT.xml:S3:13335:7	O
data	FANAPT.xml:S3:13343:4	O
from	FANAPT.xml:S3:13348:4	O
clinical	FANAPT.xml:S3:13353:8	O
studies	FANAPT.xml:S3:13362:7	O
including	FANAPT.xml:S3:13370:9	O
longer	FANAPT.xml:S3:13380:6	O
term	FANAPT.xml:S3:13387:4	O
trials	FANAPT.xml:S3:13392:6	O
are	FANAPT.xml:S3:13399:3	O
shown	FANAPT.xml:S3:13403:5	O
in	FANAPT.xml:S3:13409:2	O
Table	FANAPT.xml:S3:13412:5	O
2	FANAPT.xml:S3:13418:1	O
.	FANAPT.xml:S3:13419:1	O

Table	FANAPT.xml:S3:13425:5	O

2	FANAPT.xml:S3:13431:1	O
:	FANAPT.xml:S3:13432:1	O
Change	FANAPT.xml:S3:13434:6	O
in	FANAPT.xml:S3:13441:2	O
Glucose	FANAPT.xml:S3:13444:7	O

Mean	FANAPT.xml:S3:13455:4	O
Change	FANAPT.xml:S3:13460:6	O
from	FANAPT.xml:S3:13467:4	O
Baseline	FANAPT.xml:S3:13472:8	O
(	FANAPT.xml:S3:13481:1	O
mg	FANAPT.xml:S3:13482:2	O
dL	FANAPT.xml:S3:13485:2	O
)	FANAPT.xml:S3:13487:1	O

3	FANAPT.xml:S3:13513:1	O
-	FANAPT.xml:S3:13514:1	O
6	FANAPT.xml:S3:13515:1	O
months	FANAPT.xml:S3:13517:6	O
6	FANAPT.xml:S3:13530:1	O
-	FANAPT.xml:S3:13531:1	O
12	FANAPT.xml:S3:13532:2	O
months	FANAPT.xml:S3:13535:6	O
12	FANAPT.xml:S3:13548:2	O
months	FANAPT.xml:S3:13551:6	O

FANAPT	FANAPT.xml:S3:13566:6	O
10	FANAPT.xml:S3:13573:2	O
-	FANAPT.xml:S3:13575:1	O
16	FANAPT.xml:S3:13576:2	O
mg	FANAPT.xml:S3:13579:2	O
day	FANAPT.xml:S3:13582:3	O
1.8	FANAPT.xml:S3:13587:3	O
(	FANAPT.xml:S3:13591:1	O
N	FANAPT.xml:S3:13592:1	O
773	FANAPT.xml:S3:13594:3	O
)	FANAPT.xml:S3:13597:1	O
5.4	FANAPT.xml:S3:13604:3	O
(	FANAPT.xml:S3:13608:1	O
N	FANAPT.xml:S3:13609:1	O
723	FANAPT.xml:S3:13611:3	O
)	FANAPT.xml:S3:13614:1	O
5.4	FANAPT.xml:S3:13621:3	O
(	FANAPT.xml:S3:13625:1	O
N	FANAPT.xml:S3:13626:1	O
425	FANAPT.xml:S3:13628:3	O
)	FANAPT.xml:S3:13631:1	O

FANAPT	FANAPT.xml:S3:13641:6	O
20	FANAPT.xml:S3:13648:2	O
-	FANAPT.xml:S3:13650:1	O
24	FANAPT.xml:S3:13651:2	O
mg	FANAPT.xml:S3:13654:2	O
day	FANAPT.xml:S3:13657:3	O
-	FANAPT.xml:S3:13662:1	O
3.6	FANAPT.xml:S3:13663:3	O
(	FANAPT.xml:S3:13667:1	O
N	FANAPT.xml:S3:13668:1	O
34	FANAPT.xml:S3:13670:2	O
)	FANAPT.xml:S3:13672:1	O
-	FANAPT.xml:S3:13679:1	O
9.0	FANAPT.xml:S3:13680:3	O
(	FANAPT.xml:S3:13684:1	O
N	FANAPT.xml:S3:13685:1	O
31	FANAPT.xml:S3:13687:2	O
)	FANAPT.xml:S3:13689:1	O
-	FANAPT.xml:S3:13696:1	O
18.0	FANAPT.xml:S3:13697:4	O
(	FANAPT.xml:S3:13702:1	O
N	FANAPT.xml:S3:13703:1	O
20	FANAPT.xml:S3:13705:2	O
)	FANAPT.xml:S3:13707:1	O

Dyslipidemia	FANAPT.xml:S3:13726:12	O

Undesirable	FANAPT.xml:S3:13745:11	B-AdverseReaction

alterations	FANAPT.xml:S3:13757:11	I-AdverseReaction
in	FANAPT.xml:S3:13769:2	I-AdverseReaction
lipids	FANAPT.xml:S3:13772:6	I-AdverseReaction
have	FANAPT.xml:S3:13779:4	O
been	FANAPT.xml:S3:13784:4	O
observed	FANAPT.xml:S3:13789:8	O
in	FANAPT.xml:S3:13798:2	O
patients	FANAPT.xml:S3:13801:8	O
treated	FANAPT.xml:S3:13810:7	O
with	FANAPT.xml:S3:13818:4	O
atypical	FANAPT.xml:S3:13823:8	B-DrugClass
antipsychotics	FANAPT.xml:S3:13832:14	I-DrugClass
.	FANAPT.xml:S3:13846:1	O

Data	FANAPT.xml:S3:13852:4	O
from	FANAPT.xml:S3:13857:4	O
a	FANAPT.xml:S3:13862:1	O
placebo	FANAPT.xml:S3:13864:7	O
-	FANAPT.xml:S3:13871:1	O
controlled	FANAPT.xml:S3:13872:10	O
,	FANAPT.xml:S3:13882:1	O
4	FANAPT.xml:S3:13884:1	O
-	FANAPT.xml:S3:13885:1	O
week	FANAPT.xml:S3:13886:4	O
,	FANAPT.xml:S3:13890:1	O
fixed	FANAPT.xml:S3:13892:5	O
-	FANAPT.xml:S3:13897:1	O
dose	FANAPT.xml:S3:13898:4	O
study	FANAPT.xml:S3:13903:5	O
,	FANAPT.xml:S3:13908:1	O
in	FANAPT.xml:S3:13910:2	O
which	FANAPT.xml:S3:13913:5	O
fasting	FANAPT.xml:S3:13919:7	O
blood	FANAPT.xml:S3:13927:5	O
samples	FANAPT.xml:S3:13933:7	O
were	FANAPT.xml:S3:13941:4	O
drawn	FANAPT.xml:S3:13946:5	O
,	FANAPT.xml:S3:13951:1	O
in	FANAPT.xml:S3:13953:2	O
adult	FANAPT.xml:S3:13956:5	O
subjects	FANAPT.xml:S3:13962:8	O
with	FANAPT.xml:S3:13971:4	O
schizophrenia	FANAPT.xml:S3:13976:13	O
are	FANAPT.xml:S3:13990:3	O
presented	FANAPT.xml:S3:13994:9	O
in	FANAPT.xml:S3:14004:2	O
Table	FANAPT.xml:S3:14007:5	O
3	FANAPT.xml:S3:14013:1	O
.	FANAPT.xml:S3:14014:1	O

Table	FANAPT.xml:S3:14020:5	O
3	FANAPT.xml:S3:14026:1	O
:	FANAPT.xml:S3:14027:1	O
Change	FANAPT.xml:S3:14029:6	O
in	FANAPT.xml:S3:14036:2	O
Fasting	FANAPT.xml:S3:14039:7	O
Lipids	FANAPT.xml:S3:14047:6	O

FANAPT	FANAPT.xml:S3:14091:6	O

Placebo	FANAPT.xml:S3:14128:7	O
24	FANAPT.xml:S3:14145:2	O
mg	FANAPT.xml:S3:14148:2	O
day	FANAPT.xml:S3:14151:3	O

Mean	FANAPT.xml:S3:14182:4	O
Change	FANAPT.xml:S3:14187:6	O
from	FANAPT.xml:S3:14194:4	O
Baseline	FANAPT.xml:S3:14199:8	O
(	FANAPT.xml:S3:14208:1	O
mg	FANAPT.xml:S3:14209:2	O
dL	FANAPT.xml:S3:14212:2	O
)	FANAPT.xml:S3:14214:1	O

Cholesterol	FANAPT.xml:S3:14223:11	O
n	FANAPT.xml:S3:14240:1	O
114	FANAPT.xml:S3:14242:3	O
n	FANAPT.xml:S3:14257:1	O
228	FANAPT.xml:S3:14259:3	O

Change	FANAPT.xml:S3:14277:6	O
from	FANAPT.xml:S3:14284:4	O
baseline	FANAPT.xml:S3:14289:8	O
-	FANAPT.xml:S3:14301:1	O
2.17	FANAPT.xml:S3:14302:4	O
8.18	FANAPT.xml:S3:14318:4	O

LDL	FANAPT.xml:S3:14339:3	O
n	FANAPT.xml:S3:14356:1	O
109	FANAPT.xml:S3:14358:3	O
n	FANAPT.xml:S3:14373:1	O
217	FANAPT.xml:S3:14375:3	O

Change	FANAPT.xml:S3:14393:6	O
from	FANAPT.xml:S3:14400:4	O
baseline	FANAPT.xml:S3:14405:8	O
-	FANAPT.xml:S3:14417:1	O
1.41	FANAPT.xml:S3:14418:4	O
9.03	FANAPT.xml:S3:14434:4	O

HDL	FANAPT.xml:S3:14455:3	O
n	FANAPT.xml:S3:14472:1	O
114	FANAPT.xml:S3:14474:3	O
n	FANAPT.xml:S3:14489:1	O
228	FANAPT.xml:S3:14491:3	O

Change	FANAPT.xml:S3:14509:6	O
from	FANAPT.xml:S3:14516:4	O
baseline	FANAPT.xml:S3:14521:8	O
-	FANAPT.xml:S3:14533:1	O
3.35	FANAPT.xml:S3:14534:4	O
0.55	FANAPT.xml:S3:14550:4	O

Triglycerides	FANAPT.xml:S3:14571:13	O
n	FANAPT.xml:S3:14589:1	O
114	FANAPT.xml:S3:14591:3	O
n	FANAPT.xml:S3:14606:1	O
228	FANAPT.xml:S3:14608:3	O

Change	FANAPT.xml:S3:14626:6	O
from	FANAPT.xml:S3:14633:4	O
baseline	FANAPT.xml:S3:14638:8	O
16.47	FANAPT.xml:S3:14650:5	O
-	FANAPT.xml:S3:14667:1	O
0.83	FANAPT.xml:S3:14668:4	O

Proportion	FANAPT.xml:S3:14705:10	O
of	FANAPT.xml:S3:14716:2	O
Patients	FANAPT.xml:S3:14719:8	O
with	FANAPT.xml:S3:14728:4	O
Shifts	FANAPT.xml:S3:14733:6	O

Cholesterol	FANAPT.xml:S3:14747:11	O

Normal	FANAPT.xml:S3:14801:6	O
to	FANAPT.xml:S3:14808:2	O
High	FANAPT.xml:S3:14811:4	O
1.4%	FANAPT.xml:S3:14819:4	O
3.6%	FANAPT.xml:S3:14836:4	O

(	FANAPT.xml:S3:14857:1	O
200	FANAPT.xml:S3:14859:3	O
mg	FANAPT.xml:S3:14863:2	O
dL	FANAPT.xml:S3:14866:2	O
to	FANAPT.xml:S3:14869:2	O
240	FANAPT.xml:S3:14874:3	O
mg	FANAPT.xml:S3:14878:2	O
dL	FANAPT.xml:S3:14881:2	O
)	FANAPT.xml:S3:14883:1	O
(	FANAPT.xml:S3:14888:1	O
1	FANAPT.xml:S3:14889:1	O
72	FANAPT.xml:S3:14891:2	O
)	FANAPT.xml:S3:14893:1	O
(	FANAPT.xml:S3:14905:1	O
5	FANAPT.xml:S3:14906:1	O
141	FANAPT.xml:S3:14908:3	O
)	FANAPT.xml:S3:14911:1	O

LDL	FANAPT.xml:S3:14926:3	O

Normal	FANAPT.xml:S3:14980:6	O
to	FANAPT.xml:S3:14987:2	O
High	FANAPT.xml:S3:14990:4	O
2.4%	FANAPT.xml:S3:14998:4	O
1.1%	FANAPT.xml:S3:15015:4	O

(	FANAPT.xml:S3:15036:1	O
100	FANAPT.xml:S3:15038:3	O
mg	FANAPT.xml:S3:15042:2	O
dL	FANAPT.xml:S3:15045:2	O
to	FANAPT.xml:S3:15048:2	O
160	FANAPT.xml:S3:15053:3	O
mg	FANAPT.xml:S3:15057:2	O
dL	FANAPT.xml:S3:15060:2	O
)	FANAPT.xml:S3:15062:1	O
(	FANAPT.xml:S3:15067:1	O
1	FANAPT.xml:S3:15068:1	O
42	FANAPT.xml:S3:15070:2	O
)	FANAPT.xml:S3:15072:1	O
(	FANAPT.xml:S3:15084:1	O
1	FANAPT.xml:S3:15085:1	O
90	FANAPT.xml:S3:15087:2	O
)	FANAPT.xml:S3:15089:1	O

HDL	FANAPT.xml:S3:15105:3	O

Normal	FANAPT.xml:S3:15159:6	O
to	FANAPT.xml:S3:15166:2	O
Low	FANAPT.xml:S3:15169:3	O
23.8%	FANAPT.xml:S3:15176:5	O
12.1%	FANAPT.xml:S3:15193:5	O

(	FANAPT.xml:S3:15214:1	O
40	FANAPT.xml:S3:15218:2	O
mg	FANAPT.xml:S3:15221:2	O
dL	FANAPT.xml:S3:15224:2	O
to	FANAPT.xml:S3:15227:2	O
40	FANAPT.xml:S3:15231:2	O
mg	FANAPT.xml:S3:15234:2	O
dL	FANAPT.xml:S3:15237:2	O
)	FANAPT.xml:S3:15239:1	O
(	FANAPT.xml:S3:15244:1	O
19	FANAPT.xml:S3:15245:2	O
80	FANAPT.xml:S3:15248:2	O
)	FANAPT.xml:S3:15250:1	O
(	FANAPT.xml:S3:15261:1	O
20	FANAPT.xml:S3:15262:2	O
166	FANAPT.xml:S3:15265:3	O
)	FANAPT.xml:S3:15268:1	O

Triglycerides	FANAPT.xml:S3:15282:13	O

Normal	FANAPT.xml:S3:15337:6	O
to	FANAPT.xml:S3:15344:2	O
High	FANAPT.xml:S3:15347:4	O
8.3%	FANAPT.xml:S3:15355:4	O
10.1%	FANAPT.xml:S3:15372:5	O

(	FANAPT.xml:S3:15393:1	O
150	FANAPT.xml:S3:15395:3	O
mg	FANAPT.xml:S3:15399:2	O
dL	FANAPT.xml:S3:15402:2	O
to	FANAPT.xml:S3:15405:2	O
200	FANAPT.xml:S3:15410:3	O
mg	FANAPT.xml:S3:15414:2	O
dL	FANAPT.xml:S3:15417:2	O
)	FANAPT.xml:S3:15419:1	O
(	FANAPT.xml:S3:15424:1	O
6	FANAPT.xml:S3:15425:1	O
72	FANAPT.xml:S3:15427:2	O
)	FANAPT.xml:S3:15429:1	O
(	FANAPT.xml:S3:15441:1	O
15	FANAPT.xml:S3:15442:2	O
148	FANAPT.xml:S3:15445:3	O
)	FANAPT.xml:S3:15448:1	O

Pooled	FANAPT.xml:S3:15469:6	O
analyses	FANAPT.xml:S3:15476:8	O
of	FANAPT.xml:S3:15485:2	O
cholesterol	FANAPT.xml:S3:15488:11	O
and	FANAPT.xml:S3:15500:3	O
triglyceride	FANAPT.xml:S3:15504:12	O
data	FANAPT.xml:S3:15517:4	O
from	FANAPT.xml:S3:15522:4	O
clinical	FANAPT.xml:S3:15527:8	O
studies	FANAPT.xml:S3:15536:7	O
including	FANAPT.xml:S3:15544:9	O
longer	FANAPT.xml:S3:15554:6	O
term	FANAPT.xml:S3:15561:4	O
trials	FANAPT.xml:S3:15566:6	O
are	FANAPT.xml:S3:15573:3	O
shown	FANAPT.xml:S3:15577:5	O
in	FANAPT.xml:S3:15583:2	O
Tables	FANAPT.xml:S3:15586:6	O
4	FANAPT.xml:S3:15593:1	O
and	FANAPT.xml:S3:15595:3	O
5	FANAPT.xml:S3:15599:1	O
.	FANAPT.xml:S3:15600:1	O

Table	FANAPT.xml:S3:15606:5	O

4	FANAPT.xml:S3:15612:1	O
:	FANAPT.xml:S3:15613:1	O
Change	FANAPT.xml:S3:15615:6	O
in	FANAPT.xml:S3:15622:2	O
Cholesterol	FANAPT.xml:S3:15625:11	O

Mean	FANAPT.xml:S3:15640:4	O
Change	FANAPT.xml:S3:15645:6	O
from	FANAPT.xml:S3:15652:4	O
Baseline	FANAPT.xml:S3:15657:8	O
(	FANAPT.xml:S3:15666:1	O
mg	FANAPT.xml:S3:15667:2	O
dL	FANAPT.xml:S3:15670:2	O
)	FANAPT.xml:S3:15672:1	O

3	FANAPT.xml:S3:15698:1	O
-	FANAPT.xml:S3:15699:1	O
6	FANAPT.xml:S3:15700:1	O
months	FANAPT.xml:S3:15702:6	O
6	FANAPT.xml:S3:15715:1	O
-	FANAPT.xml:S3:15716:1	O
12	FANAPT.xml:S3:15717:2	O
months	FANAPT.xml:S3:15720:6	O
12	FANAPT.xml:S3:15733:2	O
months	FANAPT.xml:S3:15736:6	O

FANAPT	FANAPT.xml:S3:15751:6	O
10	FANAPT.xml:S3:15758:2	O
-	FANAPT.xml:S3:15760:1	O
16	FANAPT.xml:S3:15761:2	O
mg	FANAPT.xml:S3:15764:2	O
day	FANAPT.xml:S3:15767:3	O
-	FANAPT.xml:S3:15772:1	O
3.9	FANAPT.xml:S3:15773:3	O
(	FANAPT.xml:S3:15777:1	O
N	FANAPT.xml:S3:15778:1	O
783	FANAPT.xml:S3:15780:3	O
)	FANAPT.xml:S3:15783:1	O
-	FANAPT.xml:S3:15789:1	O
3.9	FANAPT.xml:S3:15790:3	O
(	FANAPT.xml:S3:15794:1	O
N	FANAPT.xml:S3:15795:1	O
726	FANAPT.xml:S3:15797:3	O
)	FANAPT.xml:S3:15800:1	O
-	FANAPT.xml:S3:15806:1	O
7.7	FANAPT.xml:S3:15807:3	O
(	FANAPT.xml:S3:15811:1	O
N	FANAPT.xml:S3:15812:1	O
428	FANAPT.xml:S3:15814:3	O
)	FANAPT.xml:S3:15817:1	O

FANAPT	FANAPT.xml:S3:15826:6	O
20	FANAPT.xml:S3:15833:2	O
-	FANAPT.xml:S3:15835:1	O
24	FANAPT.xml:S3:15836:2	O
mg	FANAPT.xml:S3:15839:2	O
day	FANAPT.xml:S3:15842:3	O
-	FANAPT.xml:S3:15847:1	O
19.4	FANAPT.xml:S3:15848:4	O
(	FANAPT.xml:S3:15853:1	O
N	FANAPT.xml:S3:15854:1	O
34	FANAPT.xml:S3:15856:2	O
)	FANAPT.xml:S3:15858:1	O
-	FANAPT.xml:S3:15864:1	O
23.2	FANAPT.xml:S3:15865:4	O
(	FANAPT.xml:S3:15870:1	O
N	FANAPT.xml:S3:15871:1	O
31	FANAPT.xml:S3:15873:2	O
)	FANAPT.xml:S3:15875:1	O
-	FANAPT.xml:S3:15881:1	O
19.4	FANAPT.xml:S3:15882:4	O
(	FANAPT.xml:S3:15887:1	O
N	FANAPT.xml:S3:15888:1	O
20	FANAPT.xml:S3:15890:2	O
)	FANAPT.xml:S3:15892:1	O

Table	FANAPT.xml:S3:15909:5	O
5	FANAPT.xml:S3:15915:1	O
:	FANAPT.xml:S3:15916:1	O
Change	FANAPT.xml:S3:15918:6	O
in	FANAPT.xml:S3:15925:2	O
Triglycerides	FANAPT.xml:S3:15928:13	O

Mean	FANAPT.xml:S3:15945:4	O
Change	FANAPT.xml:S3:15950:6	O
from	FANAPT.xml:S3:15957:4	O
Baseline	FANAPT.xml:S3:15962:8	O
(	FANAPT.xml:S3:15971:1	O
mg	FANAPT.xml:S3:15972:2	O
dL	FANAPT.xml:S3:15975:2	O
)	FANAPT.xml:S3:15977:1	O

3	FANAPT.xml:S3:16003:1	O
-	FANAPT.xml:S3:16004:1	O
6	FANAPT.xml:S3:16005:1	O
months	FANAPT.xml:S3:16007:6	O
6	FANAPT.xml:S3:16020:1	O
-	FANAPT.xml:S3:16021:1	O
12	FANAPT.xml:S3:16022:2	O
months	FANAPT.xml:S3:16025:6	O
12	FANAPT.xml:S3:16038:2	O
months	FANAPT.xml:S3:16041:6	O

FANAPT	FANAPT.xml:S3:16056:6	O
10	FANAPT.xml:S3:16063:2	O
-	FANAPT.xml:S3:16065:1	O
16	FANAPT.xml:S3:16066:2	O
mg	FANAPT.xml:S3:16069:2	O
day	FANAPT.xml:S3:16072:3	O
-	FANAPT.xml:S3:16077:1	O
8.9	FANAPT.xml:S3:16078:3	O
(	FANAPT.xml:S3:16082:1	O
N	FANAPT.xml:S3:16083:1	O
783	FANAPT.xml:S3:16085:3	O
)	FANAPT.xml:S3:16088:1	O
-	FANAPT.xml:S3:16094:1	O
8.9	FANAPT.xml:S3:16095:3	O
(	FANAPT.xml:S3:16099:1	O
N	FANAPT.xml:S3:16100:1	O
726	FANAPT.xml:S3:16102:3	O
)	FANAPT.xml:S3:16105:1	O
-	FANAPT.xml:S3:16111:1	O
17.7	FANAPT.xml:S3:16112:4	O
(	FANAPT.xml:S3:16117:1	O
N	FANAPT.xml:S3:16118:1	O
428	FANAPT.xml:S3:16120:3	O
)	FANAPT.xml:S3:16123:1	O

FANAPT	FANAPT.xml:S3:16131:6	O
20	FANAPT.xml:S3:16138:2	O
-	FANAPT.xml:S3:16140:1	O
24	FANAPT.xml:S3:16141:2	O
mg	FANAPT.xml:S3:16144:2	O
day	FANAPT.xml:S3:16147:3	O
-	FANAPT.xml:S3:16152:1	O
26.6	FANAPT.xml:S3:16153:4	O
(	FANAPT.xml:S3:16158:1	O
N	FANAPT.xml:S3:16159:1	O
34	FANAPT.xml:S3:16161:2	O
)	FANAPT.xml:S3:16163:1	O
-	FANAPT.xml:S3:16169:1	O
35.4	FANAPT.xml:S3:16170:4	O
(	FANAPT.xml:S3:16175:1	O
N	FANAPT.xml:S3:16176:1	O
31	FANAPT.xml:S3:16178:2	O
)	FANAPT.xml:S3:16180:1	O
-	FANAPT.xml:S3:16186:1	O
17.7	FANAPT.xml:S3:16187:4	O
(	FANAPT.xml:S3:16192:1	O
N	FANAPT.xml:S3:16193:1	O
20	FANAPT.xml:S3:16195:2	O
)	FANAPT.xml:S3:16197:1	O

Weight	FANAPT.xml:S3:16216:6	O
Gain	FANAPT.xml:S3:16223:4	O

Weight	FANAPT.xml:S3:16234:6	B-AdverseReaction

gain	FANAPT.xml:S3:16241:4	I-AdverseReaction
has	FANAPT.xml:S3:16246:3	O
been	FANAPT.xml:S3:16250:4	O
observed	FANAPT.xml:S3:16255:8	O
with	FANAPT.xml:S3:16264:4	O
atypical	FANAPT.xml:S3:16269:8	B-DrugClass
antipsychotic	FANAPT.xml:S3:16278:13	I-DrugClass
use	FANAPT.xml:S3:16292:3	O
.	FANAPT.xml:S3:16295:1	O

Clinical	FANAPT.xml:S3:16297:8	O
monitoring	FANAPT.xml:S3:16306:10	O
of	FANAPT.xml:S3:16317:2	O
weight	FANAPT.xml:S3:16320:6	O
is	FANAPT.xml:S3:16327:2	O
recommended	FANAPT.xml:S3:16330:11	O
.	FANAPT.xml:S3:16341:1	O

Across	FANAPT.xml:S3:16347:6	O
all	FANAPT.xml:S3:16354:3	O
short	FANAPT.xml:S3:16358:5	O
-	FANAPT.xml:S3:16363:1	O
and	FANAPT.xml:S3:16365:3	O
long	FANAPT.xml:S3:16369:4	O
-	FANAPT.xml:S3:16373:1	O
term	FANAPT.xml:S3:16374:4	O
studies	FANAPT.xml:S3:16379:7	O
,	FANAPT.xml:S3:16386:1	O
the	FANAPT.xml:S3:16388:3	O
overall	FANAPT.xml:S3:16392:7	O
mean	FANAPT.xml:S3:16400:4	O
change	FANAPT.xml:S3:16405:6	O
from	FANAPT.xml:S3:16412:4	O
baseline	FANAPT.xml:S3:16417:8	O
at	FANAPT.xml:S3:16426:2	O
endpoint	FANAPT.xml:S3:16429:8	O
was	FANAPT.xml:S3:16438:3	O
2.1	FANAPT.xml:S3:16442:3	O
kg	FANAPT.xml:S3:16446:2	O
.	FANAPT.xml:S3:16448:1	O

Changes	FANAPT.xml:S3:16454:7	O
in	FANAPT.xml:S3:16462:2	O
body	FANAPT.xml:S3:16465:4	O
weight	FANAPT.xml:S3:16470:6	O
(	FANAPT.xml:S3:16477:1	O
kg	FANAPT.xml:S3:16478:2	O
)	FANAPT.xml:S3:16480:1	O
and	FANAPT.xml:S3:16482:3	O
the	FANAPT.xml:S3:16486:3	O
proportion	FANAPT.xml:S3:16490:10	O
of	FANAPT.xml:S3:16501:2	O
subjects	FANAPT.xml:S3:16504:8	O
with	FANAPT.xml:S3:16513:4	O
7%	FANAPT.xml:S3:16520:2	O
gain	FANAPT.xml:S3:16523:4	B-AdverseReaction
in	FANAPT.xml:S3:16528:2	I-AdverseReaction
body	FANAPT.xml:S3:16531:4	I-AdverseReaction
weight	FANAPT.xml:S3:16536:6	I-AdverseReaction
from	FANAPT.xml:S3:16543:4	O
4	FANAPT.xml:S3:16548:1	O
placebo	FANAPT.xml:S3:16550:7	O
-	FANAPT.xml:S3:16557:1	O
controlled	FANAPT.xml:S3:16558:10	O
,	FANAPT.xml:S3:16568:1	O
4	FANAPT.xml:S3:16570:1	O
-	FANAPT.xml:S3:16571:1	O
or	FANAPT.xml:S3:16573:2	O
6	FANAPT.xml:S3:16576:1	O
-	FANAPT.xml:S3:16577:1	O
week	FANAPT.xml:S3:16578:4	O
,	FANAPT.xml:S3:16582:1	O
fixed	FANAPT.xml:S3:16584:5	O
-	FANAPT.xml:S3:16589:1	O
or	FANAPT.xml:S3:16591:2	O
flexible	FANAPT.xml:S3:16594:8	O
-	FANAPT.xml:S3:16602:1	O
dose	FANAPT.xml:S3:16603:4	O
studies	FANAPT.xml:S3:16608:7	O
in	FANAPT.xml:S3:16616:2	O
adult	FANAPT.xml:S3:16619:5	O
subjects	FANAPT.xml:S3:16625:8	O
are	FANAPT.xml:S3:16634:3	O
presented	FANAPT.xml:S3:16638:9	O
in	FANAPT.xml:S3:16648:2	O
Table	FANAPT.xml:S3:16651:5	O
6	FANAPT.xml:S3:16657:1	O
.	FANAPT.xml:S3:16658:1	O

Table	FANAPT.xml:S3:16664:5	O
6	FANAPT.xml:S3:16670:1	O
:	FANAPT.xml:S3:16671:1	O
Change	FANAPT.xml:S3:16673:6	O
in	FANAPT.xml:S3:16680:2	O
Body	FANAPT.xml:S3:16683:4	O
Weight	FANAPT.xml:S3:16688:6	O

FANAPT	FANAPT.xml:S3:16732:6	O
FANAPT	FANAPT.xml:S3:16749:6	O

Placebo	FANAPT.xml:S3:16786:7	O
10	FANAPT.xml:S3:16803:2	O
-	FANAPT.xml:S3:16805:1	O
16	FANAPT.xml:S3:16806:2	O
mg	FANAPT.xml:S3:16809:2	O
day	FANAPT.xml:S3:16812:3	O
20	FANAPT.xml:S3:16820:2	O
-	FANAPT.xml:S3:16822:1	O
24	FANAPT.xml:S3:16823:2	O
mg	FANAPT.xml:S3:16826:2	O
day	FANAPT.xml:S3:16829:3	O

n	FANAPT.xml:S3:16856:1	O
576	FANAPT.xml:S3:16858:3	O
n	FANAPT.xml:S3:16873:1	O
481	FANAPT.xml:S3:16875:3	O
n	FANAPT.xml:S3:16890:1	O
391	FANAPT.xml:S3:16892:3	O

Weight	FANAPT.xml:S3:16911:6	O
(	FANAPT.xml:S3:16918:1	O
kg	FANAPT.xml:S3:16919:2	O
)	FANAPT.xml:S3:16921:1	O

Change	FANAPT.xml:S3:16982:6	O
from	FANAPT.xml:S3:16989:4	O
Baseline	FANAPT.xml:S3:16994:8	O
-	FANAPT.xml:S3:17006:1	O
0.1	FANAPT.xml:S3:17007:3	O
2.0	FANAPT.xml:S3:17023:3	O
2.7	FANAPT.xml:S3:17040:3	O

Weight	FANAPT.xml:S3:17061:6	O
Gain	FANAPT.xml:S3:17068:4	O

7%	FANAPT.xml:S3:17134:2	O
increase	FANAPT.xml:S3:17137:8	O
from	FANAPT.xml:S3:17146:4	O
Baseline	FANAPT.xml:S3:17151:8	O
4%	FANAPT.xml:S3:17163:2	O
12%	FANAPT.xml:S3:17180:3	O
18%	FANAPT.xml:S3:17197:3	O

5.6	FANAPT.xml:S3:17229:3	O
Seizures	FANAPT.xml:S3:17237:8	O

In	FANAPT.xml:S3:17251:2	O

short	FANAPT.xml:S3:17254:5	O
-	FANAPT.xml:S3:17259:1	O
term	FANAPT.xml:S3:17260:4	O
placebo	FANAPT.xml:S3:17265:7	O
-	FANAPT.xml:S3:17272:1	O
controlled	FANAPT.xml:S3:17273:10	O
trials	FANAPT.xml:S3:17284:6	O
(	FANAPT.xml:S3:17291:1	O
4	FANAPT.xml:S3:17292:1	O
-	FANAPT.xml:S3:17293:1	O
to	FANAPT.xml:S3:17295:2	O
6	FANAPT.xml:S3:17298:1	O
-	FANAPT.xml:S3:17299:1	O
weeks	FANAPT.xml:S3:17300:5	O
)	FANAPT.xml:S3:17305:1	O
,	FANAPT.xml:S3:17306:1	O
seizures	FANAPT.xml:S3:17308:8	B-AdverseReaction
occurred	FANAPT.xml:S3:17317:8	O
in	FANAPT.xml:S3:17326:2	O
0.1%	FANAPT.xml:S3:17329:4	O
(	FANAPT.xml:S3:17334:1	O
1	FANAPT.xml:S3:17335:1	O
1344	FANAPT.xml:S3:17337:4	O
)	FANAPT.xml:S3:17341:1	O
of	FANAPT.xml:S3:17343:2	O
patients	FANAPT.xml:S3:17346:8	O
treated	FANAPT.xml:S3:17355:7	O
with	FANAPT.xml:S3:17363:4	O
FANAPT	FANAPT.xml:S3:17368:6	O
compared	FANAPT.xml:S3:17375:8	O
to	FANAPT.xml:S3:17384:2	O
0.3%	FANAPT.xml:S3:17387:4	O
(	FANAPT.xml:S3:17392:1	O
2	FANAPT.xml:S3:17393:1	O
587	FANAPT.xml:S3:17395:3	O
)	FANAPT.xml:S3:17398:1	O
on	FANAPT.xml:S3:17400:2	O
placebo	FANAPT.xml:S3:17403:7	O
.	FANAPT.xml:S3:17410:1	O

As	FANAPT.xml:S3:17412:2	O
with	FANAPT.xml:S3:17415:4	O
other	FANAPT.xml:S3:17420:5	O
antipsychotics	FANAPT.xml:S3:17426:14	O
,	FANAPT.xml:S3:17440:1	O
FANAPT	FANAPT.xml:S3:17442:6	O
should	FANAPT.xml:S3:17449:6	O
be	FANAPT.xml:S3:17456:2	O
used	FANAPT.xml:S3:17459:4	O
cautiously	FANAPT.xml:S3:17464:10	O
in	FANAPT.xml:S3:17475:2	O
patients	FANAPT.xml:S3:17478:8	O
with	FANAPT.xml:S3:17487:4	O
a	FANAPT.xml:S3:17492:1	O
history	FANAPT.xml:S3:17494:7	O
of	FANAPT.xml:S3:17502:2	O
seizures	FANAPT.xml:S3:17505:8	O
or	FANAPT.xml:S3:17514:2	O
with	FANAPT.xml:S3:17517:4	O
conditions	FANAPT.xml:S3:17522:10	O
that	FANAPT.xml:S3:17533:4	O
potentially	FANAPT.xml:S3:17538:11	O
lower	FANAPT.xml:S3:17550:5	O
the	FANAPT.xml:S3:17556:3	O
seizure	FANAPT.xml:S3:17560:7	O
threshold	FANAPT.xml:S3:17568:9	O
,	FANAPT.xml:S3:17577:1	O
e	FANAPT.xml:S3:17579:1	O
.	FANAPT.xml:S3:17580:1	O
g	FANAPT.xml:S3:17581:1	O
.	FANAPT.xml:S3:17582:1	O
,	FANAPT.xml:S3:17583:1	O
Alzheimer	FANAPT.xml:S3:17585:9	O
's	FANAPT.xml:S3:17594:2	O
dementia	FANAPT.xml:S3:17597:8	O
.	FANAPT.xml:S3:17605:1	O

Conditions	FANAPT.xml:S3:17607:10	O
that	FANAPT.xml:S3:17618:4	O
lower	FANAPT.xml:S3:17623:5	O
the	FANAPT.xml:S3:17629:3	O
seizure	FANAPT.xml:S3:17633:7	O
threshold	FANAPT.xml:S3:17641:9	O
may	FANAPT.xml:S3:17651:3	O
be	FANAPT.xml:S3:17655:2	O
more	FANAPT.xml:S3:17658:4	O
prevalent	FANAPT.xml:S3:17663:9	O
in	FANAPT.xml:S3:17673:2	O
a	FANAPT.xml:S3:17676:1	O
population	FANAPT.xml:S3:17678:10	O
of	FANAPT.xml:S3:17689:2	O
65	FANAPT.xml:S3:17692:2	O
years	FANAPT.xml:S3:17695:5	O
or	FANAPT.xml:S3:17701:2	O
older	FANAPT.xml:S3:17704:5	O
.	FANAPT.xml:S3:17709:1	O

5.7	FANAPT.xml:S3:17719:3	O
Orthostatic	FANAPT.xml:S3:17727:11	O
Hypotension	FANAPT.xml:S3:17739:11	O
and	FANAPT.xml:S3:17751:3	O
Syncope	FANAPT.xml:S3:17755:7	O

FANAPT	FANAPT.xml:S3:17768:6	O
can	FANAPT.xml:S3:17775:3	B-Factor
induce	FANAPT.xml:S3:17779:6	O
orthostatic	FANAPT.xml:S3:17786:11	B-AdverseReaction
hypotension	FANAPT.xml:S3:17798:11	I-AdverseReaction
associated	FANAPT.xml:S3:17810:10	O
with	FANAPT.xml:S3:17821:4	O
dizziness	FANAPT.xml:S3:17826:9	B-AdverseReaction
,	FANAPT.xml:S3:17835:1	O
tachycardia	FANAPT.xml:S3:17837:11	B-AdverseReaction
,	FANAPT.xml:S3:17848:1	O
and	FANAPT.xml:S3:17850:3	O
syncope	FANAPT.xml:S3:17854:7	B-AdverseReaction
.	FANAPT.xml:S3:17861:1	O

This	FANAPT.xml:S3:17863:4	O
reflects	FANAPT.xml:S3:17868:8	O
its	FANAPT.xml:S3:17877:3	O
alpha1	FANAPT.xml:S3:17881:6	O
-	FANAPT.xml:S3:17887:1	O
adrenergic	FANAPT.xml:S3:17888:10	O
antagonist	FANAPT.xml:S3:17899:10	O
properties	FANAPT.xml:S3:17910:10	O
.	FANAPT.xml:S3:17920:1	O

In	FANAPT.xml:S3:17922:2	O
double	FANAPT.xml:S3:17925:6	O
-	FANAPT.xml:S3:17931:1	O
blind	FANAPT.xml:S3:17932:5	O
placebo	FANAPT.xml:S3:17938:7	O
-	FANAPT.xml:S3:17945:1	O
controlled	FANAPT.xml:S3:17946:10	O
short	FANAPT.xml:S3:17957:5	O
-	FANAPT.xml:S3:17962:1	O
term	FANAPT.xml:S3:17963:4	O
studies	FANAPT.xml:S3:17968:7	O
,	FANAPT.xml:S3:17975:1	O
where	FANAPT.xml:S3:17977:5	O
the	FANAPT.xml:S3:17983:3	O
dose	FANAPT.xml:S3:17987:4	O
was	FANAPT.xml:S3:17992:3	O
increased	FANAPT.xml:S3:17996:9	O
slowly	FANAPT.xml:S3:18006:6	O
,	FANAPT.xml:S3:18012:1	O
as	FANAPT.xml:S3:18014:2	O
recommended	FANAPT.xml:S3:18017:11	O
above	FANAPT.xml:S3:18029:5	O
,	FANAPT.xml:S3:18034:1	O
syncope	FANAPT.xml:S3:18036:7	B-AdverseReaction
was	FANAPT.xml:S3:18044:3	O
reported	FANAPT.xml:S3:18048:8	O
in	FANAPT.xml:S3:18057:2	O
0.4%	FANAPT.xml:S3:18060:4	O
(	FANAPT.xml:S3:18065:1	O
5	FANAPT.xml:S3:18066:1	O
1344	FANAPT.xml:S3:18068:4	O
)	FANAPT.xml:S3:18072:1	O
of	FANAPT.xml:S3:18074:2	O
patients	FANAPT.xml:S3:18077:8	O
treated	FANAPT.xml:S3:18086:7	O
with	FANAPT.xml:S3:18094:4	O
FANAPT	FANAPT.xml:S3:18099:6	O
,	FANAPT.xml:S3:18105:1	O
compared	FANAPT.xml:S3:18107:8	O
with	FANAPT.xml:S3:18116:4	O
0.2%	FANAPT.xml:S3:18121:4	O
(	FANAPT.xml:S3:18126:1	O
1	FANAPT.xml:S3:18127:1	O
587	FANAPT.xml:S3:18129:3	O
)	FANAPT.xml:S3:18132:1	O
on	FANAPT.xml:S3:18134:2	O
placebo	FANAPT.xml:S3:18137:7	O
.	FANAPT.xml:S3:18144:1	O

Orthostatic	FANAPT.xml:S3:18146:11	B-AdverseReaction
hypotension	FANAPT.xml:S3:18158:11	I-AdverseReaction
was	FANAPT.xml:S3:18170:3	O
reported	FANAPT.xml:S3:18174:8	O
in	FANAPT.xml:S3:18183:2	O
5%	FANAPT.xml:S3:18186:2	O
of	FANAPT.xml:S3:18189:2	O
patients	FANAPT.xml:S3:18192:8	O
given	FANAPT.xml:S3:18201:5	O
20	FANAPT.xml:S3:18207:2	O
to	FANAPT.xml:S3:18210:2	O
24	FANAPT.xml:S3:18213:2	O
mg	FANAPT.xml:S3:18216:2	O
day	FANAPT.xml:S3:18219:3	O
,	FANAPT.xml:S3:18222:1	O
3%	FANAPT.xml:S3:18224:2	O
of	FANAPT.xml:S3:18227:2	O
patients	FANAPT.xml:S3:18230:8	O
given	FANAPT.xml:S3:18239:5	O
10	FANAPT.xml:S3:18245:2	O
to	FANAPT.xml:S3:18248:2	O
16	FANAPT.xml:S3:18251:2	O
mg	FANAPT.xml:S3:18254:2	O
day	FANAPT.xml:S3:18257:3	O
,	FANAPT.xml:S3:18260:1	O
and	FANAPT.xml:S3:18262:3	O
1%	FANAPT.xml:S3:18266:2	O
of	FANAPT.xml:S3:18269:2	O
patients	FANAPT.xml:S3:18272:8	O
given	FANAPT.xml:S3:18281:5	O
placebo	FANAPT.xml:S3:18287:7	O
.	FANAPT.xml:S3:18294:1	O

More	FANAPT.xml:S3:18296:4	O
rapid	FANAPT.xml:S3:18301:5	O
titration	FANAPT.xml:S3:18307:9	O
would	FANAPT.xml:S3:18317:5	O
be	FANAPT.xml:S3:18323:2	O
expected	FANAPT.xml:S3:18326:8	O
to	FANAPT.xml:S3:18335:2	O
increase	FANAPT.xml:S3:18338:8	O
the	FANAPT.xml:S3:18347:3	O
rate	FANAPT.xml:S3:18351:4	O
of	FANAPT.xml:S3:18356:2	O
orthostatic	FANAPT.xml:S3:18359:11	O
hypotension	FANAPT.xml:S3:18371:11	O
and	FANAPT.xml:S3:18383:3	O
syncope	FANAPT.xml:S3:18387:7	O
.	FANAPT.xml:S3:18394:1	O

FANAPT	FANAPT.xml:S3:18401:6	O
should	FANAPT.xml:S3:18408:6	O
be	FANAPT.xml:S3:18415:2	O
used	FANAPT.xml:S3:18418:4	O
with	FANAPT.xml:S3:18423:4	O
caution	FANAPT.xml:S3:18428:7	O
in	FANAPT.xml:S3:18436:2	O
patients	FANAPT.xml:S3:18439:8	O
with	FANAPT.xml:S3:18448:4	O
known	FANAPT.xml:S3:18453:5	O
cardiovascular	FANAPT.xml:S3:18459:14	O
disease	FANAPT.xml:S3:18474:7	O
(	FANAPT.xml:S3:18482:1	O
e	FANAPT.xml:S3:18483:1	O
.	FANAPT.xml:S3:18484:1	O
g	FANAPT.xml:S3:18485:1	O
.	FANAPT.xml:S3:18486:1	O
,	FANAPT.xml:S3:18487:1	O
heart	FANAPT.xml:S3:18489:5	O
failure	FANAPT.xml:S3:18495:7	O
,	FANAPT.xml:S3:18502:1	O
history	FANAPT.xml:S3:18504:7	O
of	FANAPT.xml:S3:18512:2	O
myocardial	FANAPT.xml:S3:18515:10	O
infarction	FANAPT.xml:S3:18526:10	O
,	FANAPT.xml:S3:18536:1	O
ischemia	FANAPT.xml:S3:18538:8	O
,	FANAPT.xml:S3:18546:1	O
or	FANAPT.xml:S3:18548:2	O
conduction	FANAPT.xml:S3:18551:10	O
abnormalities	FANAPT.xml:S3:18562:13	O
)	FANAPT.xml:S3:18575:1	O
,	FANAPT.xml:S3:18576:1	O
cerebrovascular	FANAPT.xml:S3:18578:15	O
disease	FANAPT.xml:S3:18594:7	O
,	FANAPT.xml:S3:18601:1	O
or	FANAPT.xml:S3:18603:2	O
conditions	FANAPT.xml:S3:18606:10	O
that	FANAPT.xml:S3:18617:4	O
predispose	FANAPT.xml:S3:18622:10	O
the	FANAPT.xml:S3:18633:3	O
patient	FANAPT.xml:S3:18637:7	O
to	FANAPT.xml:S3:18645:2	O
hypotension	FANAPT.xml:S3:18648:11	O
(	FANAPT.xml:S3:18660:1	O
dehydration	FANAPT.xml:S3:18661:11	O
,	FANAPT.xml:S3:18672:1	O
hypovolemia	FANAPT.xml:S3:18674:11	O
,	FANAPT.xml:S3:18685:1	O
and	FANAPT.xml:S3:18687:3	O
treatment	FANAPT.xml:S3:18691:9	O
with	FANAPT.xml:S3:18701:4	O
antihypertensive	FANAPT.xml:S3:18706:16	O
medications	FANAPT.xml:S3:18723:11	O
)	FANAPT.xml:S3:18734:1	O
.	FANAPT.xml:S3:18735:1	O

Monitoring	FANAPT.xml:S3:18737:10	O
of	FANAPT.xml:S3:18748:2	O
orthostatic	FANAPT.xml:S3:18751:11	O
vital	FANAPT.xml:S3:18763:5	O
signs	FANAPT.xml:S3:18769:5	O
should	FANAPT.xml:S3:18775:6	O
be	FANAPT.xml:S3:18782:2	O
considered	FANAPT.xml:S3:18785:10	O
in	FANAPT.xml:S3:18796:2	O
patients	FANAPT.xml:S3:18799:8	O
who	FANAPT.xml:S3:18808:3	O
are	FANAPT.xml:S3:18812:3	O
vulnerable	FANAPT.xml:S3:18816:10	O
to	FANAPT.xml:S3:18827:2	O
hypotension	FANAPT.xml:S3:18830:11	O
.	FANAPT.xml:S3:18841:1	O

5.8	FANAPT.xml:S3:18850:3	O
Leukopenia	FANAPT.xml:S3:18858:10	O
,	FANAPT.xml:S3:18868:1	O
Neutropenia	FANAPT.xml:S3:18870:11	O
and	FANAPT.xml:S3:18882:3	O
Agranulocytosis	FANAPT.xml:S3:18886:15	O

In	FANAPT.xml:S3:18907:2	O
clinical	FANAPT.xml:S3:18910:8	O
trial	FANAPT.xml:S3:18919:5	O
and	FANAPT.xml:S3:18925:3	O
postmarketing	FANAPT.xml:S3:18929:13	O
experience	FANAPT.xml:S3:18943:10	O
,	FANAPT.xml:S3:18953:1	O
events	FANAPT.xml:S3:18955:6	O
of	FANAPT.xml:S3:18962:2	O
leukopenia	FANAPT.xml:S3:18965:10	B-AdverseReaction
neutropenia	FANAPT.xml:S3:18976:11	B-AdverseReaction
have	FANAPT.xml:S3:18988:4	O
been	FANAPT.xml:S3:18993:4	O
reported	FANAPT.xml:S3:18998:8	O
temporally	FANAPT.xml:S3:19007:10	O
related	FANAPT.xml:S3:19018:7	O
to	FANAPT.xml:S3:19026:2	O
antipsychotic	FANAPT.xml:S3:19029:13	B-DrugClass
agents	FANAPT.xml:S3:19043:6	I-DrugClass
.	FANAPT.xml:S3:19049:1	O

Agranulocytosis	FANAPT.xml:S3:19051:15	B-AdverseReaction
(	FANAPT.xml:S3:19067:1	O
including	FANAPT.xml:S3:19068:9	O
fatal	FANAPT.xml:S3:19078:5	B-AdverseReaction
cases	FANAPT.xml:S3:19084:5	O
)	FANAPT.xml:S3:19089:1	O
has	FANAPT.xml:S3:19091:3	O
also	FANAPT.xml:S3:19095:4	O
been	FANAPT.xml:S3:19100:4	O
reported	FANAPT.xml:S3:19105:8	O
.	FANAPT.xml:S3:19113:1	O

Possible	FANAPT.xml:S3:19119:8	O
risk	FANAPT.xml:S3:19128:4	O
factors	FANAPT.xml:S3:19133:7	O
for	FANAPT.xml:S3:19141:3	O
leukopenia	FANAPT.xml:S3:19145:10	B-AdverseReaction
neutropenia	FANAPT.xml:S3:19156:11	B-AdverseReaction
include	FANAPT.xml:S3:19168:7	O
preexisting	FANAPT.xml:S3:19176:11	O
low	FANAPT.xml:S3:19188:3	O
white	FANAPT.xml:S3:19192:5	O
blood	FANAPT.xml:S3:19198:5	O
cell	FANAPT.xml:S3:19204:4	O
count	FANAPT.xml:S3:19209:5	O
(	FANAPT.xml:S3:19215:1	O
WBC	FANAPT.xml:S3:19216:3	O
)	FANAPT.xml:S3:19219:1	O
and	FANAPT.xml:S3:19221:3	O
history	FANAPT.xml:S3:19225:7	O
of	FANAPT.xml:S3:19233:2	O
drug	FANAPT.xml:S3:19236:4	O
induced	FANAPT.xml:S3:19241:7	O
leukopenia	FANAPT.xml:S3:19249:10	O
neutropenia	FANAPT.xml:S3:19260:11	O
.	FANAPT.xml:S3:19271:1	O

Patients	FANAPT.xml:S3:19273:8	O
with	FANAPT.xml:S3:19282:4	O
a	FANAPT.xml:S3:19287:1	O
pre	FANAPT.xml:S3:19289:3	O
-	FANAPT.xml:S3:19292:1	O
existing	FANAPT.xml:S3:19293:8	O
low	FANAPT.xml:S3:19302:3	O
WBC	FANAPT.xml:S3:19306:3	O
or	FANAPT.xml:S3:19310:2	O
a	FANAPT.xml:S3:19313:1	O
history	FANAPT.xml:S3:19315:7	O
of	FANAPT.xml:S3:19323:2	O
drug	FANAPT.xml:S3:19326:4	O
induced	FANAPT.xml:S3:19331:7	O
leukopenia	FANAPT.xml:S3:19339:10	O
neutropenia	FANAPT.xml:S3:19350:11	O
should	FANAPT.xml:S3:19362:6	O
have	FANAPT.xml:S3:19369:4	O
their	FANAPT.xml:S3:19374:5	O
complete	FANAPT.xml:S3:19380:8	O
blood	FANAPT.xml:S3:19389:5	O
count	FANAPT.xml:S3:19395:5	O
(	FANAPT.xml:S3:19401:1	O
CBC	FANAPT.xml:S3:19402:3	O
)	FANAPT.xml:S3:19405:1	O
monitored	FANAPT.xml:S3:19407:9	O
frequently	FANAPT.xml:S3:19417:10	O
during	FANAPT.xml:S3:19428:6	O
the	FANAPT.xml:S3:19435:3	O
first	FANAPT.xml:S3:19439:5	O
few	FANAPT.xml:S3:19445:3	O
months	FANAPT.xml:S3:19449:6	O
of	FANAPT.xml:S3:19456:2	O
therapy	FANAPT.xml:S3:19459:7	O
and	FANAPT.xml:S3:19467:3	O
should	FANAPT.xml:S3:19471:6	O
discontinue	FANAPT.xml:S3:19478:11	O
FANAPT	FANAPT.xml:S3:19490:6	O
at	FANAPT.xml:S3:19497:2	O
the	FANAPT.xml:S3:19500:3	O
first	FANAPT.xml:S3:19504:5	O
sign	FANAPT.xml:S3:19510:4	O
of	FANAPT.xml:S3:19515:2	O
a	FANAPT.xml:S3:19518:1	O
decline	FANAPT.xml:S3:19520:7	O
in	FANAPT.xml:S3:19528:2	O
WBC	FANAPT.xml:S3:19531:3	O
in	FANAPT.xml:S3:19535:2	O
the	FANAPT.xml:S3:19538:3	O
absence	FANAPT.xml:S3:19542:7	O
of	FANAPT.xml:S3:19550:2	O
other	FANAPT.xml:S3:19553:5	O
causative	FANAPT.xml:S3:19559:9	O
factors	FANAPT.xml:S3:19569:7	O
.	FANAPT.xml:S3:19576:1	O

Patients	FANAPT.xml:S3:19582:8	O
with	FANAPT.xml:S3:19591:4	O
neutropenia	FANAPT.xml:S3:19596:11	O
should	FANAPT.xml:S3:19608:6	O
be	FANAPT.xml:S3:19615:2	O
carefully	FANAPT.xml:S3:19618:9	O
monitored	FANAPT.xml:S3:19628:9	O
for	FANAPT.xml:S3:19638:3	O
fever	FANAPT.xml:S3:19642:5	O
or	FANAPT.xml:S3:19648:2	O
other	FANAPT.xml:S3:19651:5	O
symptoms	FANAPT.xml:S3:19657:8	O
or	FANAPT.xml:S3:19666:2	O
signs	FANAPT.xml:S3:19669:5	O
of	FANAPT.xml:S3:19675:2	O
infection	FANAPT.xml:S3:19678:9	O
and	FANAPT.xml:S3:19688:3	O
treated	FANAPT.xml:S3:19692:7	O
promptly	FANAPT.xml:S3:19700:8	O
if	FANAPT.xml:S3:19709:2	O
such	FANAPT.xml:S3:19712:4	O
symptoms	FANAPT.xml:S3:19717:8	O
or	FANAPT.xml:S3:19726:2	O
signs	FANAPT.xml:S3:19729:5	O
occur	FANAPT.xml:S3:19735:5	O
.	FANAPT.xml:S3:19740:1	O

Patients	FANAPT.xml:S3:19742:8	O
with	FANAPT.xml:S3:19751:4	O
severe	FANAPT.xml:S3:19756:6	O
neutropenia	FANAPT.xml:S3:19763:11	O
(	FANAPT.xml:S3:19775:1	O
absolute	FANAPT.xml:S3:19776:8	O
neutrophil	FANAPT.xml:S3:19785:10	O
count	FANAPT.xml:S3:19796:5	O
1000	FANAPT.xml:S3:19803:4	O
mm	FANAPT.xml:S3:19808:2	O
3	FANAPT.xml:S3:19812:1	O
)	FANAPT.xml:S3:19815:1	O
should	FANAPT.xml:S3:19817:6	O
discontinue	FANAPT.xml:S3:19824:11	O
FANAPT	FANAPT.xml:S3:19836:6	O
and	FANAPT.xml:S3:19843:3	O
have	FANAPT.xml:S3:19847:4	O
their	FANAPT.xml:S3:19852:5	O
WBC	FANAPT.xml:S3:19858:3	O
followed	FANAPT.xml:S3:19862:8	O
until	FANAPT.xml:S3:19871:5	O
recovery	FANAPT.xml:S3:19877:8	O
.	FANAPT.xml:S3:19885:1	O

5.9	FANAPT.xml:S3:19894:3	O
Hyperprolactinemia	FANAPT.xml:S3:19902:18	O

As	FANAPT.xml:S3:19926:2	O
with	FANAPT.xml:S3:19929:4	O
other	FANAPT.xml:S3:19934:5	O
drugs	FANAPT.xml:S3:19940:5	O
that	FANAPT.xml:S3:19946:4	O
antagonize	FANAPT.xml:S3:19951:10	O
dopamine	FANAPT.xml:S3:19962:8	O
D2	FANAPT.xml:S3:19971:2	O
receptors	FANAPT.xml:S3:19974:9	O
,	FANAPT.xml:S3:19983:1	O
FANAPT	FANAPT.xml:S3:19985:6	O
elevates	FANAPT.xml:S3:19992:8	B-AdverseReaction
prolactin	FANAPT.xml:S3:20001:9	I-AdverseReaction
levels	FANAPT.xml:S3:20011:6	I-AdverseReaction
.	FANAPT.xml:S3:20017:1	O

Hyperprolactinemia	FANAPT.xml:S3:20024:18	B-AdverseReaction
may	FANAPT.xml:S3:20043:3	B-Factor
suppress	FANAPT.xml:S3:20047:8	B-AdverseReaction
hypothalamic	FANAPT.xml:S3:20056:12	I-AdverseReaction
GnRH	FANAPT.xml:S3:20069:4	I-AdverseReaction
,	FANAPT.xml:S3:20073:1	O
resulting	FANAPT.xml:S3:20075:9	O
in	FANAPT.xml:S3:20085:2	O
reduced	FANAPT.xml:S3:20088:7	B-AdverseReaction
pituitary	FANAPT.xml:S3:20096:9	I-AdverseReaction
gonadotropin	FANAPT.xml:S3:20106:12	I-AdverseReaction
secretion	FANAPT.xml:S3:20119:9	I-AdverseReaction
.	FANAPT.xml:S3:20128:1	O

This	FANAPT.xml:S3:20130:4	O
,	FANAPT.xml:S3:20134:1	O
in	FANAPT.xml:S3:20136:2	O
turn	FANAPT.xml:S3:20139:4	O
,	FANAPT.xml:S3:20143:1	O
may	FANAPT.xml:S3:20145:3	B-Factor
inhibit	FANAPT.xml:S3:20149:7	B-AdverseReaction
reproductive	FANAPT.xml:S3:20157:12	I-AdverseReaction
function	FANAPT.xml:S3:20170:8	I-AdverseReaction
by	FANAPT.xml:S3:20179:2	O
impairing	FANAPT.xml:S3:20182:9	B-AdverseReaction
gonadalsteroidogenesis	FANAPT.xml:S3:20192:22	I-AdverseReaction
in	FANAPT.xml:S3:20215:2	O
both	FANAPT.xml:S3:20218:4	O
female	FANAPT.xml:S3:20223:6	O
and	FANAPT.xml:S3:20230:3	O
male	FANAPT.xml:S3:20234:4	O
patients	FANAPT.xml:S3:20239:8	O
.	FANAPT.xml:S3:20247:1	O

Galactorrhea	FANAPT.xml:S3:20249:12	B-AdverseReaction
,	FANAPT.xml:S3:20261:1	O
amenorrhea	FANAPT.xml:S3:20263:10	B-AdverseReaction
,	FANAPT.xml:S3:20273:1	O
gynecomastia	FANAPT.xml:S3:20275:12	B-AdverseReaction
,	FANAPT.xml:S3:20287:1	O
and	FANAPT.xml:S3:20289:3	O
impotence	FANAPT.xml:S3:20293:9	B-AdverseReaction
have	FANAPT.xml:S3:20303:4	O
been	FANAPT.xml:S3:20308:4	O
reported	FANAPT.xml:S3:20313:8	O
with	FANAPT.xml:S3:20322:4	O
prolactin	FANAPT.xml:S3:20327:9	B-DrugClass
-	FANAPT.xml:S3:20336:1	I-DrugClass
elevating	FANAPT.xml:S3:20337:9	I-DrugClass
compounds	FANAPT.xml:S3:20347:9	I-DrugClass
.	FANAPT.xml:S3:20356:1	O

Long	FANAPT.xml:S3:20358:4	B-AdverseReaction
-	FANAPT.xml:S3:20362:1	I-AdverseReaction
standing	FANAPT.xml:S3:20363:8	I-AdverseReaction
hyperprolactinemia	FANAPT.xml:S3:20372:18	I-AdverseReaction
when	FANAPT.xml:S3:20391:4	O
associated	FANAPT.xml:S3:20396:10	O
with	FANAPT.xml:S3:20407:4	O
hypogonadism	FANAPT.xml:S3:20412:12	B-AdverseReaction
may	FANAPT.xml:S3:20425:3	B-Factor
lead	FANAPT.xml:S3:20429:4	O
to	FANAPT.xml:S3:20434:2	O
decreased	FANAPT.xml:S3:20437:9	B-AdverseReaction
bone	FANAPT.xml:S3:20447:4	I-AdverseReaction
density	FANAPT.xml:S3:20452:7	I-AdverseReaction
in	FANAPT.xml:S3:20460:2	O
both	FANAPT.xml:S3:20463:4	O
female	FANAPT.xml:S3:20468:6	O
and	FANAPT.xml:S3:20475:3	O
male	FANAPT.xml:S3:20479:4	O
patients	FANAPT.xml:S3:20484:8	O
.	FANAPT.xml:S3:20492:1	O

Tissue	FANAPT.xml:S3:20498:6	O
culture	FANAPT.xml:S3:20505:7	O
experiments	FANAPT.xml:S3:20513:11	O
indicate	FANAPT.xml:S3:20525:8	O
that	FANAPT.xml:S3:20534:4	O
approximately	FANAPT.xml:S3:20539:13	O
one	FANAPT.xml:S3:20553:3	O
-	FANAPT.xml:S3:20556:1	O
third	FANAPT.xml:S3:20557:5	O
of	FANAPT.xml:S3:20563:2	O
human	FANAPT.xml:S3:20566:5	O
breast	FANAPT.xml:S3:20572:6	O
cancers	FANAPT.xml:S3:20579:7	O
are	FANAPT.xml:S3:20587:3	O
prolactin	FANAPT.xml:S3:20591:9	O
-	FANAPT.xml:S3:20600:1	O
dependent	FANAPT.xml:S3:20601:9	O
in	FANAPT.xml:S3:20611:2	O
vitro	FANAPT.xml:S3:20614:5	O
,	FANAPT.xml:S3:20621:1	O
a	FANAPT.xml:S3:20623:1	O
factor	FANAPT.xml:S3:20625:6	O
of	FANAPT.xml:S3:20632:2	O
potential	FANAPT.xml:S3:20635:9	O
importance	FANAPT.xml:S3:20645:10	O
if	FANAPT.xml:S3:20656:2	O
the	FANAPT.xml:S3:20659:3	O
prescription	FANAPT.xml:S3:20663:12	O
of	FANAPT.xml:S3:20676:2	O
these	FANAPT.xml:S3:20679:5	O
drugs	FANAPT.xml:S3:20685:5	O
is	FANAPT.xml:S3:20691:2	O
contemplated	FANAPT.xml:S3:20694:12	O
in	FANAPT.xml:S3:20707:2	O
a	FANAPT.xml:S3:20710:1	O
patient	FANAPT.xml:S3:20712:7	O
with	FANAPT.xml:S3:20720:4	O
previously	FANAPT.xml:S3:20725:10	O
detected	FANAPT.xml:S3:20736:8	O
breast	FANAPT.xml:S3:20745:6	O
cancer	FANAPT.xml:S3:20752:6	O
.	FANAPT.xml:S3:20758:1	O

Mammary	FANAPT.xml:S3:20760:7	B-AdverseReaction
gland	FANAPT.xml:S3:20768:5	I-AdverseReaction
proliferative	FANAPT.xml:S3:20774:13	I-AdverseReaction
changes	FANAPT.xml:S3:20788:7	I-AdverseReaction
and	FANAPT.xml:S3:20796:3	O
increases	FANAPT.xml:S3:20800:9	B-AdverseReaction
in	FANAPT.xml:S3:20810:2	I-AdverseReaction
serum	FANAPT.xml:S3:20813:5	I-AdverseReaction
prolactin	FANAPT.xml:S3:20819:9	I-AdverseReaction
were	FANAPT.xml:S3:20829:4	O
seen	FANAPT.xml:S3:20834:4	O
in	FANAPT.xml:S3:20839:2	O
mice	FANAPT.xml:S3:20842:4	B-Animal
and	FANAPT.xml:S3:20847:3	O
rats	FANAPT.xml:S3:20851:4	B-Animal
treated	FANAPT.xml:S3:20856:7	O
with	FANAPT.xml:S3:20864:4	O
FANAPT	FANAPT.xml:S3:20869:6	O
[	FANAPT.xml:S3:20877:1	O
see	FANAPT.xml:S3:20878:3	O
Nonclinical	FANAPT.xml:S3:20882:11	O
Toxicology	FANAPT.xml:S3:20894:10	O
(	FANAPT.xml:S3:20905:1	O
13.1	FANAPT.xml:S3:20906:4	O
)]	FANAPT.xml:S3:20910:2	O
.	FANAPT.xml:S3:20914:1	O

Neither	FANAPT.xml:S3:20916:7	O
clinical	FANAPT.xml:S3:20924:8	O
studies	FANAPT.xml:S3:20933:7	O
nor	FANAPT.xml:S3:20941:3	O
epidemiologic	FANAPT.xml:S3:20945:13	O
studies	FANAPT.xml:S3:20959:7	O
conducted	FANAPT.xml:S3:20967:9	O
to	FANAPT.xml:S3:20977:2	O
date	FANAPT.xml:S3:20980:4	O
have	FANAPT.xml:S3:20985:4	O
shown	FANAPT.xml:S3:20990:5	O
an	FANAPT.xml:S3:20996:2	O
association	FANAPT.xml:S3:20999:11	O
between	FANAPT.xml:S3:21011:7	O
chronic	FANAPT.xml:S3:21019:7	O
administration	FANAPT.xml:S3:21027:14	O
of	FANAPT.xml:S3:21042:2	O
this	FANAPT.xml:S3:21045:4	O
class	FANAPT.xml:S3:21050:5	O
of	FANAPT.xml:S3:21056:2	O
drugs	FANAPT.xml:S3:21059:5	O
and	FANAPT.xml:S3:21065:3	O
tumorigenesis	FANAPT.xml:S3:21069:13	O
in	FANAPT.xml:S3:21083:2	O
humans	FANAPT.xml:S3:21086:6	O
;	FANAPT.xml:S3:21092:1	O
the	FANAPT.xml:S3:21094:3	O
available	FANAPT.xml:S3:21098:9	O
evidence	FANAPT.xml:S3:21108:8	O
is	FANAPT.xml:S3:21117:2	O
considered	FANAPT.xml:S3:21120:10	O
too	FANAPT.xml:S3:21131:3	O
limited	FANAPT.xml:S3:21135:7	O
to	FANAPT.xml:S3:21143:2	O
be	FANAPT.xml:S3:21146:2	O
conclusive	FANAPT.xml:S3:21149:10	O
at	FANAPT.xml:S3:21160:2	O
this	FANAPT.xml:S3:21163:4	O
time	FANAPT.xml:S3:21168:4	O
.	FANAPT.xml:S3:21172:1	O

In	FANAPT.xml:S3:21178:2	O
a	FANAPT.xml:S3:21181:1	O
short	FANAPT.xml:S3:21183:5	O
-	FANAPT.xml:S3:21188:1	O
term	FANAPT.xml:S3:21189:4	O
placebo	FANAPT.xml:S3:21194:7	O
-	FANAPT.xml:S3:21201:1	O
controlled	FANAPT.xml:S3:21202:10	O
trial	FANAPT.xml:S3:21213:5	O
(	FANAPT.xml:S3:21219:1	O
4	FANAPT.xml:S3:21220:1	O
-	FANAPT.xml:S3:21221:1	O
weeks	FANAPT.xml:S3:21222:5	O
)	FANAPT.xml:S3:21227:1	O
,	FANAPT.xml:S3:21228:1	O
the	FANAPT.xml:S3:21230:3	O
mean	FANAPT.xml:S3:21234:4	O
change	FANAPT.xml:S3:21239:6	O
from	FANAPT.xml:S3:21246:4	O
baseline	FANAPT.xml:S3:21251:8	O
to	FANAPT.xml:S3:21260:2	O
endpoint	FANAPT.xml:S3:21263:8	O
in	FANAPT.xml:S3:21272:2	O
plasma	FANAPT.xml:S3:21275:6	B-AdverseReaction
prolactin	FANAPT.xml:S3:21282:9	I-AdverseReaction
levels	FANAPT.xml:S3:21292:6	I-AdverseReaction
for	FANAPT.xml:S3:21299:3	O
the	FANAPT.xml:S3:21303:3	O
FANAPT	FANAPT.xml:S3:21307:6	O
24	FANAPT.xml:S3:21314:2	O
mg	FANAPT.xml:S3:21317:2	O
day	FANAPT.xml:S3:21320:3	O
-	FANAPT.xml:S3:21323:1	O
treated	FANAPT.xml:S3:21324:7	O
group	FANAPT.xml:S3:21332:5	O
was	FANAPT.xml:S3:21338:3	O
an	FANAPT.xml:S3:21342:2	O
increase	FANAPT.xml:S3:21345:8	I-AdverseReaction
of	FANAPT.xml:S3:21354:2	O
2.6	FANAPT.xml:S3:21357:3	B-Severity
ng	FANAPT.xml:S3:21361:2	I-Severity
mL	FANAPT.xml:S3:21364:2	I-Severity
compared	FANAPT.xml:S3:21367:8	O
to	FANAPT.xml:S3:21376:2	O
a	FANAPT.xml:S3:21379:1	O
decrease	FANAPT.xml:S3:21381:8	O
of	FANAPT.xml:S3:21390:2	O
6.3	FANAPT.xml:S3:21393:3	O
ng	FANAPT.xml:S3:21397:2	O
mL	FANAPT.xml:S3:21400:2	O
in	FANAPT.xml:S3:21403:2	O
the	FANAPT.xml:S3:21406:3	O
placebo	FANAPT.xml:S3:21410:7	O
-	FANAPT.xml:S3:21417:1	O
group	FANAPT.xml:S3:21418:5	O
.	FANAPT.xml:S3:21423:1	O

In	FANAPT.xml:S3:21425:2	O
this	FANAPT.xml:S3:21428:4	O
trial	FANAPT.xml:S3:21433:5	O
,	FANAPT.xml:S3:21438:1	O
elevated	FANAPT.xml:S3:21440:8	B-AdverseReaction
plasma	FANAPT.xml:S3:21449:6	I-AdverseReaction
prolactin	FANAPT.xml:S3:21456:9	I-AdverseReaction
levels	FANAPT.xml:S3:21466:6	I-AdverseReaction
were	FANAPT.xml:S3:21473:4	O
observed	FANAPT.xml:S3:21478:8	O
in	FANAPT.xml:S3:21487:2	O
26%	FANAPT.xml:S3:21490:3	O
of	FANAPT.xml:S3:21494:2	O
adults	FANAPT.xml:S3:21497:6	O
treated	FANAPT.xml:S3:21504:7	O
with	FANAPT.xml:S3:21512:4	O
FANAPT	FANAPT.xml:S3:21517:6	O
compared	FANAPT.xml:S3:21524:8	O
to	FANAPT.xml:S3:21533:2	O
12%	FANAPT.xml:S3:21536:3	O
in	FANAPT.xml:S3:21540:2	O
the	FANAPT.xml:S3:21543:3	O
placebo	FANAPT.xml:S3:21547:7	O
-	FANAPT.xml:S3:21554:1	O
group	FANAPT.xml:S3:21555:5	O
.	FANAPT.xml:S3:21560:1	O

In	FANAPT.xml:S3:21562:2	O
the	FANAPT.xml:S3:21565:3	O
short	FANAPT.xml:S3:21569:5	O
-	FANAPT.xml:S3:21574:1	O
term	FANAPT.xml:S3:21575:4	O
trials	FANAPT.xml:S3:21580:6	O
,	FANAPT.xml:S3:21586:1	O
FANAPT	FANAPT.xml:S3:21588:6	O
was	FANAPT.xml:S3:21595:3	O
associated	FANAPT.xml:S3:21599:10	O
with	FANAPT.xml:S3:21610:4	O
modest	FANAPT.xml:S3:21615:6	B-Severity
levels	FANAPT.xml:S3:21622:6	I-Severity
of	FANAPT.xml:S3:21629:2	O
prolactin	FANAPT.xml:S3:21632:9	B-AdverseReaction
elevation	FANAPT.xml:S3:21642:9	I-AdverseReaction
compared	FANAPT.xml:S3:21652:8	O
to	FANAPT.xml:S3:21661:2	O
greater	FANAPT.xml:S3:21664:7	B-Severity
prolactin	FANAPT.xml:S3:21672:9	B-AdverseReaction
elevations	FANAPT.xml:S3:21682:10	I-AdverseReaction
observed	FANAPT.xml:S3:21693:8	O
with	FANAPT.xml:S3:21702:4	O
some	FANAPT.xml:S3:21707:4	O
other	FANAPT.xml:S3:21712:5	B-DrugClass
antipsychotic	FANAPT.xml:S3:21718:13	I-DrugClass
agents	FANAPT.xml:S3:21732:6	I-DrugClass
.	FANAPT.xml:S3:21738:1	O

In	FANAPT.xml:S3:21740:2	O
pooled	FANAPT.xml:S3:21743:6	O
analysis	FANAPT.xml:S3:21750:8	O
from	FANAPT.xml:S3:21759:4	O
clinical	FANAPT.xml:S3:21764:8	O
studies	FANAPT.xml:S3:21773:7	O
including	FANAPT.xml:S3:21781:9	O
longer	FANAPT.xml:S3:21791:6	O
term	FANAPT.xml:S3:21798:4	O
trials	FANAPT.xml:S3:21803:6	O
,	FANAPT.xml:S3:21809:1	O
in	FANAPT.xml:S3:21811:2	O
3210	FANAPT.xml:S3:21814:4	O
adults	FANAPT.xml:S3:21819:6	O
treated	FANAPT.xml:S3:21826:7	O
with	FANAPT.xml:S3:21834:4	O
iloperidone	FANAPT.xml:S3:21839:11	O
,	FANAPT.xml:S3:21850:1	O
gynecomastia	FANAPT.xml:S3:21852:12	B-AdverseReaction
was	FANAPT.xml:S3:21865:3	O
reported	FANAPT.xml:S3:21869:8	O
in	FANAPT.xml:S3:21878:2	O
2	FANAPT.xml:S3:21881:1	O
male	FANAPT.xml:S3:21883:4	O
subjects	FANAPT.xml:S3:21888:8	O
(	FANAPT.xml:S3:21897:1	O
0.1%	FANAPT.xml:S3:21898:4	O
)	FANAPT.xml:S3:21902:1	O
compared	FANAPT.xml:S3:21904:8	O
to	FANAPT.xml:S3:21913:2	O
0%	FANAPT.xml:S3:21916:2	O
in	FANAPT.xml:S3:21919:2	O
placebo	FANAPT.xml:S3:21922:7	O
-	FANAPT.xml:S3:21929:1	O
treated	FANAPT.xml:S3:21930:7	O
patients	FANAPT.xml:S3:21938:8	O
,	FANAPT.xml:S3:21946:1	O
and	FANAPT.xml:S3:21948:3	O
galactorrhea	FANAPT.xml:S3:21952:12	B-AdverseReaction
was	FANAPT.xml:S3:21965:3	O
reported	FANAPT.xml:S3:21969:8	O
in	FANAPT.xml:S3:21978:2	O
8	FANAPT.xml:S3:21981:1	O
female	FANAPT.xml:S3:21983:6	O
subjects	FANAPT.xml:S3:21990:8	O
(	FANAPT.xml:S3:21999:1	O
0.2%	FANAPT.xml:S3:22000:4	O
)	FANAPT.xml:S3:22004:1	O
compared	FANAPT.xml:S3:22006:8	O
to	FANAPT.xml:S3:22015:2	O
3	FANAPT.xml:S3:22018:1	O
female	FANAPT.xml:S3:22020:6	O
subjects	FANAPT.xml:S3:22027:8	O
(	FANAPT.xml:S3:22036:1	O
0.5%	FANAPT.xml:S3:22037:4	O
)	FANAPT.xml:S3:22041:1	O
in	FANAPT.xml:S3:22043:2	O
placebo	FANAPT.xml:S3:22046:7	O
-	FANAPT.xml:S3:22053:1	O
treated	FANAPT.xml:S3:22054:7	O
patients	FANAPT.xml:S3:22062:8	O
.	FANAPT.xml:S3:22070:1	O

5.10	FANAPT.xml:S3:22079:4	O
Body	FANAPT.xml:S3:22088:4	O
Temperature	FANAPT.xml:S3:22093:11	O
Regulation	FANAPT.xml:S3:22105:10	O

Disruption	FANAPT.xml:S3:22121:10	B-AdverseReaction
of	FANAPT.xml:S3:22132:2	I-AdverseReaction
the	FANAPT.xml:S3:22135:3	I-AdverseReaction
body	FANAPT.xml:S3:22139:4	I-AdverseReaction
's	FANAPT.xml:S3:22143:2	I-AdverseReaction
ability	FANAPT.xml:S3:22146:7	I-AdverseReaction
to	FANAPT.xml:S3:22154:2	I-AdverseReaction
reduce	FANAPT.xml:S3:22157:6	I-AdverseReaction
core	FANAPT.xml:S3:22164:4	I-AdverseReaction
body	FANAPT.xml:S3:22169:4	I-AdverseReaction
temperature	FANAPT.xml:S3:22174:11	I-AdverseReaction
has	FANAPT.xml:S3:22186:3	O
been	FANAPT.xml:S3:22190:4	O
attributed	FANAPT.xml:S3:22195:10	O
to	FANAPT.xml:S3:22206:2	O
antipsychotic	FANAPT.xml:S3:22209:13	B-DrugClass
agents	FANAPT.xml:S3:22223:6	I-DrugClass
.	FANAPT.xml:S3:22229:1	O

Appropriate	FANAPT.xml:S3:22231:11	O
care	FANAPT.xml:S3:22243:4	O
is	FANAPT.xml:S3:22248:2	O
advised	FANAPT.xml:S3:22251:7	O
when	FANAPT.xml:S3:22259:4	O
prescribing	FANAPT.xml:S3:22264:11	O
FANAPT	FANAPT.xml:S3:22276:6	O
for	FANAPT.xml:S3:22283:3	O
patients	FANAPT.xml:S3:22287:8	O
who	FANAPT.xml:S3:22296:3	O
will	FANAPT.xml:S3:22300:4	O
be	FANAPT.xml:S3:22305:2	O
experiencing	FANAPT.xml:S3:22308:12	O
conditions	FANAPT.xml:S3:22321:10	O
which	FANAPT.xml:S3:22332:5	O
may	FANAPT.xml:S3:22338:3	O
contribute	FANAPT.xml:S3:22342:10	O
to	FANAPT.xml:S3:22353:2	O
an	FANAPT.xml:S3:22356:2	O
elevation	FANAPT.xml:S3:22359:9	O
in	FANAPT.xml:S3:22369:2	O
core	FANAPT.xml:S3:22372:4	O
body	FANAPT.xml:S3:22377:4	O
temperature	FANAPT.xml:S3:22382:11	O
,	FANAPT.xml:S3:22393:1	O
e	FANAPT.xml:S3:22395:1	O
.	FANAPT.xml:S3:22396:1	O
g	FANAPT.xml:S3:22397:1	O
.	FANAPT.xml:S3:22398:1	O
,	FANAPT.xml:S3:22399:1	O
exercising	FANAPT.xml:S3:22401:10	O
strenuously	FANAPT.xml:S3:22412:11	O
,	FANAPT.xml:S3:22423:1	O
exposure	FANAPT.xml:S3:22425:8	O
to	FANAPT.xml:S3:22434:2	O
extreme	FANAPT.xml:S3:22437:7	O
heat	FANAPT.xml:S3:22445:4	O
,	FANAPT.xml:S3:22449:1	O
receiving	FANAPT.xml:S3:22451:9	O
concomitant	FANAPT.xml:S3:22461:11	O
medication	FANAPT.xml:S3:22473:10	O
with	FANAPT.xml:S3:22484:4	O
anticholinergic	FANAPT.xml:S3:22489:15	O
activity	FANAPT.xml:S3:22505:8	O
,	FANAPT.xml:S3:22513:1	O
or	FANAPT.xml:S3:22515:2	O
being	FANAPT.xml:S3:22518:5	O
subject	FANAPT.xml:S3:22524:7	O
to	FANAPT.xml:S3:22532:2	O
dehydration	FANAPT.xml:S3:22535:11	O
.	FANAPT.xml:S3:22546:1	O

5.11	FANAPT.xml:S3:22555:4	O
Dysphagia	FANAPT.xml:S3:22564:9	O

Esophageal	FANAPT.xml:S3:22579:10	B-AdverseReaction
dysmotility	FANAPT.xml:S3:22590:11	I-AdverseReaction
and	FANAPT.xml:S3:22602:3	O
aspiration	FANAPT.xml:S3:22606:10	B-AdverseReaction
have	FANAPT.xml:S3:22617:4	O
been	FANAPT.xml:S3:22622:4	O
associated	FANAPT.xml:S3:22627:10	O
with	FANAPT.xml:S3:22638:4	O
antipsychotic	FANAPT.xml:S3:22643:13	B-DrugClass
drug	FANAPT.xml:S3:22657:4	I-DrugClass
use	FANAPT.xml:S3:22662:3	O
.	FANAPT.xml:S3:22665:1	O

Aspiration	FANAPT.xml:S3:22667:10	O
pneumonia	FANAPT.xml:S3:22678:9	O
is	FANAPT.xml:S3:22688:2	O
a	FANAPT.xml:S3:22691:1	O
common	FANAPT.xml:S3:22693:6	O
cause	FANAPT.xml:S3:22700:5	O
of	FANAPT.xml:S3:22706:2	O
morbidity	FANAPT.xml:S3:22709:9	O
and	FANAPT.xml:S3:22719:3	O
mortality	FANAPT.xml:S3:22723:9	O
in	FANAPT.xml:S3:22733:2	O
elderly	FANAPT.xml:S3:22736:7	O
patients	FANAPT.xml:S3:22744:8	O
,	FANAPT.xml:S3:22752:1	O
in	FANAPT.xml:S3:22754:2	O
particular	FANAPT.xml:S3:22757:10	O
those	FANAPT.xml:S3:22768:5	O
with	FANAPT.xml:S3:22774:4	O
advanced	FANAPT.xml:S3:22779:8	O
Alzheimer	FANAPT.xml:S3:22788:9	O
's	FANAPT.xml:S3:22797:2	O
dementia	FANAPT.xml:S3:22800:8	O
.	FANAPT.xml:S3:22808:1	O

FANAPT	FANAPT.xml:S3:22810:6	O
and	FANAPT.xml:S3:22817:3	O
other	FANAPT.xml:S3:22821:5	O
antipsychotic	FANAPT.xml:S3:22827:13	O
drugs	FANAPT.xml:S3:22841:5	O
should	FANAPT.xml:S3:22847:6	O
be	FANAPT.xml:S3:22854:2	O
used	FANAPT.xml:S3:22857:4	O
cautiously	FANAPT.xml:S3:22862:10	O
in	FANAPT.xml:S3:22873:2	O
patients	FANAPT.xml:S3:22876:8	O
at	FANAPT.xml:S3:22885:2	O
risk	FANAPT.xml:S3:22888:4	O
for	FANAPT.xml:S3:22893:3	O
aspiration	FANAPT.xml:S3:22897:10	O
pneumonia	FANAPT.xml:S3:22908:9	O
[	FANAPT.xml:S3:22918:1	O
see	FANAPT.xml:S3:22919:3	O
Boxed	FANAPT.xml:S3:22923:5	O
Warning	FANAPT.xml:S3:22929:7	O
]	FANAPT.xml:S3:22936:1	O
.	FANAPT.xml:S3:22939:1	O

5.12	FANAPT.xml:S3:22948:4	O
Suicide	FANAPT.xml:S3:22957:7	O

The	FANAPT.xml:S3:22970:3	O
possibility	FANAPT.xml:S3:22974:11	O
of	FANAPT.xml:S3:22986:2	O
a	FANAPT.xml:S3:22989:1	O
suicide	FANAPT.xml:S3:22991:7	O
attempt	FANAPT.xml:S3:22999:7	O
is	FANAPT.xml:S3:23007:2	O
inherent	FANAPT.xml:S3:23010:8	O
in	FANAPT.xml:S3:23019:2	O
psychotic	FANAPT.xml:S3:23022:9	O
illness	FANAPT.xml:S3:23032:7	O
,	FANAPT.xml:S3:23039:1	O
and	FANAPT.xml:S3:23041:3	O
close	FANAPT.xml:S3:23045:5	O
supervision	FANAPT.xml:S3:23051:11	O
of	FANAPT.xml:S3:23063:2	O
high	FANAPT.xml:S3:23066:4	O
-	FANAPT.xml:S3:23070:1	O
risk	FANAPT.xml:S3:23071:4	O
patients	FANAPT.xml:S3:23076:8	O
should	FANAPT.xml:S3:23085:6	O
accompany	FANAPT.xml:S3:23092:9	O
drug	FANAPT.xml:S3:23102:4	O
therapy	FANAPT.xml:S3:23107:7	O
.	FANAPT.xml:S3:23114:1	O

Prescriptions	FANAPT.xml:S3:23116:13	O
for	FANAPT.xml:S3:23130:3	O
FANAPT	FANAPT.xml:S3:23134:6	O
should	FANAPT.xml:S3:23141:6	O
be	FANAPT.xml:S3:23148:2	O
written	FANAPT.xml:S3:23151:7	O
for	FANAPT.xml:S3:23159:3	O
the	FANAPT.xml:S3:23163:3	O
smallest	FANAPT.xml:S3:23167:8	O
quantity	FANAPT.xml:S3:23176:8	O
of	FANAPT.xml:S3:23185:2	O
tablets	FANAPT.xml:S3:23188:7	O
consistent	FANAPT.xml:S3:23196:10	O
with	FANAPT.xml:S3:23207:4	O
good	FANAPT.xml:S3:23212:4	O
patient	FANAPT.xml:S3:23217:7	O
management	FANAPT.xml:S3:23225:10	O
in	FANAPT.xml:S3:23236:2	O
order	FANAPT.xml:S3:23239:5	O
to	FANAPT.xml:S3:23245:2	O
reduce	FANAPT.xml:S3:23248:6	O
the	FANAPT.xml:S3:23255:3	O
risk	FANAPT.xml:S3:23259:4	O
of	FANAPT.xml:S3:23264:2	O
overdose	FANAPT.xml:S3:23267:8	O
.	FANAPT.xml:S3:23275:1	O

5.13	FANAPT.xml:S3:23284:4	O
Priapism	FANAPT.xml:S3:23293:8	O

Three	FANAPT.xml:S3:23307:5	O
cases	FANAPT.xml:S3:23313:5	O
of	FANAPT.xml:S3:23319:2	O
priapism	FANAPT.xml:S3:23322:8	B-AdverseReaction
were	FANAPT.xml:S3:23331:4	O
reported	FANAPT.xml:S3:23336:8	O
in	FANAPT.xml:S3:23345:2	O
the	FANAPT.xml:S3:23348:3	O
premarketing	FANAPT.xml:S3:23352:12	O
FANAPT	FANAPT.xml:S3:23365:6	O
program	FANAPT.xml:S3:23372:7	O
.	FANAPT.xml:S3:23379:1	O

Drugs	FANAPT.xml:S3:23381:5	B-DrugClass
with	FANAPT.xml:S3:23387:4	I-DrugClass
alpha	FANAPT.xml:S3:23392:5	I-DrugClass
-	FANAPT.xml:S3:23397:1	I-DrugClass
adrenergic	FANAPT.xml:S3:23398:10	I-DrugClass
blocking	FANAPT.xml:S3:23409:8	I-DrugClass
effects	FANAPT.xml:S3:23418:7	I-DrugClass
have	FANAPT.xml:S3:23426:4	O
been	FANAPT.xml:S3:23431:4	O
reported	FANAPT.xml:S3:23436:8	O
to	FANAPT.xml:S3:23445:2	O
induce	FANAPT.xml:S3:23448:6	O
priapism	FANAPT.xml:S3:23455:8	B-AdverseReaction
.	FANAPT.xml:S3:23463:1	O

FANAPT	FANAPT.xml:S3:23465:6	O
shares	FANAPT.xml:S3:23472:6	O
this	FANAPT.xml:S3:23479:4	O
pharmacologic	FANAPT.xml:S3:23484:13	O
activity	FANAPT.xml:S3:23498:8	O
.	FANAPT.xml:S3:23506:1	O

Severe	FANAPT.xml:S3:23508:6	B-Severity
priapism	FANAPT.xml:S3:23515:8	B-AdverseReaction
may	FANAPT.xml:S3:23524:3	O
require	FANAPT.xml:S3:23528:7	O
surgical	FANAPT.xml:S3:23536:8	O
intervention	FANAPT.xml:S3:23545:12	O
.	FANAPT.xml:S3:23557:1	O

5.14	FANAPT.xml:S3:23566:4	O
Potential	FANAPT.xml:S3:23575:9	O
for	FANAPT.xml:S3:23585:3	O
Cognitive	FANAPT.xml:S3:23589:9	O
and	FANAPT.xml:S3:23599:3	O
Motor	FANAPT.xml:S3:23603:5	O
Impairment	FANAPT.xml:S3:23609:10	O

FANAPT	FANAPT.xml:S3:23625:6	O
,	FANAPT.xml:S3:23631:1	O
like	FANAPT.xml:S3:23633:4	O
other	FANAPT.xml:S3:23638:5	O
antipsychotics	FANAPT.xml:S3:23644:14	O
,	FANAPT.xml:S3:23658:1	O
has	FANAPT.xml:S3:23660:3	O
the	FANAPT.xml:S3:23664:3	O
potential	FANAPT.xml:S3:23668:9	B-Factor
to	FANAPT.xml:S3:23678:2	O
impair	FANAPT.xml:S3:23681:6	B-AdverseReaction
judgment	FANAPT.xml:S3:23688:8	I-AdverseReaction
,	FANAPT.xml:S3:23696:1	O
thinking	FANAPT.xml:S3:23698:8	I-AdverseReaction
or	FANAPT.xml:S3:23707:2	O
motor	FANAPT.xml:S3:23710:5	I-AdverseReaction
skills	FANAPT.xml:S3:23716:6	I-AdverseReaction
.	FANAPT.xml:S3:23722:1	O

In	FANAPT.xml:S3:23724:2	O
short	FANAPT.xml:S3:23727:5	O
-	FANAPT.xml:S3:23732:1	O
term	FANAPT.xml:S3:23733:4	O
,	FANAPT.xml:S3:23737:1	O
placebo	FANAPT.xml:S3:23739:7	O
-	FANAPT.xml:S3:23746:1	O
controlled	FANAPT.xml:S3:23747:10	O
trials	FANAPT.xml:S3:23758:6	O
,	FANAPT.xml:S3:23764:1	O
somnolence	FANAPT.xml:S3:23766:10	B-AdverseReaction
(	FANAPT.xml:S3:23777:1	O
including	FANAPT.xml:S3:23778:9	O
sedation	FANAPT.xml:S3:23788:8	B-AdverseReaction
)	FANAPT.xml:S3:23796:1	O
was	FANAPT.xml:S3:23798:3	O
reported	FANAPT.xml:S3:23802:8	O
in	FANAPT.xml:S3:23811:2	O
11.9%	FANAPT.xml:S3:23814:5	O
(	FANAPT.xml:S3:23820:1	O
104	FANAPT.xml:S3:23821:3	O
874	FANAPT.xml:S3:23825:3	O
)	FANAPT.xml:S3:23828:1	O
of	FANAPT.xml:S3:23830:2	O
adult	FANAPT.xml:S3:23833:5	O
patients	FANAPT.xml:S3:23839:8	O
treated	FANAPT.xml:S3:23848:7	O
with	FANAPT.xml:S3:23856:4	O
FANAPT	FANAPT.xml:S3:23861:6	O
at	FANAPT.xml:S3:23872:2	O
doses	FANAPT.xml:S3:23875:5	O
of	FANAPT.xml:S3:23881:2	O
10	FANAPT.xml:S3:23884:2	O
mg	FANAPT.xml:S3:23887:2	O
day	FANAPT.xml:S3:23890:3	O
or	FANAPT.xml:S3:23894:2	O
greater	FANAPT.xml:S3:23897:7	O
versus	FANAPT.xml:S3:23905:6	O
5.3%	FANAPT.xml:S3:23912:4	O
(	FANAPT.xml:S3:23917:1	O
31	FANAPT.xml:S3:23918:2	O
587	FANAPT.xml:S3:23921:3	O
)	FANAPT.xml:S3:23924:1	O
treated	FANAPT.xml:S3:23926:7	O
with	FANAPT.xml:S3:23934:4	O
placebo	FANAPT.xml:S3:23939:7	O
.	FANAPT.xml:S3:23946:1	O

Patients	FANAPT.xml:S3:23948:8	O
should	FANAPT.xml:S3:23957:6	O
be	FANAPT.xml:S3:23964:2	O
cautioned	FANAPT.xml:S3:23967:9	O
about	FANAPT.xml:S3:23977:5	O
operating	FANAPT.xml:S3:23983:9	O
hazardous	FANAPT.xml:S3:23993:9	O
machinery	FANAPT.xml:S3:24003:9	O
,	FANAPT.xml:S3:24012:1	O
including	FANAPT.xml:S3:24014:9	O
automobiles	FANAPT.xml:S3:24024:11	O
,	FANAPT.xml:S3:24035:1	O
until	FANAPT.xml:S3:24037:5	O
they	FANAPT.xml:S3:24043:4	O
are	FANAPT.xml:S3:24048:3	O
reasonably	FANAPT.xml:S3:24052:10	O
certain	FANAPT.xml:S3:24063:7	O
that	FANAPT.xml:S3:24071:4	O
therapy	FANAPT.xml:S3:24076:7	O
with	FANAPT.xml:S3:24084:4	O
FANAPT	FANAPT.xml:S3:24089:6	O
does	FANAPT.xml:S3:24096:4	O
not	FANAPT.xml:S3:24101:3	O
affect	FANAPT.xml:S3:24105:6	O
them	FANAPT.xml:S3:24112:4	O
adversely	FANAPT.xml:S3:24117:9	O
.	FANAPT.xml:S3:24126:1	O
